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Transport into and out of the nucleus occurs through nuclear pore complexes (NPCs) that are
embedded in the nuclear envelope. NPCs are massive macromolecular complexes of around
125 kDa in vertebrates. Around 30 different nucleoporins (Nups) build the NPC, a third of which
contain phenylalanine glycine (FG)-repeats (FG-Nups). The FG-repeats form the permeabil-
ity barrier of the NPC, thereby restricting diffusion for most molecules larger than 20-40 kDa.
In order for larger molecules to translocate through the NPCs, they have to be actively trans-
ported in complexes with transport receptors. Transport receptors were shown to interact with
FG-repeats of nucleoporins, consequently overcoming the permeability barrier of the NPCs.
The most prominent transport receptor for nuclear import is importin β, whereas CRM1 is the
major nuclear export receptor. With the exception of some crystal structures of importin β with
short, mostly chemically synthesized, FG-repeat containing peptides, structural information on
how transport receptors interact with FG-Nups to mediate translocation through the NPC has
not been available so far.
In this work, the interactions of CRM1 export complexes with Nup214 were analyzed by struc-
tural and biochemical methods.
A complex containing CRM1, RanGTP, SPN1 and a Nup214(1916-2033) fragment was an-
alyzed by cross-linking mass spectrometry and X-ray crystallography. The crystal structure
revealed three FG-sites on the Nup214 fragment that bound to CRM1 by winding along the
outer ring from HEAT-repeat 14, across the interacting region of the N- and C- termini, through
to HEAT-repeat 4. Seven phenylalanine residues could be identified in Nup214 that bound
to hydrophobic pockets on CRM1. Moreover, the residues between the bound phenylalanine
residues seemed to be flexible or bound rather loosely to the CRM1 surface.
Structure-derived Nup214 and CRM1 mutants were analyzed for their binding properties. Anal-
ysis of CRM1 mutants revealed that mutagenesis in several regions of CRM1 can affect its
cooperative binding to RanGTP and NES. More than 90% of the CRM1 mutants designed to
decrease binding to Nup214, also showed altered binding to RanGTP and an NES peptide. Two
CRM1 mutants displayed decreased binding to Nup214 but remained unaltered with respect to
RanGTP and NES binding, verifying that the hydrophobic pockets on CRM1 binding to Nup214
residues F1938 and F1982 in the crystal structure are indeed involved in the interaction. Corre-
spondingly, mutagenesis of the Nup214 phenylalanine residues bound in the structure clearly
reduced binding to CRM1.
The obtained crystal structure of the Nup214 complex is the first structure of a karyopherin with
long fragments of a FG-nucleoporin. The crystal structure combined with data from binding-
and transport assays suggests that binding sites of FG-nucleoporins on CRM1 partially, but not





1.1 The nuclear pore complex (NPC)
1.1.1 The architecture of the NPC
The nucleus is the major cellular feature that distinguishes prokaryotes from higher organisms.
The spatial separation of transcriptional and translational events in the eukaryotic cell leads to
the need for effective transport of RNA and proteins between the nucleus and the cytoplasm.
Crossing of the nuclear membrane occurs through so-called nuclear pore complexes (NPC)
which serve as the only gateway for nucleocytoplasmic transport. NPCs function as a diffusion
barrier. Therefore, in general, only small metabolites can diffuse freely between cytoplasm
and nucleus, most macromolecules larger than 20-40 kDa have to be actively transported.
Exceptions include for example histones, which are actively transported even though they are
only around 20 kDa in size [1, 2, 3]. On the other hand, large molecules were also shown to
diffuse passively into the nucleus [4].
The NPC is one of the largest macromolecular complexes of the cell. Its size ranges from
around 60 MDa in yeast to around 125 MDa in vertebrates [5]. Early electron tomography
studies already revealed an eight-fold symmetry of the NPCs [6] which was confirmed and
refined in several studies ever since [7, 8, 9, 10]. NPCs can be divided into several structural
subunits. The main channel of the NPC consists of a central framework, which is embedded
in the nuclear envelope. The central channel is bordered by a cytoplasmic and a nuclear ring.
Eight flexible cytoplasmic filaments protrude from the cytoplasmic ring into the cytoplasm. The
nuclear basket, a structure comprised of eight filaments joined with a distal ring, is attached
to the NPC on the nuclear side. This characteristic architecture of the nuclear pore complex
is conserved in yeast, plants and vertebrates [11, 12, 13, 14], however the dimensions of the
NPCs differ across species. NPCs from Dictyostelium discoideum and human were analyzed
by high-resolution cryoelectron tomography [10, 15]. The NPCs from Dictyostelium discoideum
transport-active nuclei were found to be 100 nm in length with an outer diameter lumenal
spoke ring of 125 nm. The inner diameter of the spoke ring was only around 60 nm although
its size is thought to be flexible in presence or absence of transport cargoes. The distal nuclear
ring on the far-nuclear side of the nuclear basket was 40 nm in diameter [10]. In contrast,
the tomographic structure of the human NPC revealed an inner diameter of the nuclear and
cytoplasmic ring of 84 nm and an inner diameter of 41 nm for the spoke ring [15].
1.1.2 The composition of the NPC
Comprehensive proteomic studies in yeast and vertebrates revealed that the massive
macromolecular structure of the NPC is built of only around 30 different proteins, named
nucleoporins (Nups) [11, 14] (figure 1). Although the definite composition is still under debate
due to inconsistent results, attributed to different isolation methods and technical limitations
[11, 14, 16, 17, 18], nucleoporins are thought be be present in multiples of eight, resulting in a
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total amount of around 600 individual nucleoporins per NPC.
Nucleoporins can be classified according to their positions within the NPC. The central channel
was proposed to consist of a series of concentric cylinders. The outer layer of the channel
is built by coat nucleoporins, followed by a layer of adapter nucleoporins. The inner surface
of the channel is layered by so-termed channel nucleoporins [19]. In addition, nuclear basket
nucleoporins can be found on the nuclear side and cytoplasmic filament nucleoporins on the
cytoplasmic face of the NPC. Surprisingly, integrative approaches of structural studies com-
bined with homology modeling have revealed that most nucleoporins consist of only four struc-
tural elements (reviewed in [5]). These elements are α-helical repeats, β-propellers, coiled-coil
domains implicated in protein-protein interaction and intrinsically unstructured phenylalanine-
glycine (FG) repeats [20]. The structural features of nucleoporins are reviewed in [18]. Nu-
cleoporins containing FG-repeats are called FG-nucleoporins. About one third of nucleoporins
belong to this class [21]. FG-repeats were shown to form the permeability barrier of the NPC
and facilitate nuclear transport by interaction with transport receptors [21, 22, 23, 24]. With


















































































Figure 1: Nucleoporins sorted by (A) their position in the nuclear pore complex and (B) size (modified
from [5]).
Immunogold electron microscopy studies mapped the position and mobility of the individual
nucleoporins on the NPC, thereby determining that at least 18 of the nucleoporins are located
symmetrically on the nuclear and cytoplasmic sides of the NPC (reviewed in [14, 26, 27]). In
yeast, Nup42 and Nup159 were found to be exclusively cytoplasmic, whereas Nup1, Nup2 and
Nup60 were localized on the nuclear face of the NPC [28, 29]. In vertebrates, the fiber-like
nucleoporin Tpr is located exclusively on the nuclear side of the NPC and forms the filaments
of the nuclear basket [30]. On the cytoplasmic side, the cytoplasmic ring is formed by the
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asymmetrically located nucleoporins Nup358, Nup214 and Nup88. Aside from these fixed
structural features of the NPC, studies also revealed a mobile portion of nucleoporins. Nup98,
for example, was shown to be part of the nuclear basket and also found on the cytoplasmic
side of the NPC [31]. Furthermore, Nup98 is thought to shuttle between the NPC and "GLFG
nuclear bodies" [32]. Similarly, the N-terminus of Nup153 was mapped to the nuclear ring
and its Zinc-finger domain to the distal ring of the nuclear basket whereas the C-terminal
FG-repeats of Nup153 were found throughout the NPC and even close to the cytoplasmic
face [33]. This could be explained by a study that found FG-repeat domains to be natively
unfolded [34]. Systematic deletion of the FG-repeat domains of 11 Saccharomyces cerevisiae
nucleoporins revealed that up to half of the total FG-repeat mass can be deleted without
significant defects in protein import or the permeability barrier [29].
An extensive list of nucleoporin knock-downs and their effect on the NPC can be found in [32].
Distinct subcomplexes of the NPC have been revealed by mass spectrometry of isolated
nucleoporins [35, 36]. The Nup88-Nup214 complex was identified on the cytoplasmic side [37].
The Nup107-Nup160 complex, which is also termed Y-complex [38] due to its characteristic
Y-shaped structure, can be found at the central spoke ring. It consists of Nup160, Nup133,
Nup107, Nup96, Nup85 and Sec13. It is the major building block of the NPC and is present
in eight copies on each side of the central ring [11, 39, 40, 41, 42, 43, 44]. Recently, the the
crystal structure of the reconstituted yeast Y-complex was solved at a 7.4 Å resolution [45].
The overall composition of the NPC seems to be similar in yeast and vertebrates [9, 13, 46, 47]
and also the structure and function of two thirds of yeast and vertebrate nucleoporins are
at least partially conserved [48]. As the protein sequence homologies between yeast and
vertebrates are sometimes quite low, for example for Nup133 [40], relations of yeast and verte-
brate nucleoporins are mainly based on similar functions, NPC localization and interactions to
other nucleoporins [48]. Furthermore, as the vertebrate NPC has twice the molecular weight
compared to the yeast NPC, the vertebrate NPC probably has also some additional structural
features [48].
The major physiological and best-characterized role of the NPC is the mediation of transport
between the nucleus and the cytoplasm. Moreover, NPCs were also shown to function in gene
expression regulation, chromosome positioning during mitosis, apoptosis and in the secretory
pathway (reviewed in [32]).
1.1.3 The nucleoporin 214 (Nup214)
The nucleoporin 214 (Nup214), also named CAN, is the third largest human nucleoporin and
the one with the largest FG-repeat domain. It is asymmetrically located on the cytoplasmic face
of the NPC in a complex with Nup88 [37, 49]. Depletion of Nup214 or the adjoining Nup358
led to NPCs without cytoplasmic filaments that nevertheless seemed to be largely structurally
and functionally intact [50].
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Nup214 is quite poorly conserved between species. The yeast homologue Nup159 is about
50 kDa smaller with a different secondary structure prediction. Nup159 has an N-terminal
beta-propeller domain followed by a 200 residue region enriched in FG repeats which was
shown to be important for CRM1 binding [35], and a C-terminal coiled-coil domain for interac-
tion with Nup82. The N-terminus of Nup214 is a well structured seven-bladed-beta-propeller
domain [51, 52, 53] (figure 2) that was shown to interact with the DEAD box helicase Ddx19
[23, 51, 53, 54, 55, 56], suggesting a role in the export of mRNA. Interaction of Nup214 with
Nup88 is mediated via predicted coiled-coil domains [54, 57]. The C-terminus is comprised of
a large number of FG-repeats, suggesting that is largely unstructured. The FG-repeat region
is important for the interaction of Nup214 with CRM1 [54, 58]. An alignment of Nup214 and
Nup159 can be found in the appendix (figure S6).
Recently, a conserved FG-repeat motive in Nup214 has been characterized for its importance
in CRM1-binding [59]. This study revealed that several regions in Nup214 are important
for binding to CRM1 which could explain why Nup214 is the nucleoporin with the highest
avidity to CRM1. Binding of CRM1 to Nup214 is increased in the presence of RanGTP [24].
Furthermore, Nup214 was shown to stabilize export complexes consisting of CRM1, RanGTP
and a cargo [60]. The high affinity, RanGTP-dependent interaction as well as the stabilization
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Figure 2: Secondary structure of Nup214. Nup214 has an N-terminal beta-propeller domain
(aa 41-404) and a coiled-coil domain (aa680-1209). The C-terminal region (aa1859-2090) was shown
to interact with CRM1 and contains a large number of FG-repeats, suggesting that it is natively unfolded.
Early studies suggested an interaction of Nup214 with the import receptors importin β [61],
transportin [62] and importin 5 [63], but only its role in nuclear export has been investigated
further. Nup214 was shown to bind the export receptor CRM1 [24, 54, 64, 65] and to function
in the nuclear export of some, but not all CRM1-dependent cargoes. CRM1 cargoes that
show Nup214-dependent nuclear export include NMD3 which is the adapter for export of 60 S
ribosomal subunits [66], the nuclear factor of activated T-cells (NFAT) and HIV-1 Rev [60]. In
addition, Nup214 or its yeast homologue Nup159 were shown to bind several other transport
factors including Dbp5 [55], TAP [23, 67], scMex67p [23] and scGle1 [65].
Even though Nup214 does not affect the export of all CRM1 cargoes, it was shown to be an
essential protein in mice, as Nup214 -/- embryonic stem cells are not viable and embryos die
early in development in utero [68]. Nup214 depletion was shown to lead to cell cycle arrest
and reduced cell growth in vivo and in vitro [68, 60].
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Nup214 is one of four nucleoporins that have been observed as oncogenic fusion proteins after
chromosomal translocations [69] and in fact was first identified as a fusion protein in leuke-
mogenesis [49, 70]. Fusions of Nup214 with the histone chaperone SET [71], the chromatin-
binding protein DEK [72], the tyrosine kinase ABL [73], the membrane transporter XKR3 [74]
and SQSTM1, which functions as an activator of NFκB signaling [75] have been identified in
different kinds of leukemia. Nup214 fusions are used as a diagnostic and therapeutic markers
and are commonly associated with poor prognosis. The role of Nup214 in acute leukemias has
recently been reviewed [76, 77].
1.2 Nuclear transport
1.2.1 Models of nuclear transport
Transport kinetic studies estimated that there are around 1000 translocation events, translo-
cating around 80 MDa through a single NPC per second (reviewed in [78]). Even though much
progress has been made in revealing the structure of the NPC components and subcomplexes
as well as the overall structure, it still remains unclear how the nucleoporins function within
the NPC to mediate nucleocytoplasmic transport [14, 79, 80]. Therefore, different models
of nucleocytoplasmic transport have been proposed in the course of the years, the most
prominent being the virtual gating model [14, 27], the selective phase model or FG-hydrogel
model [81], and the oily-spaghetti model [82], which have been extensively reviewed in
[33, 78, 83, 84]. Models vary mainly in their description of the permeability barrier of the NPC.
In the virtual gating model [14, 27], the permeability barrier is explained by thermodynamic
considerations. The entropy loss that a molecule undergoes when entering the nuclear pore
has to be compensated by a change in enthalpy when it interacts with the molecules within
the pore. Molecules that bind to the FG-Nups lining the channel experience a high change in
enthalpy and can therefore translocate through the pore, whereas molecules that do not bind
to FG-Nups are repulsed due to unfavorable energy changes. In the selective phase model
[81], the interacting FG-repeats from nucleoporins form a three-dimensional sieve. The mesh
of the sieve results in size-dependent retention of proteins. Transport receptors can translocate
through the nuclear pore by interaction with the FG-repeats which leads to a temporary and
localized opening of the mesh.
Even though the molecular mechanisms of translocation are still unclear, it is well understood
that nucleocytoplasmic transport occurs with the help of soluble nuclear transport receptors
(NTRs) [85, 86]. The major transport receptors are members of the importin β superfamily,
also called karyopherins. There are at least 20 karyopherins in human and 14 in yeast [87, 88],
which can roughly be divided into importins or import receptors that mediate nuclear import
and exportins or export receptors that mediate nuclear export. So far, only importin 13, exportin
4 and Msn5 are known to have a bi-directional function in import and export [89, 90, 91]. By
definition, karyopherins can interact with the GTP-binding nuclear protein Ran [92, 93] as well
as their cargoes [94, 95]. The different karyopherins share similar molecular parameters, for
example a molecular weight between 95 and 145 kDa, an acidic isoelectric point, and similar
structural features [78, 87, 96, 97].
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In order to be recognized by transport receptors, most proteins that need to be imported or ex-
ported contain a nuclear localization signal (NLS) or a nuclear export signal (NES), respectively
[78, 88, 97]. Import receptors bind to the NLS of import cargoes and import them through the
nuclear pore complex into the nucleus. For nuclear export, the major export receptor CRM1












imp: importin exp: exportin
















Figure 3: The Ran cycle in nucleocytoplasmic transport. Upon nuclear import of RanGDP by NTF2,
RanGDP is converted to RanGTP by RanGEF. RanGTP and an NES-containing cargo bind coopera-
tively to export receptors. The export complex translocates to the cytoplasm where it dissociates upon
hydrolysis of RanGTP by RanGAP.
Karyopherin-mediated nucleocytoplasmic transport is coupled to a gradient of Ran in its
GTP or GDP-bound state [93, 98] (figure 3). The ratio of nuclear to cytoplasmic RanGTP
was estimated to be between 200 to 1000 in in silico simulations [99] and experimental
studies [100, 101]. RanGTP is constantly depleted from the nucleus in export receptor-cargo
complexes. The Ran efflux rate from the nucleus was shown to exceed 520 molecules per
second per nucleus [99] implicating the need for a tight regulation of the Ran-gradient. The
RanGTP-gradient is established by RanGAP1 in the cytoplasm [102, 103, 104], the Ran gua-
nine nucleotide exchange factor (RanGEF/ RCC1) in the nucleus [105, 106] and the RanGDP
import receptor NTF2 (reviewed by [78]). NTF2 was first identified as a stimulating factor of
NLS-mediated import [107, 108, 109, 110]. Later, NTF2 was shown to bind to the Switch II
region of Ran, a region that has different conformations in its GTP or GDP bound state. NFT2
can therefore discriminate between GDP- and GTP-loaded Ran, leading to exclusive import of
RanGDP [111]. In the nucleus, RanGDP is converted to RanGTP by RanGEF. RanGEF was
found to associate to chromatin with one copy of RanGEF binding to histones H2A and H2B
of one nucleosome [106, 112, 113]. RanGEF does not discriminate between GTP and GDP,
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but only stimulates nucleotide exchange by five orders of magnitude [106]. Conversion from
RanGDP to RanGTP is therefore achieved by the high GTP to GDP ratio in the nucleus.
Importins recognize their cargoes via the NLS in the cytoplasm and translocate through the
NPC into the nucleus [92, 93]. In the nucleus, binding of RanGTP to importins leads to
import cargo release [92, 93] whereas RanGTP binding to exportins leads to cooperative
binding of export cargoes, which are recognized via a nuclear export signal (NES) [94].
Subsequently, the trimeric exportin-RanGTP-cargo export complex is transported through the
NPC into the cytoplasm, where it dissociates upon RanGAP1 (GTPase-activating protein) and
RanBP1/RanBP2-mediated hydrolysis of RanGTP to RanGDP [24].
1.2.2 Nuclear transport receptors
Transport receptors have been extensively studied by X-ray crystallography. The structures
of human and yeast importin β [114, 115], transportin [116], and the exportins CRM1 [117]
and Cse1p [118] indicate that karyopherins consist of tandem "Huntingtin, elongation factor 3
(EF3), protein phosphatase 2A (PP2A), and the P3 kinase TOR1" (HEAT) repeats [119, 120].
HEAT repeats have a length of around 40-60 amino acids and consist of two anti-parallel
helices that are connected by a short linker [119, 120].
The best studied import receptor is importin β, which was crystallized with several cargoes,
adaptors, RanGTP and FG repeat-containing peptides [114, 121, 122, 123, 124, 125]. On the
other hand, CRM1 is the most studied export receptor and will be described in further detail in
section 1.2.3.
Even though the structure of karyopherins is similar, there are distinct differences between
import and export complexes. Import receptors bind either their cargo or RanGTP at the inner
surface of their superhelical structure [115, 121, 126] whereas export receptors bind RanGTP
at the inner surface and their cargo via the NES-binding cleft embedded on the outer surface
[116, 118, 127] (figure 4).
The so-called classical NLS with one or two clusters of basic amino acids was first characterized
in the SV40 Large T antigen and in nucleoplasmin [85].
In general, export receptors recognize their cargo by an NES (reviewed in [78, 97]). The
leucine-rich NES was initially discovered in the HIV-1 Rev protein, a viral adapter that pro-
motes export of unspliced and partially spliced viral mRNA [128] and PKI, an inhibitor of the
catalytic subunit of the cAMP-dependent protein kinase [129], and defined as a conserved motif
with three to four hydrophobic amino acids. Hydrophobic NESs are conserved in all eukaryotes
and are recognized by the also highly conserved major export factor CRM1 [94, 130].
In addition to direct interaction of the NTRs with a NLS or NES containing cargo, nuclear trans-
port can also be mediated via adapter proteins, the most prominent being importin α which
serves as an adapter for importin β [131, 132, 133]. The crystal structure of importin α [134]/
Kap60p [135] revealed that it consists of armadillo (ARM) repeats. ARM repeats were first




Figure 4: Comparison of import and export complexes. (A) Complex of importin β (colored) bound
to the IBB domain of SPN1 (gray) (PDB ID: 2QNA, [126]). (B) Complex of CRM1 (colored) bound to
RanGTP (light gray) and SPN1 (dark gray) (PDB ID: 3GJX, [127]).
helices that consist of about 40 amino acids. The ARM repeats of importin α form a super-
helical structure [134, 137, 138] which creates a shallow concave binding groove and serves
as a binding pocket for the NLS [134, 137]. The extensive contacts between the importin α
ARM repeats and the NLS are mediated though hydrophobic and charge-based interactions
[134, 137, 138, 139]. It was also discovered that the binding of importin α to its cargo can be
disturbed upon phosphorylation of an amino acid close to the NLS [140].
1.2.3 The nuclear export receptor CRM1
The major nuclear export receptor is chromosome region maintenance 1 (CRM1). CRM1
is essential in all organisms tested so far and highly conserved in eukaryotes [141]. CRM1
mediates the export of a large variety of cargoes, most of them via a leucine-rich NES
[94, 130, 142, 143, 144, 145]. CRM1 cargoes include eukaryotic translation initiation and
termination factors [146], the import adaptor snurportin1 (SPN1) [131] or ribonuclear particles
(RNPs) [147, 148].
Initially, CRM1 was identified in cold-sensitive Schizosaccharomyces pombe strains with
deformed chromosomes [149]. The first indication of its role in nuclear transport was its
interaction with the nucleoporin 214 (Nup214) [54, 58].
The most prominent inhibitor of CRM1 is leptomycin B (LMB) which was isolated from
Streptomyces sp. [150, 151, 152] and covalently modifies cysteine 528 of human CRM1 within
the NES cleft thereby inhibiting cargo binding [153, 154]. Later on, a group of inhibitors called
Ratjadones were also shown to work via the same mechanism [155]. Crystal structures of
CRM1 bound to LMB, Anguinomycin A or Ratjadone A later confirmed their mechanism of
inhibition [156].
Early on, CRM1 was implicated in the replication cycle of the human immunodefi-
ciency virus (HIV) as it interacts with the HIV-1 protein Rev. Recently, CRM1 also
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gained importance as a target in cancer therapy, as it was shown to interact with
several (proto-) oncogenes like p53, Rb, BRCA1, p21/CIP, p27/KIP1 and cyclin D1
[157, 158, 159, 160, 161], implicating a role in breast cancer, pancreatic cancer, leukemia
and lymphoma [157, 162, 163, 164, 165, 166, 167, 168, 169]. Medical research focuses on
inhibitors that target the NES binding cleft on CRM1 (reviewed in [170]).
CRM1 has been extensively studied by crystallography, yielding more than 30 crystal struc-
tures of CRM1, either alone or bound to other factors, in the Protein Data Bank (PDB).
CRM1 consists of 21 HEAT repeats that form a superhelical structure. The N-terminal
CRIME (CRM1-importin β etc.) domain [54, 171] is the most conserved region between the
karyopherins and is necessary for the binding of RanGTP [116, 121]. CRM1 was captured in
several different states of its transport cycle. There are structures of free CRM1 [172, 173],
CRM1 bound to the cargo SPN1 [174], CRM1 bound to RanGTP [175], CRM1 bound to
RanGTP and the export complex assembly factor RanBP3 [176], the CRM1-RanGTP-SPN1
export complex [127] and CRM1 bound to RanGTP and the export complex dissociation factor
RanBP1 [156, 177]. An extensive list of all crystal structures containing CRM1 can be found in
[170]. Furthermore, CRM1 has also been studied by electron microscopy, small angle X-ray
scattering and molecular dynamics simulations [172, 173, 178, 179].
All available structural information leads to the conclusion that CRM1 is a highly dynamic
protein that undergoes major conformational changes throughout its transport cycle. The
structural features most involved in these conformational changes are the acidic loop within
HEAT repeat 9, the NES binding cleft located between the A-helices of HEAT repeats 11 and
12, and the HEAT repeat 21 at the C-terminus.
The acidic loop, also termed HEAT9 loop, is a 26 residue-loop that protrudes from the two
helices of HEAT repeat 9 and forms a β-hairpin. Structure of CRM1 bound to a cargo
show the acidic loop spanning across the ring of the CRM1 molecule and interacting on the
opposite side of the toroid with the HEAT repeats 14 and 15. The acidic loop thereby acts
as a diagonal brace, stabilizing the binding of RanGTP as well as keeping the NES binding
cleft in an open conformation [127]. On the other hand, crystal structures of free CRM1 or
CRM1 bound to RanGTP and export complex dissociation factor RanBP1 have the acidic loop
folded backwards onto the inner surface of HEAT repeats 11 and 12, coinciding with a closed
conformation of the NES binding cleft [172, 177].
HEAT repeat 21 is at the C-terminus of the CRM1 molecule. In all CRM1 crystal structures, the
helix B of HEAT21 is either positioned in a stack with the other HEAT repeats (see e.g. [127])
or folded away from the stack, spanning across the ring of the CRM1 molecule and interacting
with the inner surface of the CRM1 molecule at the rear side of the NES binding cleft (see e.g.
[172, 174]).
Unbound CRM1 seems to be flexible to adapt several conformations, with a preference for an
acidic loop that is folded backwards and a ring-spanning HEAT21 helix [172].
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Although the dynamics of CRM1 have been extensively studied with crystallography, there are
no crystal structures available with CRM1 bound to any nucleoporin.
1.3 Interaction of transport receptors with the NPC
1.3.1 Karyopherins interact with FG-repeat domains on nucleoporins
All current transport models are based on transient interactions of karyopherins with FG-repeat
domains of nucleoporins. Nucleoporins contain multiple FG-repeats which are clustered into
a single FG-repeat domain in most of the nucleoporins. Nevertheless, it has been shown for
the yeast nucleoporin Nup116p that it could in principle bind two transport factors, the mRNA
export factor Mex67p and importin β homologue Kap95p, with distinct regions at the same
time [180, 181]. Of the 33 Nup116 FG-repeats, Mex67p associates with the first 12 repeats,
whereas Kap95p in interacts with the last 12 repeats [181]. Correlating to the large number
of FG-repeats in the nucleoporins, it is not surprising that transport receptors might contain
multiple nucleoporin binding sites [182]. For importin β it has been shown that it can bind to
nucleoporins with the N-terminal region (between HEAT repeats 4 - 9) [183, 184, 185] as well
as with a later identified region in the C-terminal part [84]. Furthermore, available structures
confirm that also TAP [186], exportin-t [187] and nuclear transport factor 2 (NTF2) [188] contain
at least two phenylalanine binding sites and Mtr2p even was shown to have three nucleoporin
binding regions [180]. Computational models suggest that transport receptors bind multiple
FGs at the same time [189, 190]. Interaction of importin β with the NPC seems to involve
Nup358 [191, 192, 193], the Nup62 complex [194] and Nup153 [195, 196]. An extensive list of
observed interactions between karyopherins and nucleoporins can be found in [21].
It has been suggested that weak interactions of transport receptors with the nucleoporins are
used to concentrate the transport receptors and other transport factors as well as cargoes
independently at the periphery of the NPC and therefore promote cargo-receptor complex for-
mation. This has been shown for the cargo-free Xpo-t binding to Nup214 [187] and the yeast
Kap60p binding to Nup2p [197]. Also the import adapter Snurportin 1 (SPN1) associates with
U snRNPs directly at Nup214 [198]. Similarly, importin α/β cargoes DBC-1 and DMAP-1 bind
independent of transport receptors at Nup358 [199]. The binding of RanGAP to Nup358 was
shown to be important for nuclear import [200, 201].
1.3.2 Available structures of transport factors with FG-repeats
The interaction of transport receptors and adapters with nucleoporins has been the subject
of many studies. Structural approaches to elucidate the interaction on a molecular level are
complicated by the fact that FG-repeat containing regions are natively unfolded [34]. All
available structures in the PDB of transport receptors or adapters in complex with nucleoporin
fragments or nucleoporin-derived peptides are summarized in table 1.
Of the 14 structures, 5 structures show an interaction that is not FG-mediated. This is the case
for structures containing human and yeast importin α bound either to an Nup2p N-terminal
fragment or to Nup50 as well as a structure of Kap121p bound to Nup53p [135, 197, 202, 203].
Four of the structures show an overlap of the nucleoporin interaction surface with the NLS
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binding site, which could lead to a destabilization of NLS binding by nucleoporins (PDB
IDs: 1UNO, 2C1T, 2C1M, 3W3Y), two of them show an interaction of the nucleoporin at the
C-terminus of the transport factor (PDB IDs: 3TJ3, 3W3Y).
Interactions of transport factors with FG-repeats have been characterized in complexes
containing fragments of importin β, NTF2, p15-TAP, the UBA domains of TAP and Mex67 as
well as for Xpo1p. Two structures are available that show the interaction of synthetic FXFG
peptides with the UBA domains of Tap (PDB ID: 1OAI) [204] and Mex67 (PDB ID: 2KHH)
[205]. First indications of the binding mode between transport receptors and FG-containing
nucleoporins came from a crystal structure of an N-terminal fragment of importin β bound
to a synthetic peptide containing five FxFG nucleoporin repeats from Nsp1p (PDB ID: 1F59)
[122]. Even though a 112-residue fragment of Nsp1p had been used for crystallization, only
two short regions of 8 and 13 residues could be observed in the structure. Of those only 4
and 10 residues, respectively, could actually be assigned. Both fragments each contain two
phenylalanine residues. The structure revealed two FG binding sites on the outer convex
surface of importin β. Binding of phenylalanine residues occurs in hydrophobic pockets which
are formed between HEAT repeats 5 and 6 as well as 6 and 7 of importin β. These interaction
sites could be verified by another crystal structure of the same fragments (PDB ID: 1O6O)
[206] as well as by structures containing the same importin β fragment with a synthetic GLFG
peptide (PDB ID: 1O6P) [206] and yeast importin β in complex with a 39 residue fragment of
yeast Nup1p (PDB ID: 2BPT) [207]. Moreover, the latter structure also contained an additional
binding site of a third phenylalanine residue between HEAT repeats 7 and 8 of yeast importin
β.
The export factor TAP-p15 does not contain HEAT- or ARM-repeats, but nevertheless was
shown to bind the FG-containing nucleoporins Nup214 as well as Nup98 [208]. A TAP-p15
fragment was crystallized with a Nup214-derived peptide containing one FG repeat (PDB ID:
1JN5) [209]. The binding of the phenylalanine residue of the Nup214-peptide to a hydrophobic
pocket on TAP was comparable to the binding the Nsp1p fragment to importin β [122].
Two FG-binding sites were also identified in a structure of a NTF2-dimer, each binding a
phenylalanine residue from a synthetic FXFG peptide (PDB ID: 1GYB) [210]. Only recently, a
structure of the yeast homologue of CRM1, Xpo1p, has been published in complex with the
RanBP3 homologue Yrb2p. The structure revealed two FG-binding regions on Xpo1p, each
binding three phenylalanine residues of Yrb2p (PDB ID: 3WYF) [176].
The available crystal structures of transport receptors with FG-repeat containing fragments
indicate that there are multiple possible interaction sites between phenylalanine side chains
from individual nucleoporins and hydrophobic pockets on the respective transport receptors.
However, no structures of transport receptors with a larger FG-repeat containing fragment are
available so far. Deciphering the molecular interactions of transport receptors and nucleoporins
could help to understand how transport complexes translocate through the nuclear pore - if they
immerse into the sieve-like structure as suggested in the selective phase model or if they transit
from one to the next FG-Nup through the channel as suggested in the virtual gating model.
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Table 1: Overview of structures of transport factors with FG-repeats.
PBD ID Proteins Resolution
[Å]
Reference
1F59 Hs importin β(1-442) bound to Sc FXFG repeats 2.80 [122]
1O6P Hs importin β(1-442) bound to a synthetic GLFG peptide 2.80 [206]
1O6O Hs importin β(1-442) bound to Sc Nsp1p 2.80 [206]
2BPT Sc importin β bound to Sc Nup1p 1.99 [207]
1GYB Sc NTF2(N77Y mutant) bound to synthetic FXFG
peptide
1.90 [210]
3W3Y Sc Kap121p bound to Sc Nup53p 2.80 [203]
2KHH Sc Mex67 UBA domain bound to synthetic FXFG peptide NMR [205]
1JN5 Hs p15 and Hs TAP bound to Hs Nup214 peptide with 1
FG repeat (aa1810-1815)
1.90 [209]
1OAI Hs Tap UBA domain bound to synthetic FXFG peptide 1.00 [204]
3WYF Sc Xpo1p - Sc Yrb2p - Sc Gsp1p-GTP complex 2.22 [176]
1UN0 Sc importin α bound to Nup2p N-terminal fragment 2.60 [197]
2C1T Sc importin α bound to Sc Nup2 2.60 [135]
2C1M Mm importin α bound to Mm Nup50 2.20 [135]
3TJ3 Hs importin α bound to Hs Nup50 N-terminal fragment 2.70 [202]
Sc: S. cerevisiae, Hs: H. sapiens, Mm: M. musculus
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1.4 Aim of this Work
To understand nucleocytoplasmic transport at a molecular level, it is necessary not only to
determine the NPC structure at an atomic resolution [5], but also to capture the molecular
interaction of transport complexes with components of the NPC. Available crystal structures of
karyopherins bound to FG-containing peptides only show binding of individual phenylalanines.
There is no structure available that shows binding of a larger fragment of FG-Nups to a
transport receptor.
The interaction of the major export receptor CRM1 with the cytoplasmic Nup214 was chosen
as an example to address this issue. Nup214 is the third largest nucleoporin in humans and
contains the largest FG-repeat domain of all FG-nucleoporins. The CRM1-interacting region
was initially mapped to the C-terminus of Nup214 [54, 58] and later refined to several regions
within the C-terminus [59]. On the other hand, the nucleoporin-interacting region on CRM1 is
totally unclear. Due to its characteristic structure, the identification of the Nup214-binding sites
on CRM1 with common biochemical approaches like the analysis of truncated fragments would
likely be inconclusive as truncations might not only affect binding to Nups, but also the cooper-
ative binding of RanGTP and NES-cargo. The Nup214-binding sites on CRM1 should therefore
be identified by structural approaches. Although crystal structures of importins with FG-repeat
containing peptides in conjunction with the high structural conservation between importin β
and CRM1 within the N-terminal HEAT-repeats suggests that FG-repeats might bind to a sim-
ilar region on the outer surface of CRM1, there is no experimental evidence for this assumption.
The aim of this work was therefore to identify the interacting regions of Nup214 and CRM1
with structural approaches using electron microscopy, cross-linking mass spectrometry and
X-ray crystallography. Furthermore, identified interaction sites should be verified and charac-
terized by biochemical and cellular assays. The gained insight in the interaction principles of
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Chimera 1.8 UCSF/NIH
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2.1.2 Technical Equipment
Table 3: Technical equipment.
Equipment Company
ÄKTA column HiLoad 26/60 Superdex 200 prep grade GE Healthcare
ÄKTA column HiLoad 26/60 Superdex 75 prep grade GE Healthcare
ÄKTA column HiPrep 26/10 Desalting (Sephadex G-25) GE Healthcare
ÄKTA column MonoQ GE Healthcare
ÄKTA column Superdex 200 10/300 GL GE Healthcare
ÄKTA column Superdex 75 10/300 GL GE Healthcare
ÄKTApurifier Amersham Biosciences
Autoclave Sterilizer DX-200 Systec
BioPhotometer Eppendorf
CASY 1 Schärfe System
Cell culture hood Herasafe™ KS ThermoScientific
Cell culture incubator Heracell™ 150i ThermoScientific
Centrifuge 5415R Eppendorf
Centrifuge 5424 Eppendorf
Centrifuge Allegra® X-15R with rotor SX4750 Beckman Coulter
Centrifuge Avanti™ J-30I with rotor JA30.50Ti Beckman Coulter
Centrifuge J6-MI with rotor TY-JS 4.2 Beckman Coulter
Confocal microscope LSM 510 meta Zeiss
Developer machine CURIX60 Agfa
Documentation system GelSTICK "touch" INTAS Science Imaging Instruments
Documentation system LAS-3000 Fujifilm





FACSCanto™ II BD Biosciences
Fluorescence microscope Axioskop 2 Zeiss
Incubator Heraeus function line Heraeus
Incubator Shaker INNOVA 4430 New Brunswick Scientific
Mini Trans-Blot® Cell Bio-Rad
Odyssey® Sa Infrared Imaging System LI-COR
SE250 Mighty Small II Mini Vertical Electrophoresis Unit Hoefer
Spectrophotometer NanoDrop 2000c ThermoScientific
Thermocycler FlexCycler2 Analytik Jena AG




Ultracentrifuge Optima™ MAX-XP with rotors TLA100.3,
TLA120.1
Beckman Coulter
UV cross linker with Ultratech 400 W halogen metal vapor lamp
and a B270 glass screen
Osram/ Schott
Vortexer MS2 Minishaker IKA
Waterbath with Bath Circulator LAUDA A100 Thermal Exchange
Western blot incubation boxes LI-COR




5ml Polystyrene Round-Bottom Tubes BD Biosciences
Amersham Hybond ECL Nitrocellulose Blotting
Membrane
GE Healthcare
Amersham Hyperfilm™ ECL GE Healthcare
Amersham Protran 0.45 µm NC Nitrocellulose Blotting
Membrane
GE Healthcare
Amicon ® Ultra Centrifugal Filters, Ultracel ® Millipore
Cell culture consumables Sarstedt, Nalge Nunc International, greiner bio-one
Cell culture plastic ware Sarstedt, greiner bio-one
Diagnostic Microscope Slides, 10 wells Erie Scientific Company
DNA Pick-Tips Süd-Laborbedarf GmbH
Medix XBU medical x-ray film FOMA Bohemia
Microscope cover slips (12 mm Ø) Marienfeld
Microscope slides (76x26 mm) Glaswarenfabrik Karl Hecht GmbH & Co KG
Minisart RC 15, single use syringe filters
(0.45 µm, 0.20 µm)
sartorius stedim biotech
Minisart single use filter units (0.45 µm) sartorius stedim biotech
Novex® 10-20% Tricine Protein Gels life technologies
NuPAGE® Novex® 4-12% Bis-Tris Protein Gels life technologies
Parafilm "M" Bemis Company, Inc.
pH indicator strips Machery-Nagel




Spin-XR, PES membrane Corning
Syringes and needles Braun, servoprax




CloneJET PCR Cloning Kit ThermoScientific
NucleoBond™ Xtra Midi Macherey-Nagel
NucleoSpin® Gel and PCR Clean-up Macherey-Nagel
NucleoSpin® Plasmid Macherey-Nagel
Pierce® BCA Protein Assay Kit ThermoScientific
Pierce® Silver Stain Kit ThermoScientific
SilverQuest™ Staining Kit invitrogen
2.1.5 Chemicals, Reagents, Enzymes
All standard chemicals and solvents used for this work were obtained from AppliChem
GmbH (Darmstadt), Carl Roth GmbH + Co. KG (Karslruhe), Serva Electrophoresis GmbH
(Heidelberg), Sigma-Aldrich (Taufkirchen) or Merck (Darmstadt).
Table 6: Chemicals and Reagents.
Reagent Company
β-Mercaptoethanol Roth
Acrylamide 4K Solution (30%) AppliChem
Adenosine 5’-triphosphate disodium salt hydrate (A3377) Sigma-Aldrich
Advanced protein assay reagent 5x Cytoskeleton Inc.
Amersham Cy3™ Mono-Reactive Dye Pack GE Healthcare
Amylose Resin High Flow New England BioLabs
Bio-Rad Protein Assay dye reagent concentrate Bio-Rad Laboratories GmbH
Bovine Serum Albumin (BSA) (20 mg/ml) ThermoScientific




Cyanogen bromide-activated Sepharose 4B Sigma-Aldrich
Dako Fluorescent Mounting Medium Dako
dNTP Set, 100 mM Solutions ThermoScientific
FBS Superior Biochrom
FluorSave Reagent Millipore
Formaldehyde solution min. 37% Millipore
Gelatin from cold water fish Sigma-Aldrich
GeneRuler 100bp DNA Ladder ThermoScientific




Gibco® DMEM (1x) life technologies
Gibco® Opti-MEM® (1x) life technologies
Gibco® Penicillin Streptomycin (Pen Strep) life technologies
Glutathione Sepharose 4 Fast Flow GE Healthcare
Glutathione Sepharose High Performance GE Healthcare
Guanosine 5’-diphosphate sodium salt (G7127) Sigma-Aldrich
Guanosine 5’-triphosphate sodium salt hydrate (51120) Sigma-Aldrich
HistoGel Linaris Biologische Produkte GmbH
Immobilon™ Western Chemiluminescent HRP Substrate Millipore
IPTG ThermoScientific
L-Glutamine 200 mM Gibco (life technologies)
Lectin from Triticum vulgaris Sigma-Aldrich
Lectin from Triticum vulgaris-Agarose Sigma-Aldrich
Leptomycin B Enzo Life Sciences




Novex® Tricine SDS Running Buffer (10X) life technologies
NuPAGE® MES SDS Running Buffer (20x) life technologies
NuPAGE® MOPS SDS Running Buffer (20x) life technologies
NuPAGE® LDS Sample Buffer (4x) life technologies
Oligofectamine™ Reagent life technologies
Oligonucleotides Sigma-Aldrich
ortho-Phosphoric acid 85% p.A. AppliChem
PageRuler Plus Prestained Protein Ladder ThermoScientific
PageRuler Prestained Protein Ladder ThermoScientific
PageRuler Unstained Protein Ladder ThermoScientific
Poly-L-lysine solution 0.1% (w/v) Sigma-Aldrich
Protein A-Agarose Roche
SERVA DNA Stain Clear G SERVA
Spectra Multicolor Low Range Protein Ladder ThermoScientific
Streptavidin HRP BD Pharmingen
TALON® Metal Affinity Resin Takara Bio Company
Trichostatin A (T8552) Sigma-Aldrich
Table 7: Enzymes.
Enzyme Company
Creatine phosphokinase, Rabbit Skeletal Muscle CALBIOCHEM
DNAseI AppliChem
Pfu Ultra II polymerase Agilent
Phusion High-Fidelity DNA Polymerase ThermoScientific
Restriction enzymes ThermoScientific
T4 DNA ligase ThermoScientific
Gibco® Trypsin/ EDTA 0.25% (1x) life technologies
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2.1.6 Buffers, Stock solutions, Media
Table 8: Buffers and Solutions.
Buffer Composition
Coomassie destaining solution 10% acetic acid
Coomassie fixing solution 40% ethanol, 10% acetic acid
Coomassie staining 5% aluminum sulfate-(14-18)-hydrate, 10% ethanol, 2%
ortho-phosphoric acid, 0.02% CBB-G250
CRM1 desalting buffer 50 mM HEPES pH 7.5, 50 mM NaCl, 2 mM Mg(OAc)2, 2 mM DTT
CRM1 high salt buffer 50 mM HEPES pH 7.5, 500 mM NaCl, 2 mM Mg(OAc)2, 2 mM DTT
CRM1 prep buffer 50 mM HEPES pH 7.5, 500 mM NaCl, 2 mM MgCl2, 20 mM
β-mercaptoethanol, 100 µM PMSF, 1 µg/ml of each AP and LP
DNA loading buffer (6x) 0.2% bromophenol blue, 0.2% xylene cyanole, 60% glycerol, 60 mM
EDTA
Export complex buffer 20 mM Tris pH 7.4, 50 mM NaCl, 1 mM Mg(OAc)2, 2 mM DTT
EM buffer 20 mM HEPES pH 7.4, 50 mM NaCl, 1 mM Mg(OAc)2, 1 mM DTT
GST prep buffer 50 mM Tris pH 6.8, 300 mM NaCl, 1 mM MgCl2, 0.25 mM EDTA, 1 mM
DTT, 1 µg/ml of each AP and LP
Halo mix (4x) 500 mM NaCl, 40 mg/ml BSA, 1 mM DTT, 2% 1,6-hexanediole
HBS (2x) buffer 50 mM HEPES, 250 mM NaCl, 1.5 mM Na2HPO4, pH 6.98
His prep buffer 50 mM Tris pH 6.8, 200 mM NaCl, 1 mM MgCl2, 10% glycerol, 4 mM
β-mercaptoethanol, 100 µM PMSF, 1 µg/ml of each AP and LP
Laemmli running buffer (10x) 250 mM Tris, 1.92 M glycine, 0.5% SDS
Nup214 complex buffer 20 mM Tris pH7.4, 50 mM NaCl, 1 mM Mg(OAc)2, 2% sucrose, 1 mM
DTT
PBS (10x) 1.37 M NaCl, 27 mM KCl, 100 mM Na2HPO4, 18 mM KH2PO4, pH 7.5
PBST 1x PBS + 0.1% Tween-20
PonceauS staining solution 0.5% PonceauS in 1% acetic acid
Pulldown buffer 50 mM Tris pH 7.4, 200 mM NaCl, 1 mM MgCl2, 5% glycerol, 1 mM
DTT
Ran prep buffer 50 mM HEPES pH 8.0, 500 mM NaCl, 5 mM MgCl2, 100 µM PMSF, 1
µg/ml of each AP and LP
SDS sample buffer (4x) 125 mM Tris pH 6.8, 4% SDS, 0.02% Bromophenol blue, 10% glycerol
Silver staining - fixing solution 50% methanol, 10% acetic acid, 100 mM ammonium acetate
Silver staining - sensitizing solution 0.005% sodium thiosulfate
Silver staining - staining solution 0.1% silver nitrate
Silver staining - developing solution 0.037% formaldehyde, 2% sodium carbonate
Silver staining - stopping solution 50 mM EDTA
TAE buffer (50x) 2 M Tris, 0.05 M EDTA, 5.71% acetic acid
TFB-I 30 mM potassium acetate, 10 mM CaCl2, 50 mM MnCl2, 100 mM
RbCl, 15% glycerol
TFB-II 100 mM MOPS, 75 mM CaCl2, 10 mM RbCl, 15% glycerol
Transport buffer (10x) 200 mM HEPES, 1.1 M KOAc, 20 mM Mg(OAc)2, 10 mM EGTA, pH 7.3
Western blot transfer buffer (10x) 250 mM Tris, 1.93 M glycine, 0.2% SDS
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Table 9: Stock solutions.
Stock solution Composition
1,4-Dithiothreitol (DTT) 1 M in H2O
Ammonium persulfate (APS) 10% APS (Sigma) in H2O
Ampicillin 100 mg/ml in H2O
Aprotinin 1 mg/ml in 20 mM HEPES pH 7.4
Adenosine triphosphate (ATP) 100 mM ATP in 100 mM Mg(OAc)2, 20 mM HEPES (pH 7.4)
Chloramphenicol 30 mg/ml
Creatine phosphokinase 2000 U/ml in 50% glycerol, 20 mM HEPES pH 7.4
Creatine Phosphate 80 mg/ml in H2O
Dexamethasone 2.5 mM in EtOH
digitonin 10% (w/v) in DMSO
Hoechst 33258 10 mg/ml
Ionomycin 1 mM in DMSO
Isopropyl β-D-1-thiogalactopyranoside
(IPTG)
1 M in H2O
Kanamycin 60 mg/ml in H2O
Leupeptin/Pepstatin 1 mg/ml each, in DMSO
Phenylmethylsulfonyl fluoride (PMSF) 100 mM in 2-propanol
Trichostatin A (TSA) 1 mM in EtOH
Lectin (WGA) 2 mg/ml
Table 10: Bacterial media.
Medium Composition
2YT 1.6% (w/v) tryptone, 1% (w/v) yeast extract, 0.5% (w/v) NaCl, pH 7.0
LB 1% (w/v) bacto-tryptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl, pH 7.0
LB agar plates LB supplemented with 1.5% (w/v) bacto-agar
MBP rich medium 1% (w/v) tryptone, 0.5% (w/v) yeast extract, 0.5% (w/v) NaCl, 0.2% (w/v) glucose
SOC 2% (w/v) tryptone, 0.5% (w/v) yeast extract, 10 mM NaCl, 2.5 mM KaCl, 10 mM
MgCl2, 10 mM MgSO4, 0.36% (w/v) glucose, pH 7.0
2.1.7 Cell lines
Table 11: Cell lines.
Cell line Specification Origin
HeLa P4 adherent human cervix carcinoma cells that express CD4 [211]
HeLa NFAT spinner HeLa cells that are stably transfected with a vector coding for the




2.1.8 E. coli strains
Table 12: E. coli strains.
E. coli strain Specification & Genotype
DH5α F- Φ80lacZ∆M15 ∆(lacZYA-argF) U169 recA1 endA1 hsdR17 (rK-, mK+) phoA
supE44 λ- thi-1 gyrA96 relA1
XL10-Gold endA1 glnV44 recA1 thi-1 gyrA96 relA1 lac Hte ∆(mcrA)183
∆(mcrCB-hsdSMR-mrr)173 tetR F’[proAB lacIqZ∆M15 Tn10(TetR Amy CmR)]
JM109 endA1 glnV44 thi-1 relA1 gyrA96 recA1 mcrB+ ∆(lac-proAB) e14- [F’ traD36 proAB+
lacIq lacZ∆M15] hsdR17(rK- mK+)
BL21 (DE3) codon+ F- ompT hsdS(rB- mB-) dcm+ Tetr gal λ (DE3) endA Hte [argU proL Camr]
LEMO21 (DE3) fhuA2 [lon] ompT gal (λDE3) [dcm] ∆hsdS/ pLemo(CamR)
TG1 F’ [traD36 proAB+ lacIq lacZ∆M15]supE thi-1 ∆(lac-proAB) ∆(mcrB-hsdSM)5, (rK-
mK-)
M15 F-, Φ80∆lacM15, thi, lac-, mtl-, recA+ , KmR Phenotype: NaI[s] Str[s] Rif[s] Thi[-]
lac[-] Ara[+] Gal[+] Mtl[-] F[-] RecA[+] Uvr[+] Lon[+]
SG13009 Phenotype: NaI[s] Str[s] Rif[s] Thi[-] lac[-] Ara[+] Gal[+] Mtl[-] F[-] RecA[+] Uvr[+]
Lon[+]
2.1.9 Antibodies
Table 13: Primary antibodies.
Name Species Origin Application Dilution Number
α-CRM1 goat [59] IF/ WB 1:1000 Ab004
α-GST goat Amersham IF/ WB 1:1000/ 1:2000 Ab127
α-HA rabbit Sigma IF 1:500 Ab134
α-HA mouse Convance IF/ WB 1:1000 Ab186
α-His mouse Qiagen WB 1:1000 Ab140
α-Nup214 rabbit Covalab WB 1:1000 Ab204
α-Nup214 rabbit Covalab WB 1:1000 Ab205
α-Nup214 rabbit Genosphere Biotechnologies WB 1:5000 Ab206
α-Nup214 rabbit Genosphere Biotechnologies IF/ WB 1:1000/ 1:5000 Ab207
α-Nup214 "D" rabbit against CASSSFGEQKPTGT IF/ WB 1:200 Ab038
α-Nup214 "F" rabbit R. Kehlenbach IF/ WB 1:200/ 1:500 Ab039
α-Ran mouse BD 1:2000 1:5000 Ab051
α-RanBP3 mouse BD IF/ WB 1:2000/ 1:2500 Ab059
α-Rev #7 mouse J. Hauber, Hamburg IF/ WB 1:1000 Ab176
α-SPN1 rabbit ProteinTech WB 1:1000 Ab065
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Table 14: Secondary antibodies.
Name Species Origin Application Dilution
α-mouse HRP goat Jackson ImmunoResearch WB 1:10000
α-rabbit HRP goat Jackson ImmunoResearch WB 1:10000
α-goat HRP donkey Jackson ImmunoResearch WB 1:10000
α-mouse 680 donkey LI-COR WB 1:10000
α-mouse 800 donkey LI-COR WB 1:10000
α-rabbit 680 donkey LI-COR WB 1:10000
α-rabbit 800 donkey LI-COR WB 1:10000
α-goat 680 donkey LI-COR WB 1:10000
α-goat 800 donkey LI-COR WB 1:10000
α-goat 488 donkey Molecular Probes IF 1:1000
α-goat 594 donkey Molecular Probes IF 1:1000
α-mouse 488 donkey Molecular Probes IF 1:1000
α-mouse 594 donkey Molecular Probes IF 1:1000
α-mouse 647 donkey Molecular Probes IF 1:1000
α-rabbit 488 donkey Molecular Probes IF 1:1000
α-rabbit 594 donkey Molecular Probes IF 1:1000
α-rabbit 647 donkey Molecular Probes IF 1:1000
2.1.10 Oligonucleotides
All oligonucleotides were obtained from Sigma-Aldrich either lyophilized or as a 100 µM
solution at a synthesis scale of 0.025 µmol and the purification grade "desalted".
Oligonucleotides for cloning
Recognition sites for restriction enzymes were inserted at the 5’ end of the oligonucleotides
according to the respective cloning strategy. A 3-6 bp tail at the 5’ end was added to en-
sure cleavage efficiency of the respective restriction enzymes as specified by the manufacturer
(ThermoScientific). Commonly, primers for cloning were designed to have an initial melting
temperature of 57-59 °C.
Table 15: Oligonucleotides for cloning. Capital letters highlight the recognition sites for restriction
enzymes.
Number Name Sequence (5’→ 3’)
G117 Nup214 F NcoI aaCCATGGgtggaatagtctttggccagc
G118 Nup214 R KpnI gaGGTACCttatcagcttcgccagccacc
G864 Nup214 1990 SalI R tttGTCGACttaccctccaaacccaggggat
G865 Nup214 a1 1968 EcoRI F tttGAATTCtaggtggtagtggtgcagcac
G866 Nup214 a1 1990 SalI R tttGTCGACttaaccacctgaacccggagaac
G867 Nup214 a1 2033 SalI R tttGTCGACttaggtggtattactgctgctaccaaa
G897 Nup214 1859 a1 EcoR F tttGAATTCggtattgtttttggtcagcagagc







Number Name Sequence (5’→ 3’)
G954 GST-214 1991 Na EcoRI F tttGAATTCtagttccggcaagcggtagc
G955 GST-214 2090 N SalI R tttGTCGACgctacgccaaccaccaaaacc
G956 GST-214 1991 C EcoRI F tttGAATTCtagttccggcatttggtagcgc
G957 GST214 2090 Ca SalI R tttGTCGACgctacgccaaccaccgcta
G958 His214a4 1859 EcoRI F tttGAATTCggtattgttagcggtcagcag
G959 His214a4 2090 SalI R tttGTCGACggctacgccaaccaccgct
G970 GST-214 2090 N SalI R Stop tttGTCGACttagctacgccaaccaccaaaacc








G989 Nup214 1859 a1N EcoRI F tttGAATTCtagctattgtttttggtcagcagagc
G990 Nup214 2090 a1N SalI R tttGTCGACttagctacgccaaccaccaaagc
G991 Nup214 2090 a1A SalI R tttGTCGACttagctacgccaaccacctgaac
G992 Nup214 1859 all EcoRI F tttGAATTCtaggtattgttagcggtcagcaga
G993 Nup214 2090 all SalI R tttGTCGACttagctacgccaaccaccgct
G994 Nup214 2090 WT SalI R tttGTCGACttagcttcgccagccaccaaaac
G1006 GST214 1993 SalIR tttGTCGACttatgctggcacccctccaaac
G1007 GST214 1999 SalIR tttGTCGACttaggctggggctgaaccgaa
G1008 RFP214 1993 SalIR tttGTCGACtgctggcacccctccaaac






































Oligonucleotides were used for site-directed mutagenesis as well as for insertion of additional
amino acids. Primers for site-directed mutagenesis were designed with the mutated bases in
the middle flanked by 15-20 pairing bases on each side and usually not more than three amino
acids changed at a time. Codons were chosen that needed the least amount of changed bases.
Table 16: Oligonucleotides for mutagenesis. Capital letters highlight the mutated or inserted codons.










































































































































For sequencing of plasmids at GATC Biotech, standard primers from GATC were chosen via
the PrimerScout tool on the GATC website (http://www.gatc-biotech.com/). For sequencing
of pmRFP-cNLS plasmids or CRM1 mutants, the respective primers (10 µM) were sent with the
sample.
Table 17: Oligonucleotides for sequencing.






























Synthesized genes were purchased either cloned into a pEX-A vector or as DNA fragment.
The sequences of the synthesized genes can be found in the appendix (A) .
Table 18: Synthesized Genes.
Name Type Company
NdeI-Nup214K1942C-XhoI cloned in pEX-A eurofins
NdeI-Nup214K1966C-XhoI cloned in pEX-A eurofins




NdeI-Nup214(1916-2033)KA-XhoI cloned in pEX-A eurofins
EcoRI-Nup214(1859-2090)KA-SalI cloned in pEX-A eurofins
EcoRI-Nup214(1859-2090)KAa1-SalI cloned in pEX-A eurofins
EcoRI-Nup214(1859-2090)KE-SalI cloned in pEX-A eurofins
EcoRI-Nup214(1859-2090)a1(5SGs)-SalI cloned in pEX-A eurofins
EcoRI-Nup214(1916-2033)a1(4SGs)-SalI cloned in pEX-A eurofins
SacI-CRM1_K680Q_A731Q-MssI GeneArt Strings™ DNA Fragment life technologies
SacI-CRM1_K680Q_A731Q_L679R-MssI GeneArt Strings™ DNA Fragment life technologies
SacI-CRM1_K680Q_A731Q_C723M-MssI GeneArt Strings™ DNA Fragment life technologies
SalI-CRM1_I102W_F149W-SacI GeneArt Strings™ DNA Fragment life technologies
SalI-CRM1_I102W_N167R-SacI GeneArt Strings™ DNA Fragment life technologies
SalI-CRM1_I102W_D152F-SacI GeneArt Strings™ DNA Fragment life technologies
EcoRI-Nup214(aa1859-2090)-SalI_mutant1 GeneArt Strings™ DNA Fragment life technologies
EcoRI-Nup214(aa1859-2090)-SalI_mutant2 GeneArt Strings™ DNA Fragment life technologies
EcoRI-Nup214(aa1859-2090)-SalI_mutant3 GeneArt Strings™ DNA Fragment life technologies
2.1.12 Vectors
Table 19: Available Vectors.
Number Name Tag Resistance Application Source
4 pET-28a His (N/C-terminal) kan expression Novagen
29 pMal-C2 MBP (N-terminal) amp expression NEB
30 pEGFP-C1 EGFP kan transfection Clontech
37 pETM41 MBP-His (N-terminal) kan expression EMBL
46 pGex-6P-1 GST (N-terminal) amp expression Amersham
47 pGex-6P-1-MCS GST (N-terminal) amp expression S. Hutten
52 pcDNA3.1(+)-HA HA-Tag (C-terminal) amp transfection S. Wälde
Table 20: Generated Vectors.
Number Name Tag Cloning
74 pMal-linkerAAA MBP (modified) PCR(pMal-C2, G1120, G1121) cloned with BglII,
EcoRI




MBP (modified) PCR(pMal-linkerAAA, G1211, G1213 cloned with
EcoRI, NcoI
78 pMal-His-MCS-MBP His, MBP (modified) PCR(pMal-C2, G1152, G1153) cloned with EheI,





The pMal-c2 vector was modified to resemble a vector used in [212]. The charged residues at
the C-terminus of the MBP-tag were mutated to alanine and the linker length was shortened by
PCR on pMal-c2 with a revers primer containing the modified C-terminal region of MBP, a linker
consisting of 3 alanines and an EcoRI recognition site.
GCCGCGGCCGAATTCGGATCCTCTAGAGTCGACCTGCAGGCAAGCTTGGC-3’MBP (modied)
EcoRI BamHI XbaI SalI PstI HindIIIlinkerAAA
5’
Figure 5: Multiple cloning site of the vector pMal-linkerAAA.
pMal-PreScission
The Factor Xa site of the pMal-c2 vector was changed to a PreScission protease site by PCR
with a revers oligo coding for the PreScission recognition site.
CTGGAAGTTCTGTTCCAGGGGCCCGAATTCGGATCCTCTAGAGTCGACCTGCAGGCAAGCTTGGC-3’MBP
PreScission site EcoRI BamHI XbaI SalI PstI HindIII
5’
Figure 6: Multiple cloning site of the vector pMal-PreScission.
pMal-linkerAAA-PreScission
A PreScission protease recognition site was inserted between the modified MBP and the multi-
ple cloning site of the pMal-linkerAAA vector by PCR with a revers oligo coding for the PreScis-
sion recognition site.
GCCGCGGCCCTGGAAGTTCTGTTCCAGGGGCCCGAATTCGGATCCTCTAGAGTCGACCTGCAGGCAAGCTTGGC-3’MBP (modied)
PreScission site EcoRI BamHI XbaI SalI PstI HindIIIlinkerAAA
5’
Figure 7: Multiple cloning site of the vector pMal-linkerAAA-PreScission.
pMal-His-MCS-MBP
The pMal-linkerAAA vector was modified by 2 cloning steps to yield a vector with an N-terminal
His-tag and a C-terminal modified MBP-tag as described for the vector pMal-linkerAAA.
5’-ATGCATCACCATCACCATCACGAATTCGGATCCTCTAGAGTCGAC MBP (modied)
6x His tag EcoRI BamHI XbaI SalI HindIII
AAGCTT-3’




Table 21: Available Plasmids.
Number Name Application Source
1 pET11d-Ran expression
2 pET3d-RanQ69L expression
41 pGEX-PKI-NES expression S. Taylor
47 pBluescript-Nup214 transfection G. Grosfeld
79 pGEX-6P-SPN1 expression A. Dickmanns
145 pMAL-Nup214C expression R. Kehlenbach
146 pGEX3x-Rev expression J. Hauber
532 pcDNA3.1(+)-CRM1-HA transfection C. Spillner
628 pcDNA3.1(+)-CRM1(C528S)-HA transfection S. Roloff
736 pGEX-4T3-CRM1 expression Y. M. Chook
856 pET30b-SPN1 expression I. Waldmann
857 pEGFP-c1-SPN1 transfection I. Waldmann
987 pmRFP-cNLS transfection C. Spillner
994 pmRFP-Nup214(1916-2033)a1-cNLS (5SGs) transfection C. Spillner
996 pmRFP-Nup214(1916-2033)a3-cNLS transfection C. Spillner
1007 pGEX-6P1-Nup214(1968-1990) expression S. Roloff
1008 pGEX-6P1-Nup214(1968-1990)a1 expression S. Roloff
1009 pGEX-6P1-Nup214(1968-2033) expression S. Roloff
1010 pGEX-6P1-Nup214(1968-2033)a1 (5SGs) expression S. Roloff
1023 pmRFP-Nup214(1859-2090)F1982S-cNLS transfection C. Spillner
1024 pmRFP-Nup214(1859-2090)F1988S-cNLS transfection C. Spillner
1029 pmRFP-Nup214(1859-2090)F1976S-cNLS transfection C. Spillner
1030 pmRFP-Nup214(1859-2090)a1-cNLS transfection C. Spillner
1037 pmRFP-Nup214(1859-2090)a4-cNLS transfection C. Spillner
1064 pGEX-6P1-Nup214(1859-2090) expression C. Spillner
1065 pGEX-6P1-Nup214(1859-2090)a1 (4SG) expression C. Spillner
1066 pGEX-6P1-Nup214(1991-2090) expression C. Spillner
1069 pGEX-6P1-Nup214(1859-2090)FGless expression S. Roloff
1070 pGEX-6P1-Nup214(1968-2090) expression S. Roloff
1258 pTH24-TEV-SH expression A. Dickmanns
1316 pQE80-His-ZZ-RanQ69L(1-180) expression T. Güttler
1317 pGEX-6P1-RanBP3 expression A. Dickmanns
Table 22: Generated Plasmids.
Number Name Cloning
1135 pET28a-His-Nup214(1930-2021)-His PCR Nup214 (#47, G1071, G1072), cloned into
vector #4 (NdeI, XhoI)
1136 pET28a-His-Nup214(1916-2033)KA-His fragment from #1132 cloned into vector #4 (NdeI,
XhoI)
1159 pQE60-CRM1(430AAA432)-His fragment from #1160 cloned into plasmid #31
(SacI/SalI)
1160 pcDNA3.1(+)-CRM1(430AAA432 C528S)-HA mutagenesis (G1073, G1074) on plasmid #628





1162 pmRFP-Nup214(1968-2033)KA-cNLS PCR Nup214 (#1136, G889, G833), cloned into
plasmid #987 (EcoRI/ SalI)
1163 pmRFP-Nup214(1916-2033)-cNLS PCR Nup214 (#47, G1075, G833), cloned into
plasmid #987 (EcoRI/SalI)
1164 pmRFP-Nup214(1916-2033)KA-cNLS PCR Nup214 (#1136, G1075, G833), cloned into
plasmid #987 (EcoRI/SalI)
1169 pGEX-6P1-Nup214(1930-2021) PCR Nup214 (#47, G1118, G1119), cloned into
vector #46 (EcoRI/SalI)
1170 pMAl-linkerAAA-Nup214(1930-2021) PCR Nup214 (#47, G1118, G1144), cloned into
vector #74 (EcoRI/SalI)
1174 pmRFP-Nup214(1859-2090)KA-cNLS fragment from #1171 cloned into plasmid #987
(EcoRI, SalI)
1175 pmRFP-Nup214(1859-2090)KAa1-cNLS fragment from #1172 cloned into plasmid #987
(EcoRI, SalI)
1176 pmRFP-Nup214(1859-2090)KE-cNLS fragment from #1173 cloned into plasmid #987
(EcoRI, SalI)
1177 pmRFP-Nup214(1916-2033)KE-cNLS PCR Nup214 (#1176, G1075, G833), cloned into
plasmid #987 (EcoRI/SalI)
1178 pETM41-Nup214(1858-2090)KA PCR Nup214 (#1174, G117, G118), cloned into
vector #37 (NcoI/KpnI)
1179 pETM41-Nup214(1858-2090)KAa1 PCR Nup214 (#1175, G117, G118), cloned into
vector #37 (NcoI/KpnI)
1180 pETM41-Nup214(1858-2090)KE PCR Nup214 (#1176, G117, G118), cloned into
vector #37 (NcoI/KpnI)
1184 pET28a-His-Nup214(1916-2033)a1-His PCR Nup214 (#949, G1126, G1127), cloned into
vector #4 (NdeI, XhoI)
1185 pmRFP-Nup214(1859-2090)-cNLS PCR Nup214 (#47, G1128, G1129), cloned into
plasmid #987 (EcoRI/SalI)
1188 pmRFP-Nup214(1859-2090)KE 2SG-cNLS mutagenesis (G1122, G1123) on plasmid #1176
1189 pmRFP-Nup214(1859-2090) 5SG-cNLS fragment from #1186 cloned into plasmid #987
(EcoRI, SalI)
1190 pmRFP-Nup214(1916-2033) 4SG-cNLS fragment from #1187 cloned into plasmid #987
(EcoRI, SalI)
1192 pGEX-6P1-Nup214(2022-2033) PCR Nup214( #47, G1147, G1149), cloned into
vector #46 (EcoRI/SalI)
1193 pGEX-6P1-Nup214(1916-1929) PCR Nup214( #47, G1150, G806), cloned into
vector #46 (EcoRI/SalI)
1194 pMal-linkerAAA-Nup214(1930-2033) PCR Nup214 (#47, G1118, G1148), cloned into
vector #74 (EcoRI/SalI)
1195 pMal-linkerAAA-Nup214(1916-2033) PCR Nup214 (#47, G1147, G1148), cloned into
vector #74 (EcoRI/SalI)
1196 pMal-linkerAAA-Nup214(1916-2021) PCR Nup214 (#47, G1147, G1144), cloned into
vector #74 (EcoRI/SalI)
1273 pGEX-6P-Nup214(1961-2033) S1963C PCR Nup214 (#948, G952, G806), cloned into
vector #46 (EcoRI, SalI)
1277 pET28a-Nup214(1916-2033)-His PCR Nup214 (#47, G985, G987), cloned into vector
#4 (NcoI, XhoI)
1278 pET28a-His-Nup214(1916-2033)-His PCR Nup214 (#47, G986, G987), cloned into vector
#4 (NdeI, XhoI)





1280 pET28a-HisNup214(1916-2090)-His PCR Nup214 (#47, G986, G988), cloned into vector
#4 (NdeI, XhoI)
1281 pETM41-Nup214(1858-2033) PCR Nup214 (#48, G117, G837), cloned into vector
#37 (NcoI, EcoRI)
1282 pET28a-His-Nup214(C1916-2033)-His PCR Nup214 (#47, G1050, G987), cloned into
vector #4 (NdeI, XhoI)
1283 pET28a-His-Nup214(1916-2033C)-His PCR Nup214 (#47, G986, G1051), cloned into
vector #4 (NdeI, XhoI)
1287 pET28a-His-Nup214(1916-2033) K1942C-His fragment from #1284 cloned into vector #4 (NdeI,
XhoI)
1288 pET28a-His-Nup214(1916-2033) K1966C-His fragment from #1285 cloned into vector #4 (NdeI,
XhoI)
1289 pET28a-His-Nup214(1916-2033) K2010C-His fragment from #1286 cloned into vector #4 (NdeI,
XhoI)
1291 pmRFP-Nup214(1859-2090)K1928E-cNLS mutagenesis (G1130, G1131) on plasmid #1185
1292 pmRFP-Nup214(1859-2090)K1942E-cNLS mutagenesis (G1132, G1133) on plasmid #1185
1293 pmRFP-Nup214(1859-2090)KE 4SG-cNLS mutagenesis (G1122, G1123) on plasmid #1176,
then mutagenesis (G1124, G1125)
1294 pMal-linkerAAA-Nup214(1930-2021)-His PCR Nup214 (#47, G1118, G1144) digested with
EcoRI/SalI , cloned into vector #74 (EcoRI/SalI)
1295 pmRFP-Nup214(1859-2090)K1966D-cNLS mutagenesis (G1134, G1135) on plasmid #1185
1296 pmRFP-Nup214(1859-2090)K2010E-cNLS mutagenesis (G1136, G1137) on plasmid #1185
1297 pmRFP-Nup214(1859-2090)D1896K-cNLS mutagenesis (G1138, G1139) on plasmid #1185
1298 pmRFP-Nup214(1859-2090)E2014K-cNLS mutagenesis (G1142, G1143) on plasmid #1185
1299 pmRFP-Nup214(1859-2090)K1966E-cNLS mutagenesis (G1134, G1135) on plasmid #1185
1300 pmRFP-Nup214(1859-2090)E1940K-cNLS mutagenesis (G1140, G1141) on plasmid #1185
1301 pmRFP-Nup214(1859-2090)F1994S-cNLS mutagenesis (G1145, G1146) on plasmid #1185
1302 pmRFP-Nup214(1859-2090)KA 5SG-cNLS mutagenesis (G1145, G1146) on plasmid #1175
1303 pmRFP-Nup214(1859-2090)KE 5SG-cNLS mutagenesis (G1145, G1146) on plasmid SAP604
1304 pmRFP-Nup214(1859-2090)KA(F1994S)-cNLS mutagenesis (G1145, G1146) on plasmid #1174
1305 pmRFP-Nup214(1859-2090)KE(F1994S)-cNLS mutagenesis (G1145, G1146) on plasmid #1176
1306 pmRFP-Nup214(1859-2090) D1896K
E1940K-cNLS
mutagenesis (G1138, G1139) on plasmid #1300
1307 pmRFP-Nup214(1859-2090) DE/K-cNLS mutagenesis (G1142, G1143) on plasmid #1306
1308 pMal-linkerAAA-Nup214(1859-2090)-His PCR Nup214 (#47, G973, G1151), cloned into
vector #74 (EcoRI/SalI)
1309 pMal-His-Nup214(1916-2033)-MBP(mod.) PCR Nup214 (#47, G1147, G833), cloned into
vector #78 (EcoRI/SalI)
1310 pmRFP-Nup214(1859-2090)DE/K 2SG-cNLS mutagenesis (G1122, G1123) on plasmid #1307
1311 pmRFP-Nup214(1859-2090)DE/K
F1976S-cNLS
mutagenesis (G1122, G1123) on plasmid #1307
1312 pmRFP-Nup214(1859-2090)DE/K
F1994S-cNLS
mutagenesis (G1145, G1146) on plasmid #1307
1313 pmRFP-Nup214(1859-2090)DE/K 4SG-cNLS mutagenesis (G1124, G1125) on plasmid #1310
1314 pmRFP-Nup214(1859-2090)DE/K 3SG-cNLS mutagenesis (G1124, G1125) on plasmid #1310
1315 pmRFP-Nup214(1859-2090)DE/K 5SG-cNLS mutagenesis (G1145, G1146) on plasmid #1313
1318 pMal-C2-Nup214(1859-2090)-His PCR Nup214 (#47, G973, G1151), cloned into
vector #29 (EcoRI/SalI)
1319 pET28a-His-Nup214(K1916-2033)-His PCR Nup214 (#47, G1184, G987) , cloned into
vector #4 (NdeI/XhoI)




1321 pET28a-His-Nup214(1916-2033)A1995K-His mutagenesis (G1188, G1189) on plasmid #1278
1322 pcDNA3.1(+)-CRM1(C528S A992S L996S)-HA mutagenesis (G1201, G1202) on plasmid #628
1323 pcDNA3.1(+)-CRM1(C528S F1034S
L1035S)-HA
mutagenesis (G1203, G1204) on plasmid #628
1325 pcDNA3.1(+)-CRM1(C528S L864A)-HA mutagenesis (G1218, G1219) on plasmid #628
1326 pcDNA3.1(+)-CRM1(C528S F871A)-HA mutagenesis (G1220, G1221) on plasmid #628
1327 pcDNA3.1(+)-CRM1(C528S L718)-HA mutagenesis (G1226, G1227) on plasmid #628
1328 pcDNA3.1(+)-CRM1(C528S L781A)-HA mutagenesis (G1228, G1229) on plasmid #628
1329 pcDNA3.1(+)-CRM1(C528S F860A)-HA mutagenesis (G1232, G1233) on plasmid #628
1330 pcDNA3.1(+)-CRM1(C528S P861A)-HA mutagenesis (G1234, G1235) on plasmid #628
1331 pcDNA3.1(+)-CRM1(C528S W142A P143A)-HA mutagenesis (G1216, G1217) on plasmid #628
1332 pcDNA3.1(+)-CRM1(C528S W880A F882A)-HA mutagenesis (G1222, G1223) on plasmid #628
1333 pcDNA3.1(+)-CRM1(C528S P964A)-HA mutagenesis (G1242, G1243) on plasmid #628
1334 pcDNA3.1(+)-CRM1(C528S P967A V968A)-HA mutagenesis (G1244, G1245) on plasmid #628
1335 pcDNA3.1(+)-CRM1(C528S F973A)-HA mutagenesis (G1248, G1249) on plasmid #628
1336 pMal-PP-Nup214(1916-2033)-His PCR Nup214 (#47, G1147, G1148), cloned into
vector #75 (EcoRI/SalI)
1337 pMal-PP-Nup214(1859-2090)-His PCR Nup214 (#47, G973, G1151), cloned into
vector #75 (EcoRI/SalI)
1338 pMal-PP-linkerAAA-Nup214(1916-2033)-His PCR Nup214 (#47, G1147, G1148), cloned into
vector #76 (EcoRI/SalI)
1339 pMal-PP-linkerAAA-Nup214(1859-2090)-His PCR Nup214 (#47, G973, G1151), cloned into
vector #76 (EcoRI/SalI)
1340 pcDNA3.1(+)-CRM1(C528S P867A)-HA mutagenesis (G1238, G1239) on plasmid #628
1341 pcDNA3.1(+)-CRM1(C528S E907A E908A)-HA mutagenesis (G1240, G1241) on plasmid #628
1342 pcDNA3.1(+)-CRM1(C528S I972A)-HA mutagenesis (G1246, G1247) on plasmid #628
1343 pcDNA3.1(+)-CRM1(C528S I866A)-HA mutagenesis (G1236, G1237) on plasmid #628
1344 pMal-PP-RanBP3 PCR RanBP3 (SAP0666, G1156, G1256), cloned
into vector #75 (EcoRI/SalI)
1345 pMal-linkerAAA-PP-RanBP3 PCR RanBP3 (SAP0666, G1156, G1256), cloned
into vector #76 (EcoRI/SalI)
1346 pcDNA3.1(+)-CRM1(C528S L715A)-HA mutagenesis (G1224, G1225) on plasmid #628
1347 pcDNA3.1(+)-CRM1(C528S P778A P779A)-HA mutagenesis (G1230, G1231) on plasmid #628
1348 pMal-linkerAAA-Nup214(1916-2042)-His PCR Nup214 (#47, G1147, G1267), cloned into
vector #74 (EcoRI/SalI)
1349 pMal-linkerAAA-Nup214(1906-2033)-His PCR Nup214 (#47, G1266, G1148), cloned into
vector #74 (EcoRI/SalI)
1350 pMal-linkerAAA-Nup214(1906-2042)-His PCR Nup214 (#47, G1266, G1267), cloned into
vector #75 (EcoRI/SalI)
1355 pQE60-CRM1(L83F)-His mutagenesis (G1276, G1277) on plasmid #31
1356 pQE60-CRM1(L83R)-His mutagenesis (G1278, G1279) on plasmid #31
1357 pQE60-CRM1(I102Q)-His mutagenesis (G1280, G1281) on plasmid #31
1358 pQE60-CRM1(A156F)-His mutagenesis (G1290, G1291) on plasmid #31
1359 pQE60-CRM1(K680Q)-His mutagenesis (G1298, G1299) on plasmid #31
1360 pQE60-CRM1(K680R)-His mutagenesis (G1300, G1301) on plasmid #31
1361 pQE60-CRM1(L744W)-His mutagenesis (G1306, G1307) on plasmid #31
1362 pQE60-CRM1(L679W K680R)-His mutagenesis (G1312, G1313) on plasmid #31
1363 pQE60-CRM1(K680Q A731Q)-His GeneArt fragment cloned into plasmid #31
(MssI/SacI)





1365 pQE60-CRM1(K680Q A731Q C723M)-His GeneArt fragment cloned into plasmid #31
(MssI/SacI)
1366 pQE60-CRM1(L679R)-His mutagenesis (G1294, G1295) on plasmid #31
1367 pQE60-CRM1(C723M)-His mutagenesis (G1302, G1303) on plasmid #31
1368 pQE60-CRM1(M748R)-His mutagenesis (G1310, G1311) on plasmid #31
1369 pQE60-CRM1(I102W N167R)-His GeneArt fragment cloned into plasmid #31
(SalI/SacI)
1370 pQE60-CRM1(I102W)-His mutagenesis (G1282, G1283) on plasmid #31
1371 pQE60-CRM1(L134F)-His mutagenesis (G1284, G1285) on plasmid #31
1372 pQE60-CRM1(F149W)-His mutagenesis (G1286, G1287) on plasmid #31
1373 pQE60-CRM1(D152W)-His mutagenesis (G1288, G1289) on plasmid #31
1374 pQE60-CRM1(N167R)-His mutagenesis (G1292, G1293) on plasmid #31
1375 pQE60-CRM1(L679W)-His mutagenesis (G1296, G1297) on plasmid #31
1376 pQE60-CRM1(A731Q)-His mutagenesis (G1304, G1305) on plasmid #31
1377 pQE60-CRM1(L83R F149W)-His mutagenesis (G1286, G1287) on plasmid #1356
1378 pQE60-CRM1(I102Q F149W)-His mutagenesis (G1286, G1287) on plasmid #1357
1379 pQE60-CRM1(L83F D152W)-His mutagenesis (G1288, G1289) on plasmid #1355
1380 pQE60-CRM1(L83R D152W)-His mutagenesis (G1288, G1289) on plasmid #1356
1381 pQE60-CRM1(L83F A156F)-His mutagenesis (G1290, G1291) on plasmid #1355
1382 pQE60-CRM1(L679R L744W)-His mutagenesis (G1294, G1295) on plasmid #1361
1383 pQE60-CRM1(L679W L744W)-His mutagenesis (G1296, G1297) on plasmid #1361
1384 pQE60-CRM1(C723M L744W)-His mutagenesis (G1302, G1303) on plasmid #1361
1385 pQE60-CRM1(I102W F149W)-His GeneArt fragment cloned into plasmid #31
(SalI/SacI)
1386 pQE60-CRM1(C528W)-His mutagenesis (G1317, G1318) on plasmid #31
1387 pQE60-CRM1(A541K)-His mutagenesis (G1319, G1320) on plasmid #31
1388 pQE60-CRM1(L83F F149W)-His mutagenesis (G1286, G1287) on plasmid #1355
1389 pQE60-CRM1(I102Q D152W)-His mutagenesis (G1288, G1289) on plasmid #1357
1390 pQE60-CRM1(I102W D152F)-His GeneArt fragment cloned into plasmid #31
(SalI/SacI)
1391 pQE60-CRM1(I102Q A156F)-His mutagenesis (G1290, G1291) on plasmid #1357
1392 pQE60-CRM1(L83F D152W K680Q A731Q
C723M)-His
cloning fragment from #1365 into #1379 (SacI/MssI)
1393 pQE60-CRM1(L83F D152W L679W
L744W)-His
cloning fragment from #1383 into #1379 (SacI/MssI)
1394 pQE60-CRM1(L83F D152W C723M
L744W)-His
cloning fragment from #1384 into #1379 (SacI/MssI)
1395 pQE60-CRM1(L83F A156F K680Q A731Q
C723M)-His
cloning fragment from #1365 into #1381 (SacI/MssI)
1396 pQE60-CRM1(L83F A156F L679W L744W)-His cloning fragment from #1383 into #1381 (SacI/MssI)
1397 pQE60-CRM1(L83F A156F C723M L744W)-His cloning fragment from #1384 into #1381 (SacI/MssI)
1398 pQE60-CRM1(L83F L744W)-His cloning fragment from #1361 into #1355 (SacI/MssI)
1399 pQE60-CRM1(L83F C723M)-His cloning fragment from #1367 into #1355 (SacI/MssI)
1400 pQE60-CRM1(L83F K680Q A731Q L679R)-His cloning fragment from #1364 into #1355 (SacI/MssI)
1401 pQE60-CRM1(I102Q F149W K680Q A731Q
C723M)-His
cloning fragment from #1365 into #1378 (SacI/MssI)
1402 pQE60-CRM1(I102Q F149W L679W
L744W)-His
cloning fragment from #1383 into #1378 (SacI/MssI)
1403 pQE60-CRM1(I102Q F149W C723M
L744W)-His
cloning fragment from #1384 into #1378 (SacI/MssI)




1405 pQE60-CRM1(I102Q F149W C723M)-His cloning fragment from #1367 into #1373 (SacI/MssI)
1406 pQE60-CRM1(L83R A156F)-His mutagenesis (G1290, G1291) on plasmid #1356
1407 pQE60-CRM1(D824K)-His mutagenesis (G1321, G1322) on plasmid #31
1408 pQE60-CRM1(F823A)-His mutagenesis (G1323, G1324) on plasmid #31
1409 pQE60-CRM1(H925W)-His mutagenesis (G1325, G1326) on plasmid #31
1410 pQE60-CRM1(S928K)-His mutagenesis (G1327, G1328) on plasmid #31
1411 pQE60-CRM1(T917E)-His mutagenesis (G1329, G1330) on plasmid #31
1412 pQE60-CRM1(W880A)-His mutagenesis (G1331, G1332) on plasmid #31
1413 pQE60-CRM1(Y918W)-His mutagenesis (G1333, G1334) on plasmid #31
1414 pET28a-His-Nup214(1916-2033)KAa1-His PCR Nup214 (#1172, G986, G987), cloned into
vector #4 (NdeI, XhoI)
1415 pET28a-His-Nup214(1916-2033)KE-His PCR Nup214 (#1173, G986, G987), cloned into
vector #4 (NdeI, XhoI)
1426 pmRFP-Nup214(1859-2090)X1-cNLS GeneArt fragment cloned into plasmid #987
(EcoRI/SalI)
1427 pmRFP-Nup214(1859-2090)X2-cNLS GeneArt fragment cloned into plasmid #987
(EcoRI/SalI)
1428 pmRFP-Nup214(1859-2090)X3-cNLS GeneArt fragment cloned into plasmid #987
(EcoRI/SalI)
1429 pQE60-CRM1(D824K S928K)-His mutagenesis (G1327, G1328) on plasmid #1407
1430 pQE60-CRM1(K680Q A731Q L679R
F149W)-His
mutagenesis (G1286, G1287) on plasmid #1364
1431 pQE60-CRM1(K680Q A731Q L679R
D824K)-His
mutagenesis (G1321, G1322) on plasmid #1364
1432 pQE60-CRM1(K680Q A731Q L679R
S928K)-His
mutagenesis (G1327, G1328) on plasmid #1364
1433 pET28a-His-Nup214(1916-2033)X1-His PCR Nup214 (#1426, G1352, G987), cloned into
vector #4 (NdeI, XhoI)
1434 pET28a-His-Nup214(1916-2033)X2-His PCR Nup214 (#1427, G1352, G987), cloned into
vector #4 (NdeI, XhoI)
1435 pET28a-His-Nup214(1916-2033)X3-His PCR Nup214 (#1428, G1352, G987), cloned into
vector #4 (NdeI, XhoI)
1436 pMal-linkerAAA-Nup214(1916-2033)X1-His PCR Nup214 (#1426, G1353, G1148), cloned into
vector #74 (EcoRI/SalI)
1437 pMal-linkerAAA-Nup214(1916-2033)X2-His PCR Nup214 (#1427, G1353, G1148), cloned into
vector #74 (EcoRI/SalI)
1438 pMal-linkerAAA-Nup214(1916-2033)X3-His PCR Nup214 (#1428, G1353, G1148), cloned into
vector #74 (EcoRI/SalI)
1444 pcDNA3.1(+)-CRM1(K680Q A731Q L679R)-HA PCR CRM1 (#1364, G275, G276), cloned into
vector #52 (NheI, BamHI)
1445 pcDNA3.1(+)-CRM1(D824K)-HA PCR CRM1 (#1407, G275, G276), cloned into
vector #52 (NheI, BamHI)
1446 pcDNA3.1(+)-CRM1(K680Q A731Q L679R
D824K)-HA
PCR CRM1 (#1431, G275, G276), cloned into
vector #52 (NheI, BamHI)
1447 pcDNA3.1(+)-CRM1(K680Q A731Q L679R
C528S)-HA
mutagenesis (G336, G337) on plasmid #1444
1448 pcDNA3.1(+)-CRM1(D824K C528S)-HA mutagenesis (G336, G337) on plasmid #1445
1449 pcDNA3.1(+)-CRM1(K680Q A731Q L679R
D824K C528S)-HA
mutagenesis (G336, G337) on plasmid #1446
– 41 –
Material and Methods
2.2 Molecular Biology Methods
2.2.1 RbCl chemically competent cells
The protocol was adapted from [213] and used for preparing RbCl chemical competent TG1
cells.
4 ml LB was inoculated with half an aliquot of RbCl-competent TG1 clone #17 cells and
incubated at 37 °C overnight. 100 ml LB supplemented with 10 mM MgSO4 was inoculated
with 1.5 ml of starter culture and incubated at 37 °C and 170 rpm until an OD600 of 0.5-0.6 was
reached. The culture was transferred to two pre-chilled 50 ml tubes and cooled down on ice for
15 minutes before harvesting in a pre-chilled centrifuge at 3000 g and 4 °C for 10 minutes.
All subsequent steps were performed on ice with pre-chilled reaction tubes.
The supernatant was discarded and the two cell pellets of each tube were resuspended in
20 ml of ice-cold TFB-I (30 mM KOAc, 10 mM CaCl2, 50 mM MnCl2, 100 mM RbCl, 15%
glycerol, pH 5.8) by pipetting up and down. The resuspended cells were combined in one
tube and incubated on ice for 15 minutes. The cells were pelleted in a pre-chilled centrifuge
at 1000 g and 4 °C for 15 minutes. The supernatant was discarded and the cell pellet was
resuspended in 4 ml of ice-cold TFB-II (100 mM MOPS, 75 mM CaCl2, 10 mM RbCl, 15%
glycerol, pH 6.5) by pipetting up and down. The resuspended cells were incubated on ice for
15 minutes. Aliquots of 40-100 µl were snap frozen in liquid nitrogen and stored at -80 °C until
used.
2.2.2 Agarose gel electrophoresis
For separation of DNA fragments 0.7-2.0% agarose gels were prepared. The agarose was dis-
solved in 1x TAE buffer in an Erlenmeyer flask and boiled in a microwave oven until completely
dissolved. 1 µl of SERVA DNA Stain Clear G (SERVA) per 100 ml gel was added to the solution
prior to casting the gel.
The gel electrophoresis was run in 1x TAE buffer at 120 V for 20 to 50 minutes depending on
the size of the gel and the intended resolution.
The GeneRuler 100bp DNA Ladder or the GeneRuler 1kb DNA Ladder (ThermoScientific) were
used as molecular weight markers.
For extracting DNA fragments for further use, the bands were cut on an UV transilluminator with
DNA Pick-Tips (Süd-Laborbedarf GmbH). The gel was documented with the GelSTICK "touch"
system (INTAS Science Imaging Instruments).
2.2.3 Quantification of dsDNA
The concentration and purity of dsDNA was determined by measuring the UV absorbance at
260 nm and 280 nm with the NanoDrop 2000c (ThermoScientific).
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2.2.4 Polymerase chain reaction (PCR)
PCR reactions were assembled with Phusion High-Fidelity DNA Polymerase (ThermoScientific)
according to the manufacturer’s instructions. Preparative PCR was done in 50 µl reactions. For
control PCR of mini prep DNA the reaction was scaled down to 20 µl reactions. No additional
DMSO or MgCl2 was added. The PCR reaction was run for 35 cycles in standard conditions.
Elongation time was adjusted to the expected size of the PCR product. The annealing temper-
ature chosen was generally 2-4 °C below the initial primer melting temperature as calculated
by the SerialCloner Software.
6x DNA sample buffer was added to the reactions after PCR. Depending on the expected
size of the PCR products the sample was loaded on 0.7 - 2.0% agarose gels. PCR products
were cut from agarose gels with DNA Pick-Tips (Süd-Laborbedarf GmbH) and purified with the
NucleoSpin® Gel and PCR Clean-up kit (Macherey-Nagel). Purified DNA was eluted in 25 µl
elution buffer.
2.2.5 Site-directed mutagenesis
Site-directed mutagenesis reactions were assembled with Pfu Ultra II polymerase (Agilent) ac-
cording to the manufacturer’s instructions. The PCR reaction was run for 35 cycles in standard
conditions with an annealing temperature of 60 °C. Elongation time was adjusted to the size
of the respective template plasmid. 1 µl DpnI was added to the reaction after PCR and the
template plasmid was digested at 37 °C for 3 hours or overnight. 10-13 µl of the reaction
was transformed into chemically competent DH5α cells or, in case of pQE60-CRM1 mutants,
into chemically competent XL10 gold cells. The transformed cells were plated onto LB-agar
plates with the respective antibiotic and incubated overnight at 37 °C. At least three clones
were picked for inoculating 3 ml mini prep cultures. Plasmid from 2 ml of cultures was isolated
with the NucleoSpin® Plasmid Kit (Macherey-Nagel). 20 µl plasmid was sent for sequencing at
GATC Biotech.
2.2.6 Restriction enzyme digest
Restriction enzyme digest was performed in 20 µl reaction volume for plasmids and
30 µl reaction volume for purified PCR products. The buffer and restriction enzyme ra-
tio was chosen as suggested by the DoubleDigest tool on the ThermoScientific website
(http://www.thermoscientificbio.com/webtools/doubledigest/).
Control digest of mini prep DNA
14-16 µl of mini prep DNA was digested. The digest was performed for at least 1 hour at
37 °C. After digestion, 6x DNA sample buffer was added and the sample was loaded on a
0.7 - 2.0% agarose gel depending on the sizes of the expected fragments. The band pat-
tern was documented with the GelSTICK "touch" system (INTAS Science Imaging Instruments).
Preparative digest of PCR products and plasmids
25 µl of purified PCR products or 5 µl of plasmid DNA was digested. The digest was performed
for 2-3 hours at 37 °C. After digestion 6x DNA sample buffer was added and the sample was
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loaded on a 0.7 - 2.0% agarose gel depending on the sized of the expected fragment. The
DNA was visualized with an UV transluminator and the intended bands were cut with DNA
Pick-Tips (Süd-Laborbedarf GmbH). The gel was documented with the GelSTICK "touch"
system (INTAS Science Imaging Instruments). The DNA was purified with the NucleoSpin®
Gel and PCR Clean-up kit (Macherey-Nagel). Purified DNA was eluted in 25 µl elution buffer.
2.2.7 Ligation of DNA fragments
The ligation reaction was performed in 10 µl reaction volume containing 10 mM ATP, 1x T4 DNA
Ligase Reaction Buffer (ThermoScientific) and 0.5 µl of T4 DNA Ligase (ThermoScientific).
20-30 ng of the vector DNA fragment was ligated with at least 5x molar excess of the insert DNA
fragment. The reaction mixture was incubated at room temperature for 1 hour and subsequently
transformed into chemically competent DH5α cells or, in case of pQE60-CRM mutants, into
chemically competent XL10 gold cells.
2.2.8 Transformation of E. coli strains with plasmid DNA
An aliquot of RbCl competent cells was thawed on ice. 0.5 µg of plasmid or 5 µl of a ligation
mixture was added to the cells. The cells were mixed thoroughly and incubated on ice for
30 minutes. A heat shock was performed at 42 °C for 90 seconds. The cells were cooled down
on ice for 2 minutes before adding 500 µl ice-cold SOC medium (2% (w/v) tryptone, 0.5% (w/v)
yeast extract, 10 mM NaCl, 2.5 mM KaCl, 10 mM MgCl2, 10 mM MgSO4, 0.36% (w/v) glucose,
pH 7.0). The mixture was incubated in a ThermoMixer (Eppendorf) at 37 °C, 850 rpm for
1 hour.
For ligations, cells were harvested by centrifugation (3000 rpm, 2.5 minutes). About 400 µl
of the supernatant was removed and the cells were resuspended in the remaining liquid by
pipetting up and down before plating on an LB-agar plate with an appropriate antibiotic.
In case of re-transformations, 70 µl of the cell suspension was plated directly on an LB-agar
plate (LB supplemented with 1.5% (w/v) bacto-agar and the respective antibiotic).
The plates were incubated overnight at 37 °C.
2.2.9 Purification of plasmid DNA
Mini preps
3 ml of LB (1% (w/v) bacto-tryptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl (pH7.0))
supplemented with the appropriate antibiotic was inoculated with one colony picked from an
LB-agar plate. Cultures were incubated overnight at 37 °C, 180 rpm.
2 ml of culture was transferred to a 2 ml reaction tube and cells were harvested by cen-
trifugation (11000 g, 4 °C, 1 minute). DNA was extracted with the NucleoSpin® Plasmid
(Macherey-Nagel) according to the manufacturer’s instructions. The purified DNA was eluted




200 ml of LB (1% (w/v) bacto-tryptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl (pH7.0)) sup-
plemented with the appropriate antibiotic was inoculated with one colony picked from an LB-
agar plate or with the rest of a mini prep culture. Cultures were incubated overnight at 37 °C,
180 rpm.
The cells were harvested by centrifugation (5250 g, 4 °C, 15 minutes). DNA was extracted with
the NucleoBond™ Xtra Midi kit according to the manufacturer’s instructions. The precipitated
DNA was dissolved in 70 µl H20. The dsDNA concentration was determined with the NanoDrop
2000c (ThermoScientific) and adjusted to 1 mg/ml with H2O.
2.2.10 DNA sequencing
Plasmids sequences were analyzed by GATC Biotech. 20 µl of mini prep DNA or 2 µg of midi
prep DNA in a total volume of 20 µl were sent for sequencing.
Standard primers from GATC Biotech were chosen via the PrimerScout tool on the website
(http://www.gatc-biotech.com/). For sequencing of pmRFP-cNLS plasmids or CRM1 mu-
tants, 20 µl the respective primers (10 µM) were sent with the sample. A list of sequencing





Proteins were separated by SDS-PAGE. According to the size of the proteins of interest resolv-
ing gels from 6% to 20% were chosen. SDS sample buffer was added to the sample. Cell
lysates and pulldown samples were incubated at 98 °C for 5 minutes prior to loading on the
gel. The gel electrophoresis was performed with Laemmli running buffer (25 mM Tris, 192 mM
glycine, 0.05% SDS) in SE250 Mighty Small II Mini Vertical Electrophoresis Units (Hoefer) with
25 mA per gel and 300 V for 65 minutes.
For better visualization of samples containing small as well as large proteins NuPAGE® Novex®
4-12% Bis-Tris gradient gels were used with either NuPAGE® MES SDS or MOPS SDS running
buffer. NuPAGE® sample buffer and 50 mM DTT was added to the samples prior to incubation
at 70 °C for 10 minutes. The gel electrophoresis was performed in XCell SureLock® Mini-Cells
at 200 V for 45 minutes.
The PageRuler Unstained, PageRuler Prestained or PageRuler Plus Prestained protein ladders
were run next to the samples on every gel.
Gels were used either for Western blotting (see section 2.3.4) or proteins were visualized with
Coomassie (see section 2.3.2) or silver staining (see section 2.3.3).
2.3.2 Coomassie staining of SDS-PAGE gels
The SDS-PAGE gel was rinsed in deionized water and then incubated with Coomassie fixing
solution (40% ethanol, 10% acetic acid) for 5 minutes up to 1 hour. Coomassie staining
solution (5% Aluminum sulfate-(14-18)-hydrate, 10% EtOH, 2% ortho-phosphoric acid, 0.02%
CBB-G250) was applied for at least 15 minutes or overnight. As this method gives only
minimal background, washing with deionized water for 15 minutes removed most of the
residual background staining. Gels that were stained overnight were additionally incubated
with Coomassie destaining solution (10% acetic acid) to speed up the destaining process.
Stained gels were documented using the LAS-3000 (Fujifilm) and imported to ImageJ software
for editing and quantification.
2.3.3 Silver staining of SDS-PAGE gels
Low amounts of protein on gels were visualized by silver staining. Silver staining was
performed with self-made solutions according to a protocol adapted from [214]. Alternatively
the Pierce® Silver Stain Kit (ThermoScientific) was used according to the manufacturer’s
instructions. Novex® pre-cast gels were stained with the SilverQuest™ Staining Kit (invitrogen)
according to the manufacturer’s instructions.
Stained gels were documented using the LAS-3000 (Fujifilm) and imported to ImageJ software
for editing and quantification.
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Protocol for Silver staining (adapted from [214]):
The SDS-PAGE or Tricine-SDS-PAGE gels were rinsed in deionized water and incubated in
fixing solution (50% methanol, 10% acetic acid, 100 mM ammonium acetate) for at least
30 minutes or overnight. The gel was washed twice with deionized water and sensitized by
incubating in sensitizing solution (0.005% sodium thiosulfate) for 60 minutes. Staining solution
(0.1% silver nitrate) for 60 minutes, followed by a 10 second-rinse with water. Developing solu-
tion (0.037% formaldehyde, 2% sodium carbonate) was added to the gel until bands appeared
(2- 3 minutes) and the development was stopped by adding stopping solution (50 mM EDTA)
for 60 minutes. The gels were rinsed twice with water before documentation.
2.3.4 Western blotting
SDS-PAGE and Tricine-SDS-PAGE gels were blotted to nitrocellulose membrane. Amersham
Hybond ECL Nitrocellulose Blotting Membrane (GE Healthcare) was used for detection of
proteins with fluorophore-coupled secondary antibodies and Amersham Protran 0.45 µm NC
Nitrocellulose Blotting Membrane (GE Healthcare) was used for detection with HRP-coupled
secondary antibodies.
The transfer was performed at 300 V, 400 mA in wet-blot chambers or at 150 V, 350 mA in a
Mini Trans-Blot® Cell (Bio-Rad) with Western blot transfer buffer (25 mM Tris, 193 mM glycine,
0.02% SDS, 20% methanol). Blotting time was adjusted according to the size of the proteins
and the percentage of the resolving gel and varied from 90 to 150 minutes.
Optionally, after transfer the membrane was stained with PonceauS staining solution for
1 minute. Excess staining solution was removed by several rinsing steps with 0.1% acetic acid.
Stained membranes were documented using the LAS-3000 (Fujifilm) and imported to ImageJ
software for editing.
To reduce unspecific binding, the membrane was blocked for 30 minutes with 4% milk powder
in PBST (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, 0.1% Tween-20)
or 2% BSA in PBST depending on the primary antibody. Primary antibodies were diluted in
freshly prepared blocking solution. A list of the primary antibodies used in this work and their
respective dilutions can be found in section 2.1.9. Blots were incubated in a 50 ml tube with
5 ml of diluted antibody solution on a blot roller for 2 hours at room temperature or overnight at
4 °C. The antibody solution was recovered and could be reused several times when stored at
-20 °C. The membrane was washed 3x 10 minutes with PBST. The secondary antibody was
diluted in 20 ml of 4% milk powder in PBST and applied for 1 hour at room temperature. A list




Protocol for detection with fluorophore-coupled secondary antibodies:
Western blot incubation boxes (LI-COR) were used for the blocking step, all washing steps and
incubation with the secondary antibody.
After incubation with the secondary antibody the membrane was washed 1-3x for 10 minutes
with PBST and then transferred to PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM
KH2PO4) until detection.
The signal was analyzed with the Odyssey® Sa Infrared Imaging System (LI-COR) using the
ImageStudio software (version 4.0.21, LI-COR).
Protocol for detection with HRP-coupled secondary antibodies:
After incubation with the secondary antibody the membrane was washed 3x 10 minutes with
PBST. Signals after addition of Immobilon™ Western Chemiluminescent HRP Substrate (Milli-
pore) were detected with Amersham Hyperfilm™ ECL (GE Healthcare) or Medix XBU medical
x-ray films (FOMA Bohemia). Films were developed with the developer machine CURIX60
(Agfa).
2.3.5 Chemically synthesized peptides
An NES peptide corresponding to the sequence CVDEMTKKFGTLTIHDTEK was obtained from
Pepscan Presto B. V. (Lelystad, The Netherlands) with a purity of 63.8%.
2.3.6 Protein purification
Ran(1-180)Q69L [127] and SPN1(1-291) were purified by Thomas Monecke (Molecular
Structural Biology, Universität Göttingen).
GST-PDCD2L wildtype and NES mutant were a gift from François Bachand (Université de
Sherbrooke, Canada).
RanC4A [215], RanGAP [103], RanBP1 [216], GST-CCP1 [217] and GST-Rev [218] were
available in the common laboratory stock.
Ran and RanQ69L were expressed and purified as described before [219].
GST-PKI-NES and GST-Rev-NES were purified with a standard protocol for purification of GST-
fusion proteins [220, 221] in GST prep buffer (50 mM Tris pH 6.8, 300 mM NaCl, 1 mM MgCl2,
0.25 mM EDTA, 1 mM DTT, 1 mM AP, 1 mM LP).
Importin α, importin β, importin 5, transportin and importin 13 were available in the common
laboratory stock.
SPN1




A glycerol stock of TG1 cells transformed with pQE60-CRM1-His [223] was plated on an
LB-agar plate with ampicillin. The plate was incubated at 37 °C overnight. 200 ml 2YT (16 g/l
tryptone, 10 g/l yeast extract, 5 g NaCl, pH 7.0) supplemented with ampicillin was inoculated
with several colonies from the plate and incubated at 37 °C, 170 rpm overnight. 2 liters 2YT
medium supplemented with ampicillin was inoculated with 10 ml starter culture in Erlenmeyer
flasks without baffles. CRM1-His was expressed at 37 °C overnight without induction. Cells
were harvested, washed once in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM
KH2PO4) and stored at -80 °C until purification.
TG1 cells were transformed with pQE60-CRM1-His mutants and plated on an LB-agar plate
with ampicillin. The plate was incubated at 37 °C overnight. 100 ml LB supplemented with
ampicillin was inoculated with several colonies from the plate and incubated at 37 °C, 170 rpm
overnight. 2 liters 2YT medium supplemented with ampicillin was inoculated with 10 ml starter
culture in Erlenmeyer flasks without baffles. Expression was induced at an OD600 of 0.5-0.7
with 100 µM Isopropyl β-D-1-thiogalactopyranoside. CRM1-His mutants were expressed at
37 °C for 5 hours. Cells were harvested, washed once in PBS and stored at -80 °C until
purification.
For purification, a pellet from 2 liter culture was resuspended in 35 ml CRM1 prep buffer
(50 mM HEPES pH 7.5, 500 mM NaCl, 2 mM MgCl2, 20 mM β-mercaptoethanol, 100 µM
PMSF, 1 µg/ml of each AP and LP). Cells were lysed with an EmulsiFlex-C3 (Avestin) and
the lysate was cleared by centrifugation at 100000 g and 4 °C for 30-45 minutes. The super-
natant was incubated with 1 ml Ni-NTA sepharose (Qiagen) equilibrated in CRM1 prep buffer
at 4 °C for 1 hour. The beads were washed 4x with CRM1 prep buffer supplemented with
30 mM imidazole, transferred to an empty column and eluted with CRM1 prep buffer contain-
ing 300 mM imidazole. The eluted protein was changed into CRM1 desalting buffer (50 mM
HEPES pH 7.5, 50 mM NaCl, 2 mM Mg(OAc)2, 2 mM DTT) with PD-10 Desalting Columns (GE
Healthcare) or a HiPrep 26/10 Desalting (Sephadex G-25) column (GE Healthcare) attached
to an ÄKTApurifier (Amersham Biosciences). The protein solution was filtered with Minisart RC
15 single use syringe filters (0.2 µm, sartorius stedim biotech) before purification with a MonoQ
anion exchanger column (GE Healthcare). CRM1-His was bound to the column in CRM1 de-
salting buffer and eluted with an increasing concentration of CRM1 high salt buffer (50 mM
HEPES pH 7.5, 500 mM NaCl, 2 mM Mg(OAc)2, 2 mM DTT). The peak fractions containing
CRM1-His were pooled, aliquoted, snap-frozen in liquid nitrogen and stored at -80 °C. For sub-
sequent complex formations for electron microscopy or crystallization CRM1-His was prepared
freshly and the complex was formed immediately.
GST-Nup214 fragments
GST-Nup214 fragments were expressed and purified as described before [59]. Glutathione was
removed from the eluted protein by buffer exchange into GST prep buffer (50 mM Tris pH 6.8,
300 mM NaCl, 1 mM MgCl2, 0.25 mM EDTA, 1mM DTT, 1 µg/ml of each AP and LP) with PD-10




His-Nup214 fragments were expressed and purified as described before [59]. After elu-
tion from Ni-NTA agarose (Qiagen), the protein was concentrated to a volume smaller than
5 ml with 20 ml/5 kDa Spin-XR concentrators (Corning), filtered with Minisart RC 15 single
use syringe filters (0.2 µm, sartorius stedim biotech) before purification with a HiLoad 26/60
Superdex 75 prep grade column (GE Healthcare) attached to an ÄKTApurifier (Amersham Bio-
sciences) in His prep buffer (50 mM Tris pH 6.8, 200 mM NaCl, 1 mM MgCl2, 10% glycerol,
4 mM β-mercaptoethanol, 100 µM PMSF, 1 µg/ml of each AP and LP). The fractions containing
the His-Nup214 were determined via SDS-PAGE, pooled and concentrated with 20 ml/5 kDa
Spin-XR concentrators (Corning).
MBP-Nup214-His fragments
Plasmids coding for MBP-Nup214-His fragments were transformed into BL21 (DE3) codon+
cells and plated onto LB-agar plates supplemented with ampicillin and chloramphenicol. 200 ml
MBP rich medium (10 g/l tryptone, 5 g/l yeast extract, 5 g/l NaCl, 2 g/l glucose) supplemented
with ampicillin and chloramphenicol was inoculated with several colonies from an LB-agar plate
and incubated overnight at 37 °C, 170 rpm. 1.5 liters MBP rich medium supplemented with
ampicillin was inoculated with 15 ml starter culture, grown at 37 °C, 130 rpm to an OD600 of
0.5-0.7. Expression was induced with 300 µM Isopropyl β-D-1-thiogalactopyranoside and cells
were grown overnight at 18 °C, 130 rpm. Cells were harvested, washed once in PBS (137 mM
NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4) and stored at -80 °C until purification.
A pellet from 1.5 liters of culture was resuspended in 35 ml His prep buffer (50 mM Tris pH 6.8,
200 mM NaCl, 1 mM MgCl2, 10% glycerol, 4 mM β-mercaptoethanol, 100 µM PMSF, 1 µg/ml
of each AP and LP). Cells were lysed with the EmulsiFlex-C3 (Avestin) and the lysate was
cleared by centrifugation at 100000 g, 4 °C for 30-45 minutes. The supernatant was added to
0.75 ml Ni-NTA sepharose and incubated at 4 °C for 1 hour. The beads were washed 3x with
His prep buffer containing 30 mM imidazole and eluted with His prep buffer containing 300 mM
imidazole. The eluted protein was diluted with His prep buffer to 10 ml, added to amylose resin
and incubated at 4 °C for 1 hour. The protein was eluted with His prep buffer containing 15 mM
maltose, aliquoted and stored at -80 °C.
2.3.7 Loading of Ran with GTP/GDP
Loading of Ran with GTP or GDP was performed with a protocol adapted from [24].
Ran was incubated with 20x molar excess of GTP or GDP and 15 mM EDTA in transport buffer
(20 mM HEPES, 110 mM KOAc, 2 mM Mg(OAc)2, 1 mM EGTA, pH 7.3) for 30 minutes at room
temperature. Afterwards 40 mM MgCl2 was added and the mixture was incubated on ice for
15 minutes.
Loaded Ran was immediately used or snap-frozen in small aliquots and stored at -80 °C.
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Aliquoted RanGTP was only thawed once.
RanGTP that was intended for loading with 32P-γ-GTP was changed into transport buffer with
2 ml Zeba Desalting Spin Columns (Pierce) to remove unbound GTP. Afterwards the load-
ing procedure was repeated to exchange the bound GTP with 32P-γ-GTP. 10 µl of 32P-γ-GTP
(6000 Ci/mmol, 10 mCi/ml) was used for loading 150-200 µg of Ran in transport buffer con-
taining 1 mg/ml BSA and 2 mM MgCl2. Unbound 32P-γ-GTP was removed by PD-10 Desalting
Columns (GE Healthcare).
2.3.8 In vitro binding assays
Pulldowns
Pulldowns were used to study the interaction of the nucleoporins with the CRM1 export com-
plex. Per sample, 50 pmol GST or GST-fusion protein was immobilized on 25 µl glutathione
sepharose High Performance beads (GE Healthcare) equilibrated in pulldown buffer (50 mM
Tris pH 7.4, 200 mM NaCl, 1 mM MgCl2, 5% glycerol, 1 mM DTT) supplemented with 20 mg/ml
BSA. Either the nucleoporin, a cargo or RanQ69L pre-loaded with GDP or GTP was immo-
bilized. The beads were washed with 3 times 500 µl pulldown buffer supplemented with 20
mg/ml BSA and incubated with an equal or excess molar amount of the proteins of interest in a
total volume of 400 µl pulldown buffer supplemented with 20 mg/ml BSA for 1hour at 4 °C. The
beads were washed with 3 times 500 µl pulldown buffer. Bound proteins were eluted in 2x SDS
sample buffer before analysis by SDS-PAGE and optional Western blotting.
Halo assay
For the detection of low affinity interactions and better quantification a flow cytometry-based
binding assay was developed (section 3.1).
CRM1 was labeled with Cy3 (Mono Reactive Dye Pack, GE Healthcare) according to the man-
ufacturer’s instructions. 50 pmol GST or GST-fusion protein was immobilized on 2.5 µl glu-
tathione sepharose High Performance beads (GE Healthcare) equilibrated in transport buffer
(20 mM HEPES pH7.3, 110 mM KOAc, 2 mM Mg(OAc)2, 1 mM EGTA, 1 mM DTT) supple-
mented with 10 mg/ml BSA. Either a nucleoporin, a cargo or Ran pre-loaded with GDP or GTP
was immobilized. The beads were washed and incubated with 7.3 pmol CRM1-Cy3, an excess
of the other proteins of interest and 5 µl 4x Halo mix (500 mM NaCl, 40 mg/ml BSA, 1 mM DTT,
2% 1,6-hexanediole) in a total volume of 20 µl transport buffer containing 10 mg/ml BSA for
1 hour at 4 °C. The beads were washed once in transport buffer and bound CRM1-Cy3 was
analyzed by flow cytometry using a FACSCanto II (BD Biosciences) and FACS Diva 6.1.1 soft-





RanGAP assays were performed as described previously to quantitatively assess complex for-
mation [24, 64]. CRM1 wildtype or mutants were incubated with Ran loaded with 32P-γ-GTP
and increasing concentrations of Nup214 or cargo or combinations thereof. GTP-hydrolysis of
unbound RanGTP was initiated upon addition of 10 nM RanGAP and analyzed by determining
free radioactive phosphate with a scintillation counter. Results were normalized to a reaction
without RanGAP and plotted as percent GTP-hydrolysis.
2.3.10 Complex formation tests
About 200 µg of complex were prepared by mixing the purified proteins of interest at 4 °C for
1 hour and loading on a Superdex 200 10/300 GL column (GE Healthcare) equilibrated in export
complex buffer (20 mM Tris pH 7.4, 50 mM NaCl, 1 mM Mg(OAc)2, 1 mM DTT). 1 ml fractions
were collected and the protein content was analyzed by SDS-PAGE followed by Coomassie or
silver staining or Western blotting.
2.3.11 Purification of Antibodies
Anti-Nup214 antibodies against an internal Nup214 peptide ((C)ASSSFGEQKPTGT) were
raised in rabbit (Covalab). 10 ml rabbit serum (rabbit 1314036, Covalab project 3882) was
diluted with 40 ml PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4) and
incubated with immobilized antigen on beads (provided by Covalab) at 4 °C overnight. Beads
were washed twice with 50 ml PBS supplemented with 0.5 M NaCl, transferred to a column and
eluted with 0.2 M acetic acid (pH 2.7) containing 0.5 M NaCl. 500 µl fractions were collected
and immediately neutralized with 100 µl 1M Tris/Base. The protein content of the fractions was
tested by adding 5 µl of the fraction to 200 µl Bradford assay solution. The three fractions con-
taining protein were pooled, changed into PBS with PD-10 Desalting Columns (GE Healthcare)
and concentrated with 50 kDa/6 ml Concentrators (Corning) to 1.6 ml. The purified antibody
was tested in immunofluorescence and Western blotting by Christiane Spillner.
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2.4 Cell Biology Methods
2.4.1 Cultivation of mammalian cells
HeLa P4 cells and HeLa cells stably transfected with NFAT [60, 24] were grown at 37 °C and
5% CO2 and 95% humidity on 10 cm or 15 cm diameter plates in Dulbecco’s Modified Eagle
Medium (DMEM) containing 10% fetal bovine serum (FBS), 2 mM L-glutamine and optionally
100 U/ml penicillin and 100 µg/ml streptomycin.
For passaging, cells were washed with PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4,
1.8 mM KH2PO4) once and incubated with 0.025% Trypsin/ EDTA until detached. Medium was
added and the cells were transferred to 10 cm, 15 cm or 24-well plates.
2.4.2 Transfection of DNA in mammalian cells
Plasmids were transfected with the calcium phosphate method [224]. For transfection in 24-
well plates, cells were grown in 500 µl medium to a confluency of 40-50%. 1 µg plasmid DNA
was transfected per well. 20 µl CaCl2 (250 mM) was added to the DNA in a reaction tube
followed by vortexing for 5 seconds. 20 µl 2x HEPES (50 mM HEPES, 250 mM NaCl, 1.5 mM
Na2HPO4, pH 6.98) buffer was added followed by 10 seconds vortexing and incubation at room
temperature for 25 minutes. After addition of the mixture, the cells were grown at 37 °C with
3% or 5% CO2 for 24 hours.
For co-transfection experiments, HeLa cells were transfected with 0.3 µg of a plasmid coding
for GFP-SPN1 [222] and 0.5-0.6 µg of plasmids coding for RFP-Nup214-cNLS fragments.
For transfection of 10 cm plates, the reaction mixture was upscaled using 15 µl DNA, 500 µl
CaCl2 and µl 2x HBS buffer.
2.4.3 In vitro export assays
In vitro export assays were adapted from [145]. GFP-NFAT spinner cells were grown in a
15 cm diameter plate to 40-50% confluency and expression of GFP-NFAT was induced by
1 µM trichostatin A in DMEM overnight. Import of GFP-NFAT into the nucleus was induced
by 1 µM ionomycin in DMEM for 25 minutes. Cells were washed once with PBS (137 mM
NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4) and detached from the plate by
addition of 0.025% Trypsin/ EDTA. Cells were resuspended in ice-cold transport buffer (20 mM
HEPES, 110 mM KOAc, 2 mM Mg(OAc)2, 1 mM EGTA, pH 7.3) supplemented with 10% FBS.
Cells were counted with the CASY 1 (Schärfe System) and centrifuged at 300 g and 4 °C for
5 minutes. The pellet was resuspended in transport buffer, centrifuged again and resuspended
in transport buffer at a concentration of 1x 107 cells/ml. 0.7 µl of 1% digitonin was added per
1x 106 cells for 3 minutes. 5 µl of cell suspension was mixed with 5 µl of a trypan blue solution
on a cover slide to confirm sufficient permeabilization.
For transport assays with recombinant Nup214 fragments, cells were washed once with 50 ml
transport buffer and resuspendend in transport buffer at a concentration of 2x 107 cells/ml.
Transport reactions containing 200000 pre-incubated cells, Ran, an ATP-regenerating system
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(1 mM ATP, 4 mM creatine phosphate, 10 U/ml creatine phosphokinase), NFAT oligo and the
respective Nup214 protein of interest were assembled in reaction tubes and incubated at 30 °C
in a thermomixer for 25 minutes. The samples were transferred to ice and the reaction was
stopped with 500 µl ice-cold transport buffer.
For transport assays with recombinant CRM1 mutants, permeabilized cells were pre-treated
to remove soluble transport factors and block endogenous CRM1. Cells were washed twice
with 50 ml transport buffer and resuspendend in transport buffer at a concentration of 0.5 x 107
cells/ml. 50000 cells per sample were incubated with ATP-regenerating system (1 mM ATP,
4 mM creatine phosphate, 10 U/ml creatine phosphokinase), and 100 nM LMB in a 30 °C water
bath for 15 minutes. The cells were washed twice with 50 ml transport buffer and afterwards
resuspendend in transport buffer at a concentration of 0.5 x 107 cells/ml.
The export reactions were assembled on ice in FACS tubes. 50000 pre-incubated cells, Ran,
ATP regenerating system, NFAT oligo and the respective CRM1 mutant were incubated in a
30 °C water bath for 25 minutes. The samples were transferred to ice and the reaction was
stopped with 4 ml ice-cold transport buffer. After centrifugation at 300 g and 4 °C for 5 minutes,
most of the supernatant was removed.
The efficiency of export was analyzed by measuring the fluorescence of GFP-NFAT in the nuclei
by a FACSCanto™ II flow cytometer (BD Biosciences).
2.4.4 Detection of proteins by indirect immunofluorescence
For detection of endogenous or HA-tagged protein, cells were grown on coverslips in 24-well
plates. The coverlids were washed with PBS and fixed with 4% formaldehyde in PBS containing
1 µg/ml Hoechst 33258 for 10 minutes at room temperature. After washing twice with PBS the
coverslips were transferred to a dark humidity chamber and permeabilized with 0.5% Triton
X-100 in PBS for 5 minutes. To reduce unspecific staining cells were afterwards blocked with
2% BSA in PBS for 10 minutes before incubation with the primary antibody diluted in 2% BSA
in PBS for 1 hour. The coverslips were washed twice in PBS and once in 2% BSA in PBS
and the secondary antibody was added for 1 hour. Unbound antibodies were removed by three
washing steps with PBS. The coverslips were dried and mounted with mounting medium. A list
of primary and secondary antibodies used for this work is found in section 2.1.9.
2.4.5 Quantification of GFP-SPN1 distribution
The effect of Nup214 or CRM mutants on nuclear export was analyzed by quantifying the
distribution of overexpressed GFP-SPN1 [222]. The localization in 50-100 cells was divided
into the three categories "N>C" (mainly nuclear), "N=C" (homogenous distribution throughout
the cell) and "N<C" (mainly cytoplasmic). Results were presented as percent of the individual
categories as a mean of at least three experiments as described previously [59].
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2.5 Structural Biology Methods
2.5.1 Preparative purification of protein complexes
CRM1-SPN1-RanGTP or CRM1-SPN1-RanGTP-Nup214 complexes were prepared by mixing
purified CRM1, RanQ69L-GTP, SPN1 and optionally a Nup214-fragment with at least 3 times
molar excess of all components compared to CRM1 and incubation on ice for 1 hour. The
assembled complex was further purified by gel filtration on a HiLoad 26/60 Superdex 200 prep
grade column (GE Healthcare) in export complex buffer (20 mM Tris pH 7.4, 50 mM NaCl, 1 mM
Mg(OAc)2, 2 mM DTT). The fractions containing the purified complex were concentrated with
20 ml/50 kDa Concentrators (Corning) to a concentration of at least 3 mg/ml, flash frozen in
liquid nitrogen and stored at -80 °C.
2.5.2 Cross-linking of protein complexes
The Nup214-Lys mutants were generated either with a PCR primer containing an additional
codon for lysine or with site-directed mutagenesis yielding the plasmids pET28a-His-
Nup214(K1916-2033)-His, pET28a-His-Nup214(1916-2033)A1995K-His and pET28a-His-
Nup214(1916-2033)A1999K-His.
Pre-purified CRM1-SPN1-RanGTP-Nup214 complexes (see section 2.5.1) were changed into
PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4) with Zeba Desalting
Spin columns (ThermoScientific) as the primary amines from the export complex buffer would
hinder the function of all amine-reactive cross-linkers. Cross-linking of Nup214 complexes with
BS3, BS2G and EGS was performed at 25 °C for 30 minutes.
A detailed description of the development of the different cross-linking strategies can be found
in section 3.3.2.
2.5.3 Mass spectrometry
Cross-linked protein complexes either as a solution or on a Coomassie-stained SDS-PAGE
were given to Romina Hofele (MPIbpc, Göttingen) for further sample preparation and MS/MS
analysis.
2.5.4 Electron microscopy
For electron microscopy experiments, only freshly prepared CRM1 was used. 500 pmol
CRM1-SPN1-RanGTP-Nup214 complex were formed by incubating the individual purified
proteins at a 1:1.2:1.5:2 molar ratio and an estimated complex concentration of ∼1 mg/ml on
ice for 1 hour. The complex was changed into EM buffer (20 mM HEPES pH 7.4, 50 mM NaCl,
1 mM Mg(OAc)2, 1 mM DTT) with Zeba Desalting Spin columns (ThermoScientific).
Prepared complexes were given to David Haselbach (MPIbpc, Göttingen) for further sample
preparation and electron microscopy. GraFix was performed as described in [225], followed by




The CRM1/SPN1(1-291)/RanQ69L(1-180)GTP/MBP-Nup214(1916-2033)-His complex was
prepared as described in section 2.5.1 with a molar ratio of 1:3:5:5 and concentrated to
5 mg/ml. The Nup214 complex was crystallized in 24-well sitting drop crystallization plates
by mixing 2 µl of the protein solution with 1 µl of the reservoir solution containing 5% (w/v)
polyethylene glycol (PEG) 8000, 0.2 M L-proline, 0.1 M Tris/HCl pH 7.5, 4 mM D-maltose
and 180 mM LiCl. Cross-seeding with older crystals of the same protein complex was used
to control the number of crystals per well. Several seeds were added to the pre-incubated
protein-reservoir mixture after 20 minutes. Crystals with dimensions of around 150 x 150 x
80 µm grew at 20°C after 5 days.
Crystals were optimized and analyzed and the model was built and refined by Thomas
Monecke (Molecular Structural Biology, Universität Göttingen).
All crystals belonged to the orthorhombic space group C2221 and diffracted X-rays to a max-
imum resolution of 7Å. In order to improve the diffraction quality, crystals were successively
dehydrated by transferring to conditions with increasing PEG 8000 concentrations. The PEG
8000 concentration was increased from 5% to 45% in 5% steps with 15 minutes of incubation
in between. Crystal dehydration resulted in a significant reduction of the unit cell lengths by
∼10% for each axis (e.g. a-axis from 126 Å to 112 Å (13%), b-axis from 263 Å to 248 Å (6%)
and c-axis from 229 Å to 210 Å (8%)) thereby decreasing the crystal solvent content from
69% to 59%. Dehydrated crystals were fished on micro meshes (MiTeGen) and mounted on
beamline 14.3 (BESSY II, Berlin) equipped with an HC1c crystal humidifier [226]. Residual
mother liquor was completely removed from the crystals using a paper wick. The crystals were
flash frozen in liquid nitrogen and transferred to beamline 14.1 equipped with a 6M Pilatus
detector for data collection (BESSY II, Berlin) [226]. Complete diffraction datasets of two
treated crystals were collected. Data were processed using XDS and XSCALE [227].
Molecular replacement with PHASER [228] was used to solve the structure using the CRM1-
RanGTP-SPN1 export complex (PDB ID: 3GJX) [127] as a starting model. Localization of the
MBP (PDB ID: 1ANF) [229] by molecular replacement routines of PHASER did not provide
an unambiguous solution and was therefore fitted manually into positive |Fo-Fc| difference
electron density. After replacement and initial rigid body refinement, positive |Fo-Fc| difference
electron density compared to the CRM1-RanGTP-SPN1 export complex structure (PDB ID:
3GJX) allowed for building of three regions of the Nup214 fragment. The structure refinement
was done by iterative cycles of CNS [230] and manual model building in Coot [231].




3.1 Development of a bead-based flow cytometry assay for protein-protein in-
teractions (Halo assay)
A bead-based microscopy assay was previously described to analyze the interactions of
different nucleoporins with each other [232]. In that assay, GST-nucleoporins were immobilized
on beads and incubated with soluble CFP-fusions of other nucleoporins to test for interactions.
The interaction was assessed with a microscope and a fluorescent halo could be observed
around the dark beads in case the two nucleoporins interacted with each other [232].
Another study described a flow cytometry protein interaction assay (FCPIA), which used
immobilized protein on polystyrene beads to detect interaction with a fluorescently labeled
binding partner by flow cytometry [233]. FCPIA was used to calculate protein-protein interac-
tion affinities and to perform competition experiments with unlabeled binding partners or small
molecules [233].
In this work, both previously described assays were combined and developed into a stable,
semi-quantitative assay to analyze the interaction of Cy3-labeled CRM1 with a variety of car-
goes and Nup214 fragments.
When analyzing binding of Cy3-labeled CRM1 to immobilized Nup214 fragments by fluores-
cence microscopy, fluorescent halos appeared around the beads, similar as observed in [232],
which led to the naming of the assay (appendix, figure S1).
3.1.1 Optimization of assay conditions
Optimization of the assay conditions included the composition of the buffer and additives as
well as the amounts and ratios of the proteins. The two buffers commonly used for CRM1
in vitro binding assays are the Tris-based pulldown buffer and the HEPES-based transport
buffer. In a first step, the two buffers were compared and their effect on the fluorescence
signal was analyzed. Equal amounts of GST-RanGDP or GST-RanGTP were immobilized
on beads and incubated with a constant amount of CRM1-Cy3 in the absence or presence
of SPN1 and a Nup214 fragment. The fluorescence intensities measured in transport buffer
were consistently higher than the intensities measured in Tris buffer (figure 9). This held true
for samples with RanGDP or RanGTP and in the presence or absence of any other protein.
Transport buffer was therefore used in all further experiments, as it showed consistently higher
fluorescence intensities without increasing unspecific background binding.
Next, additives to the assay buffer were optimized. The described microscope assay used a 4x
assay buffer containing 40 mM EDTA, 500 mM NaCl, 40 mg/ml BSA and 2% 1,6-hexanediole
[232]. As EDTA is used to remove bound nucleotides from Ran, the effect of an assay buffer
with and without EDTA was tested. A Nup214 fragment was immobilized and incubated with
two different amounts of CRM1-Cy3 and NES peptides and increasing amounts of RanGTP
with either the described buffer or the same buffer without EDTA (data not shown). No major




1,6-hexanediole was described as a reagent to minimize unspecific hydrophobic protein-protein
interactions [232]. Its effect on the assay was tested by adding 2%, 5% or 10% 1,6-hexanediole
to the 4x Halo mix (500 mM NaCl, 40 mg/ml BSA, 1 mM DTT) and probing the interaction of
immobilized GST-SPN1 with a constant amount of CRM1-Cy3 in the absence or presence of
RanGTP. No consistent effect could be observed (data not shown). 2% 1,6-hexanediole was
anyway included in the assay buffer in accordance with the literature [232].
The optimized 4x Halo mix (500 mM NaCl, 40 mg/ml BSA, 1 mM DTT, 2% 1,6-hexanediole)
was used for all subsequent experiments, leading to a total buffer concentration of 20 mM
HEPES pH 7.3, 110 mM KOAc, 2 mM Mg(OAc)2, 125 mM NaCl, 1 mM EGTA, 10 mg/ml BSA,
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Figure 9: Transport buffer gave higher fluorescence signals in the
bead-based flow cytometry assay. About 470 pmol of GST-RanGTP or
GST-RanGDP were immobilized on 2.5 µl glutathione sepharose. CRM1-
Cy3 alone or with SPN1 or SPN1 and a Nup214(1916-2033) fragment
were added to the beads. CRM1-binding was analyzed by flow cytometry.
The absolute fluorescence intensities were plotted.
3.1.2 Biochemical verification of the novel CRM1-binding assay
In addition to the optimization of the assay conditions, the biochemical specificity of the assay
had to be verified. First, it was tested if a saturation of CRM1-binding to immobilized GST-SPN1
could be reached. Increasing amounts from 2.5 pmol to 60 pmol CRM1-Cy3 were titrated to
50 pmol of immobilized GST-SPN1 in the presence of RanGTP. The detected fluorescence
intensities increased with increasing CRM1-Cy3 amounts and a plateau was reached when
SPN1 and CRM1-Cy3 were present at nearly equimolar levels, indicating specificity of the
binding (figure 10A).
Next, the specificity of the binding was investigated by pre-incubating CRM1 with its inhibitor
LMB to allow covalent modification of Cys528 and titrating increasing amounts of LMB-treated
or mock-treated CRM1-Cy3 to immobilized GST-SPN1 in the presence of an excess of
RanGTP. The samples with LMB-treated CRM1-Cy3 showed a decrease of more than 80% in
fluorescence intensities for all CRM1 amounts tested (figure 10B).
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The binding of Cy3-labeled CRM1 was compared to the binding of unlabeled CRM1 by titrating
increasing amounts of unlabeled CRM1 to immobilized GST-cargoes, namely SPN1 and HIV-1
Rev, in the presence of a constant amount of CRM1-Cy3. Increasing amounts of unlabeled
CRM1 lead to a decrease in fluorescence intensity, suggesting that the Cy3-labeling does not
have major effect on the binding properties of CRM1. The relative decrease varied between
SPN1 and Rev, indicating different on- and off-rates in the binding of CRM1 (figure 10C).
In the cellular context, the CRM1-RanGTP-cargo complex dissociates in the cytoplasm after
translocation through the NPC upon hydrolysis of RanGTP. GTP-hydrolysis is mediated by
RanBP1 and RanGAP. Therefore, it was tested if the binding of CRM1Cy3-RanGTP-cargo
complex was sensitive to the presence of RanBP1 and RanGAP. GST-SPN1 and GST-Rev
were immobilized and CRM1-Cy3 and RanGTP were added. After incubation for 1 hour,
RanGAP was added to the samples with RanBP1 and fluorescence intensities were compared
to samples without RanBP1 and RanGAP. Addition of RanGTP increased the fluorescence
intensity for by a factor of 2 for SPN1 and more than 20 for Rev. RanBP1 and RanGAP reduced
the fluorescence intensities for both cargoes tested (figure 10D).
Taken together, CRM1-Cy3 binding in the assay can be saturated, blocked by LMB, competed
with unlabeled CRM1 and reduced by the addition of RanGAP and RanBP1. The interactions
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Figure 10: Controls verified the specificity of the Halo assay. (A-B) Increasing amounts of CRM1-
Cy3 were titrated to 50 pmol immobilized GST-SPN1 in the presence of an excess amount of RanGTP.
(A) The mean and standard deviation of duplicates were plotted. (B) CRM1-Cy3 was incubated with a
5x molar excess of LMB or ethanol as a solvent control at room temperature for 2.5 hours. Fluorescence
intensities were normalized to the values of CRM1-Cy3 pre-incubated with ethanol as 100%. (C) 50 pmol
GST or a GST-tagged cargo were immobilized on 2.5 µl beads and incubated with10 pmol of CRM1-Cy3
and an increasing amount of unlabeled CRM1 in the presence of RanGTP. Fluorescence intensities were
normalized to the value of the sample without any competing unlabeled CRM1 as 100%. (D) 50 pmol
of GST-tagged cargo was immobilized on 2.5 µl beads and incubated with a constant amount of CRM1-
Cy3 alone, in the presence of RanGTP or RanGTP and RanBP1. After 1 hour, RanGAP was added
to the condition with RanBP1 and the samples were incubated for another 30 minutes. Fluorescence
intensities were normalized to the value of the sample with RanGTP as 100%. The mean and standard
deviation of two independent experiments were plotted.
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3.1.3 Comparison of CRM1-binding to different Nup214 fragments reveals a detection
range of 3 orders of magnitude
The newly developed assay was applied to quantify the binding of CRM1 to Nup214 fragments
of different lengths. Several GST-Nup214 fragments were immobilized and incubated with
CRM1-Cy3 in the absence or presence of RanGTP and CRM1-Cy3 binding was quantified by
flow cytometry (figure 11). The observed fluorescence intensities increased with the size of the
Nup214 fragments and were reduced when comparing fragments with mutated FG-repeats to
non-mutated fragments of the same length.
The potency of the assay lies in the analysis of protein-protein interactions of very different
strengths. Binding of CRM1-Cy3 to the different Nup214 fragments yields fluorescence
intensities from ∼90 to ∼90000, therefore covering a range of 3 orders of magnitude, which is
a lot more then with a conventional gel-based pulldown assay. The developed assay therefore
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Figure 11: Comparison of CRM1 binding to different Nup214-fragments. 50 pmol of GST-tagged
Nup214 fragments were immobilized on 2.5 µl beads and incubated with a constant amount of CRM1-
Cy3 and excess of an NES peptide in the presence or absence of RanGTP. The average fluorescence
intensities and standard deviations of three independent experiments were plotted.
An increase of CRM1-binding upon addition of RanGTP was detected for all Nup214 fragments,
except one, indicating a specific binding. Interestingly, the ratio of CRM1-binding in the pres-
ence of RanGTP compared to the absence of RanGTP varied for the different fragments. It
was between a 1.5 and 3.0 fold change for very short as well as very long Nup214 fragments.
Only a medium sized fragment containing the Nup214 residues 1968-2033 showed a ∼60 fold
increase of binding upon addition of RanGTP. The only fragment not showing an increase in
fluorescence upon RanGTP addition was Nup214(1968-1990)4SG, which was expected as
this fragment does not contain any FG-repeats. The fluorescence intensity of this fragment is




3.1.4 Application of the Halo assay to analyze CRM1-cargo interactions
As an application for the developed Halo assay, CRM1-binding to several of its cargoes was
compared. Cytosolic carboxypeptidase 1 (CCP1) and programmed cell death protein 2-like
protein (PDCD2L) were recently identified as novel CRM1 cargoes [217].
GST-fusions of SPN1 and a fragment of CCP1(1-120) were immobilized on glutathione
sepharose and incubated with CRM1-Cy3 in the absence and presence of RanGTP (figure
12A). The increased binding of CRM1 to both of the cargoes in the presence of RanGTP
reflects the specificity of the export complex formation. The detected fluorescence intensities
indicate that the binding of CRM1 to SPN1 is very strong compared to the binding to the
CCP1(1-120) fragment.
Binding of CRM1 to its cargo PDCD2L and a PDCD2L version with a mutated NES was
compared (see figure 12B). GST, GST-PDCD2L and the GST-PDCD2L mutant were im-
mobilized and incubated with CRM1-Cy3 alone, in the presence of RanGTP or RanGTP
and a Nup214(1916-2033) fragment. The presence of RanGTP increased CRM1 binding
to PDCD2L, but not the PDCD2L mutant, indicating that the mutated NES prevents specific
interaction of PDCD2L with CRM1. Accordingly, the additional incubation with Nup214 lead to
a massive increase of CRM1 binding to PDCD2L, but did not have an effect on CRM1-binding
to the PDCD2L mutant.
To sum up, the Halo assay is a bead-based flow cytometry assay that is well suited for semi-
quantitative analysis of CRM1-binding to nucleoporins and its cargoes. The application range
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Figure 12: Analysis of CRM1-cargo interactions. (A) GST, GST-SPN1 and GST-CCP1(1-120) were
immobilized on glutathione sepharose and incubated with CRM1-Cy3 in the absence or presence of
RanGTP. Absolute fluorescence intensities and standard deviations of three experiments were plotted.
The figure is modified from [217]. (B) GST, GST-PDCD2L and a GST-PDCD2L mutant with inactivated
NES were immobilized on glutathione sepharose and incubated with CRM1-Cy3 alone or in the pres-
ence of RanGTP, with or without a Nup214(1916-2033) fragment. Absolute fluorescence intensities and
standard deviations of 6 independent experiments were plotted.
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3.2 Biochemical characterization of CRM1-Nup214 binding
3.2.1 CRM1 is the karyopherin with the highest avidity for Nup214
All current models of nuclear transport rely on an interaction of karyopherins with FG-
nucleoporins to facilitate translocation through the nuclear pore complex. The C-terminal frag-
ment of Nup214 (residues 1859-2090) contains a large number of FG-repeats and was previ-
ously shown to interact with CRM1 in a RanGTP-dependent manner [54, 58]. It was therefore
investigated if this fragment could also interact with other nuclear transport receptors. The
Nup214 C-terminus was immobilized on beads and incubated with a variety of nuclear trans-
port receptors in the absence and presence of RanQ69L-GTP (figure 13). In addition to the
export receptor CRM1, the import receptors importin α and importin β, individually or in com-
bination, importin 5 and transportin were tested, as well as the bi-directional transport receptor
importin 13. An interaction of Nup214 with CRM1 in the presence of RanQ69L-GTP could be
observed, which could be further increased by addition of an NES peptide. None of the other
receptors bound to the C-terminal Nup214 fragment. The specificity of Nup214-binding to
CRM1 emphasizes the importance of Nup214 in the export of some CRM1-dependent cargoes
[60]. The high avidity of the interaction is in accordance with observations that CRM1-export
complexes get stalled in hydrogels derived from the Nup214 C-terminus, but not in hydrogels

































































Figure 13: CRM1 is the karyopherin with the highest avidity for Nup214. 50 pmol GST-
Nup214(1859-2090) were immobilized on glutathione beads and incubated with 50 pmol of the respec-
tive transport receptors in the absence or presence of 150 pmol RanQ69L-GTP and, for CRM1, an NES
peptide. (A) Bound proteins were analyzed by SDS-PAGE, followed by Coomassie-staining. (B) shows
10% input samples of the transport receptors used in the assay.
3.2.2 Nup214 promotes the formation of CRM1 export complexes in a RanGTP-
dependent manner
Nup214 was previously shown to have a stabilizing effect on CRM1 export complexes [60].
The relative effect of stabilization by Nup214 was further assessed with in vitro binding
assays (figure 14). Immobilized GST-SPN1 or GST-Rev was incubated with CRM1 alone or in
combination with RanGTP or a Nup214(1916-2033) fragment. No binding between CRM1 and
any of the cargoes was observed in the absence of RanGTP in a pulldown assay (figure 14A).
A clear binding of CRM1 to SPN1 was observed in the presence of RanGTP which was even
stronger upon addition of the Nup214 fragment. For Rev, no increase in binding was observed
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when incubated with only CRM1 and RanGTP. CRM1 binding to Rev could only be observed
in the presence of the Nup214 fragment. Probing the same interactions with the Halo assay
gave a more differentiated result (figure 14B). A specific interaction of SPN1 and CRM1 was
observed even in the absence of RanGTP. This is in line with the fact that a CRM1-SPN1
complex was stable enough to crystallize [174]. Addition of RanGTP increased the binding of
CRM1 to SPN1 by a factor of around 2 and addition Nup214 fragment increased the binding
even further by a factor of around 1.5. The interaction of CRM1 with Rev is influenced the
same way, but the extent of the effect of RanGTP and Nup214 differ a lot compared to SPN1.
The interaction of CRM1 with Rev was only minimal in the absence of RanGTP. Addition of
RanGTP led to a roughly 6-fold increase in CRM1 binding, which is increased even further by
a factor of nearly 7 upon addition of the Nup214 fragment.
The relative effect of the stabilization by Nup214 observed in the assays is in accordance with
the importance of Nup214 for the export of certain cargoes in vivo. The export of Rev by CRM1
is abolished in Nup214-knockdown cells [60] whereas Nup214-knockdown does not influence




































































Figure 14: The relative effect of Nup214 varies with different cargoes. (A) 500 pmol of GST or GST-
fusion protein was immobilized on glutathione beads and incubated with 250 pmol CRM1, RanGTP,
Nup214(1916-2033) alone or with combinations thereof. Bound proteins were eluted with SDS sample
buffer and analyzed by SDS-PAGE, followed by Coomassie-staining. (B) 50 pmol of GST or GST-fusion
protein was immobilized on glutathione beads and incubated with 8.6 pmol CRM1-Cy3 and an excess of
RanGTP or Nup214(1916-2033) alone or with combinations thereof. The bound fluorescence was ana-
lyzed by flow cytometry. Results were normalized against the sample with immobilized GST incubated
with CRM1-Cy3, RanGTP and Nup214. The fold change of five independent experiments was plotted.
Error bars indicate the standard deviation.
The stabilizing effect of Nup214 on export complexes was quantitatively assessed with Ran-
GAP assays. CRM1 was incubated with Ran loaded with 32P-γ-GTP and increasing amounts
of SPN1 or an NES peptide in the absence or presence of a Nup214 fragment. GTP-hydrolysis
was induced by addition of RanGAP. Hydrolysis of RanGTP by RanGAP releases radioactively
labeled phosphate, which is analyzed by a scintillation counter. The more stable the complex,
the less radioactively labeled phosphate gets released as RanGTP in a complex with CRM1 is
resistant towards RanGAP-induced GTP-hydrolysis. The titration of a cargo, either SPN1 or an
NES peptide in a RanGAP assay in the absence or presence of a Nup214 fragment confirms
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that the tetrameric CRM1-RanGTP-cargo-Nup214 complex is clearly more resistant towards










































Figure 15: Nup214 increases stability of CRM1 export complexes towards RanGAP-induced GTP-
hydrolysis. (A) SPN1 or (B) an NES peptide were titrated to CRM1 and Ran loaded with 32P-γ-GTP
in the absence of presence of 300 nM Nup214(1916-2033). GTP-hydrolysis was initiated by RanGAP.
Counts were normalized to a sample without RanGAP and plotted as % GTP-hydrolysis. The mean of
three independent experiments is shown. Error bars indicating the standard deviation are too small to
be seen.
The interaction of CRM1 with its cargoes depends on the presence of RanGTP, as only the
structural changes of CRM1 that follow upon binding of RanGTP open up the NES binding
cleft on CRM1 and allow for cargo recognition. As it was established that Nup214 stabilizes
CRM1 export complexes, it was investigated if the interaction of CRM1 and its cargoes could be
stabilized by only Nup214 or if it was still dependent on RanGTP. Purified CRM1 was incubated
with either SPN1 or an NES peptide, a Nup214 fragment and Ran loaded with GTP or GDP
and complex formation was assessed by gel filtration (figure 16). No complex with Nup214 was
formed in the presence of RanGDP, whereas RanGTP lead to the formation of Nup214-export
complex for SPN1 as well as for the NES peptide. Therefore, Nup214 alone, at least the tested
Nup214(1916-2033) fragment, is not able to promote CRM1-cargo interaction in the absence






































Figure 16: Nup214 binds to export complexes in the presence of RanGTP. 1.16 nmol of CRM1 and
RanGTP or GDP were mixed with either an equimolar amount of SPN1 (A, B) or a 3-fold excess of the
NES peptide (C, D) and incubated at 4 °C for 30 minutes. An equimolar amount of the Nup214(1916-
2033) fragment was added and the complex was incubated at 4°C for another 30 minutes before analysis
on an analytical S200 gel filtration column in export complex buffer. 1ml fractions were collected and
analyzed by SDS-PAGE, followed by Coomassie-staining. Arrows indicate the bands for the respective
proteins. Brackets indicate the fractions in which a formed complex is expected.
3.2.3 Binding of Nup214 fragments to the export complex is independent of their stabi-
lization effect in RanGAP assays
The binding of a large variety of Nup214 fragments to CRM1 export complexes was tested in
this work. Most of the fragments were built around a conserved motif of FG-repeats between
residues 1968 and 1996 [59]. The standard Nup214 fragment used for most of the assays and
also for our structural analysis (see below) contained the residues from 1916-2033. Based on
this standard fragment, several shorter constructs were generated to narrow down the binding
sites and improve purification efficiency (appendix figure S9). An N- and C-terminal truncated
fragment ranging from residues 1930 to 2021 showed similar purification efficiency as the
standard fragment. Also the formation of a CRM1-RanGTP-SPN1-Nup214 complex worked

























Figure 17: The Nup214-fragments 1930-2021 and 1916-2033 both bind stably to the export com-
plex. 2.5 nmol of CRM1 were incubated with excess amounts of SPN1, RanQ69L-GTP and His-tagged
(A) Nup214(1930-2021) or (B) Nup214(1916-2033) at 4 °C for 30 minutes. Complex formation was
assessed by analytical gel filtration with a S200 column in export complex buffer. 1ml fractions were
collected and analyzed by SDS-PAGE, followed by Coomassie-staining. Arrows indicate the bands for
the respective proteins. Brackets indicate the fractions in which a formed complex is expected.
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The comparison of the Nup214(1916-2033) fragment with the slightly truncated Nup214(1930-
2021) fragment in RanGAP assays revealed unexpected differences in the ability of the Nup214
fragments to stabilize the CRM1-RanGTP complex towards RanGAP-induced GTP-hydrolysis.
The addition of 300 nM of an MBP-tagged Nup214(1916-2033) standard fragment lead to
a reduction of GTP-hydrolysis to 40%, whereas the MBP-tagged Nup214(1930-2021) did
not show any stabilizing effect (figure 18A). This is remarkable, as Nup214(1930-2021)
was able to form a stable tetrameric export complex (figure 17). Based on these results,
several other constructs were designed (figure 18F). Fragments containing only the N- or the
C-terminal truncation compared to the standard fragment, namely Nup214(1930-2033) and
Nup214(1916-2021) showed increased GTP-hydrolysis with 300 nM of the Nup214(1930-2033)
and Nup214(1916-2021) leading to around 60% and 80% GTP-hydrolysis, respectively (figure
18A). Comparing the same MBP-tagged Nup214 fragments in a pulldown assay revealed that
the different ability of the Nup214 fragments to stabilize the complex in the RanGAP assay
is only partially reflected by their ability to bind the CRM1 export complex. Incubating the
fragments with immobilized GST-Rev and CRM1 in the absence or presence of RanQ69L-GTP
revealed that all of the tested Nup214 fragments bind to the CRM1-RanGTP-Rev export
complex in a RanGTP-dependent manner (figure 18B). The different stabilization effects from
the RanGAP assay are partially reflected by decreased binding efficiencies of the Nup214
and CRM1 in the individual samples. The presence of residues 1916-1929 and 2022-2033
therefore has an obvious effect on the stability of the complex. Hence, it was investigated if
these short peptides alone were able to bind and stabilize the complex. SPN1 was titrated
in the presence of either GST or a GST-Nup214 fragment in a RanGAP assay (figure 18C).
None of the short peptides showed any stabilizing effect compared to GST whereas the
longer Nup214(1968-2033) fragment totally inhibited GTP-hydrolysis. This was confirmed by
a pulldown assay in which the same constructs were immobilized on glutathione beads and
incubated with pre-purified CRM1-RanGTP-SPN1 export complex. GST-Nup214(1968-2033)
showed a clear binding of CRM1 and SPN1 whereas no CRM1-binding could be observed
for immobilized GST-Nup214(1916-1929) and GST-Nup214(2022-2033) (figure 18D). Probing
the different GST-Nup214 in a halo assay with CRM1-Cy3 and NES peptide in absence and










































































































































1916 -         -1929
1930 -                                                                  - 2033
1916 -                                                                         - 2033
1916 -                                                                 - 2021
1930 -                                                         - 2021
2022 -           - 2033
F
1968 -                                            - 2033
Figure 18: Binding of Nup214 fragments to CRM1 export complexes. (A) RanGAP assay: MBP-
tagged Nup214 fragments were titrated to CRM1 and Ran loaded with 32P-γ-GTP in the absence of
cargo. GTP-hydrolysis was initiated by addition of RanGAP. Counts were normalized to a sample without
RanGAP and plotted as % GTP-hydrolysis. The mean and standard deviation of three independent
experiments are shown. (B) 50 pmol GST or GST-Rev were immobilized on beads and incubated with
CRM1 and MBP-Nup214-His fragments in the absence or presence of RanGTP. Bound proteins were
analyzed by SDS-PAGE, followed by Coomassie-staining. (C) RanGAP assay: SPN1 is titrated to CRM1
and 32P-γ-GTP in the absence and presence of 2.5 µM GST or GST-Nup214 fragments as in (A). (D) 500
pmol GST or GST-Nup214 fragments were immobilized on beads and incubated with pre-purified CRM1-
RanGTP-SPN1 export complex. Bound proteins were analyzed by SDS-PAGE, followed by Coomassie-
staining. (E) 50 pmol GST- of GST-Nup214 fragments were immobilized on beads and incubated with
CRM1-Cy3 and an NES peptide in absence or presence of RanGTP. Bound CRM1 was detected by flow
cytometry. Average fluorescence intensities and standard deviations of three independent experiments
were plotted. (F) Scheme of the Nup214 fragments used in the above assays.
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The previous results showed that the binding of short Nup214 fragments to the export complex
is independent of their stabilization effect in RanGAP assays. Therefore it was tested if
longer Nup214 fragments would stabilize the CRM1-RanGTP-cargo export complex more
effectively. GST-Nup214(1968-2033) and GST-Nup214(1859-2090) were immobilized on
glutathione beads and incubated with either CRM1 alone or in combination with RanGTP,
with or without an NES peptide. Whereas Nup214(1968-2033) could only form a complex
with CRM1 in the presence of the NES cargo, Nup214(1859-2090) could also form a trimeric
CRM1-RanGTP-Nup214 complex without cargo (figure 19A).
The obvious differences between the Nup214 fragments could be confirmed with a previ-
ously described in vivo interaction assay [59]. Nup214 fragments fused to RFP-cNLS were
co-transfected with GFP-SPN1. The cNLS targeted the expressed Nup214 fragment to the
nucleus. In case the transfected Nup214 fragment did not interact with CRM1, GFP-SPN1
was exported normally by CRM1 and localized exclusively to the cytoplasm. An interaction of
the Nup214 fragment with CRM1 would trap CRM1 to the nucleus. Therefore, CRM1 would
not be available for nuclear export and GFP-SPN1 would accumulate in the nucleus. The
Nup214 fragments 1968-2033, 1916-2033 and 1859-2090 were compared for their effect on
GFP-SPN1 localization (figure 19B). All three fragments had previously exhibited efficient
binding to the export complex as well as export complex stabilization. Nup214(1968-2033) only
exhibited minor effects when co-transfected with GFP-SPN1, shifting its localization in ∼30%
of the cells from an exclusively cytoplasmic to an equally distributed localization. The effect
of Nup214(1916-2033) was more apparent. Nearly 80% of the cells showed a predominant
nuclear GFP-SPN1 localization, in ∼20% of the cells the GFP-SPN1 was distributed equally.
Nup214(1859-2090) showed the most dramatic effect, as it apparently trapped all CRM1 in the
nucleus thereby completely abolishing GFP-SPN1 export.
The observed effects on the stabilization of the export complex of the different Nup214 frag-

















































































Figure 19: In vivo and in vitro binding assays indicate that the length of the Nup214 fragment in-
fluences the stability of CRM1-binding. (A) 50 pmol GST-Nup214(1968-2033) or GST-Nup214(1859-
2090) was immobilized on beads and incubated with CRM1 in the absence or presence of RanGTP
and NES peptide. Bound proteins were analyzed by SDS-PAGE, followed by Coomassie-staining. (B)
Nup214 fragments 1968-2033, 1916-2033 and 1859-2090 fused to RFP-cNLS or the empty RFP-cNLS
vector were co-transfected with GFP-SPN1 in HeLa P4 cells. Cells were analyzed by fluorescence
microscopy after 24 hours.The localization of GFP-SPN1 in 100 cells was quantified for predominant
cytoplasmic (C > N), equally distributed (C = N) and predominant nuclear (C < N) localization. Cells
were transfected and localization was counted by Christiane Spillner. The mean and standard deviation
of three independent experiments were plotted.
3.2.4 The Ran C-terminus destabilizes the CRM1-RanGTP-Nup214 complex
It was previously shown that the Ran C-terminus influences the stability of CRM1 export
complexes by mediating its binding to RanBP1 [216, 235, 236]. An acid patch with the amino
acid sequence DEDDDL at the Ran C-terminus was important for the binding of RanGTP to
RanBP1, as its truncation abolished binding to RanBP1 completely [235, 236]. A Ran mutant
named RanC4A in which 4 of these 5 acidic residues were mutated to alanine, yielding the
sequence AAADAL, reduced the binding affinity to RanBP1 by a factor of around 20 [216].
The effect of wildtype Ran on CRM1-Nup214 complex stability was compared to RanC4A and
truncated Ran(1-180). CRM1 and His-tagged Nup214(1916-2033) were incubated with the
respective Ran species loaded with GTP in the absence or presence of SPN1. All three Ran
species were able to form a tetrameric CRM1-Ran-SPN1-Nup214 complex (figure 20A,C,E).
Interestingly, wildtype Ran was not able to complex with CRM1 in the absence of SPN1
(figure 20B), whereas a trimeric CRM1-Ran-Nup214 complex could be observed with RanC4A





























































Figure 20: The C-terminus of Ran influences the stability of the CRM1-RanGTP-Nup214 complex.
2.5-3.0 nmol CRM1 were incubated with an excess amount of His-Nup214(1916-2033)-His and the
respective Ran mutant loaded with GTP, in the presence or absence of SPN1. Complex formation was
assessed by analytical gel filtration with a S200 column in export complex buffer. 1 ml fractions were
collected and analyzed by SDS-PAGE, followed by Coomassie-staining. Arrows indicate the bands for
the respective proteins. Brackets indicate the fractions in which a formed complex is observed. (A)-(B)
show complex formations of the Ran wildtype in the (A) presence or (B) absence of SPN1. (C)-(D) show
the same for Ran(1-180) and (E)-(F) for RanC4A.
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3.3 Structural characterization of CRM1-RanGTP-SPN1-Nup214 complexes
Previous studies could narrow down the region on Nup214 that interacts with CRM1, but nothing
was known about the interacting region on CRM1 [59]. The structure of CRM1, its coopera-
tive binding mechanism and its sophisticated confirmation changes upon binding of RanGTP or
cargo, made the use of CRM1 truncation mutants and therefore a biochemical approach unsuit-
able. Therefore, several structural approaches were applied to characterize the CRM1-Nup214
interaction on a molecular level.
3.3.1 Electron microscopy
Analysis of the protein complexes with single particle electron microscopy
In single particle electron microscopy (EM), a 3D structure of a macromolecule is calculated
from thousands of 2D images of randomly oriented single macromolecules that are extracted
from digitized micrographs. Technical advances in the field of electron microscopy, especially
the development of direct electron detectors now allow the analysis of single particles at a
near-atomic resolution. The major limit to resolution for biological samples is the damage of the
sample by the beam itself. To preserve the sample, the beam intensity has to be very low, which
on the other hand increases the noise level of the images and therefore also the challenges of
data analysis [237, 238, 239].
Based on the single particle EM analysis of the unbound CRM1 [172], it was attempted to
analyze the Nup214-CRM1-Ran-SPN1 complex accordingly.
The Nup214 fragment interacting with CRM1 is quite small (around 15 kDa) compared to the
size of the export complex (around 184 kDa). Therefore, it was attempted to obtain two EM
models, one of the export complex without Nup214 and one of the export complex with Nup214,
and to identify Nup214 bound to CRM1 by subtracting the two density maps.
Sample preparation as a crucial step for EM sample quality
Sample preparation was the first crucial step. Gel filtration, concentration of the complex with
spin concentrators or even thawing of frozen CRM1 had a massive negative effect on sample
quality. Therefore, CRM1 was always prepared freshly and immediately used for EM sample
preparation. Also, no additional purification step such as gel filtration was performed as this
also decreased the quality of the obtained EM particles.
The complexes for EM were formed on ice for 1 hour, then the buffer was exchanged to EM
buffer with Zeba Desalting Spin Columns (ThermoScientific). Afterwards the samples were
given to David Haselbach (MPIbpc, Göttingen) for further sample preparation and analysis,
starting with GraFix, a method developed by the same group [225]. GraFix combined a su-
crose gradient for separation of the protein complex from unbound protein components with
a glutaraldehyde gradient for simultaneous fixation of the complex. After GraFix Nup214 was

































Figure 21: Nup214 bound to the export complex was fixed and purified
with GraFix. (A) The α-His antibody recognizes the bands for CRM1, SPN1
and Nup214 before GraFix (-) and detects a band at the size of the complex
after GraFix (+). (B) The α-Nup214 antibody detects a band at the size of the
Nup214 fragment before GraFix (-), and a band at the size of the complex after
GraFix (+).
Analysis of the Nup214-CRM1-RanGTP-SPN1 complex with EM
Single particles of the fixed complex were imaged by either negative stain- or cryo-electron
microscopy. The ring- and S-shaped particles that are characteristic for CRM1 [172] could be
readily identified (figure 22).





Figure 22: Single particles of the Nup214 complex. (A) Negative-stained
particles were imaged and picked by an algorithm. (B-D) show randomly se-
lected particles from (A).
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Unfortunately, analysis of all obtained data sets, negative-stain or cryo images, was inconclu-
sive. This was probably due to the resolution of around 20 Å combined with the small size of
the Nup214 complex (around 200 kDa) and the small size of the Nup214 fragment in the com-
plex. Another major problem seemed to be the flexibility of the Nup214 fragment and the high
dynamic of the complex. Additional attempts were made to improve the stability of the complex
and to increase the size of Nup214. This included using shorter or longer Nup214 fragments,
GST- or MBP-tagged Nup214 fragments, the addition of Nup214 antibodies to the complex or
Nup214 mutants that were labeled with an Mts-Atf-Biotin linker (ThermoScientific) and bound
to NeutrAvidin or gold particles. None of the attempts could further improve the results and we
concluded that the complex was not suited for EM analysis with the current methods available.
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3.3.2 Cross-linking mass spectrometry
Cross-linking mass spectrometry is an established method to identify interacting regions in a
protein complex. The protein complex is cross-linked with one of the various commercially
available cross-linkers, trypsinized and analyzed by MS/MS analysis. Identified intermolecular
cross-links, i.e. cross-linked peptides of two different proteins, allow conclusions about which
regions of the proteins are in close proximity to each other. This method allows only for an
approximate mapping of protein-protein interactions, it is not possible to identify interacting
residues. Therefore, cross-linking mass spectrometry is the ideal method to give initial clues
about the interacting regions of two proteins when no further information is available.
Efficient cross-linking of the Nup214-CRM1-RanGTP-SPN1 complex with various cross-
linkers
There are a plethora of cross-linkers commercially available targeting amine (e.g. lysines),
sulfhydryl (e.g. cysteines), carbohydrates (e.g. oxidized sugars) and carboxyls (e.g.
C-terminus) groups or photoreactive cross-linkers that link nonspecifically. There are homobi-
functional cross-linkers, meaning that both reactive groups target the same functional groups
on the proteins or heterobifunctional cross-linkers with two different functional groups. Some
of the cross-linkers can also be cleaved, for example by DTT, after cross-linking to leave only
the individual proteins with modified residues or to reverse the linking.
The most common cross-linker for cross-linking mass spectrometry is BS3
(Bis[sulfosuccinimidyl] suberate), which is an amine-to-amine homobifunctional cross-linker
that is water-soluble and non-cleavable. BS3 has amine-reactive N-hydroxysulfosuccinimide
(NHS) groups linked by a 11.4 Å spacer arm. The sulfo-NHS esters interact with primary
amines such as lysine side chains or the N-terminus of a protein by forming a stable
amine bond upon release of N-hydroxysulfosuccinimide. The reaction is performed at
pH 7-9 and as BS3 is soluble up to 100 mM in water it can be used in most commonly
used buffers that do not contain free amines. Other common cross-linkers include BS2G
(Bis[Sulfosuccinimidyl] glutarate), which is similar to BS3, but has a 7.7 Å spacer arm, EDC
(1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride), which is a zero-length heter-
obifunctional cross-linker that links carboxyl groups and primary amines, and EGS (Ethylene
glycol bis[succinimidylsuccinate]), an amine-to-amine homobifunctional cross-linker with a
16.1 Å spacer arm.
For cross-linking, the initial step was to pre-purify the Nup214-CRM1-RanGTP-SPN1 complex
by gel filtration. Subsequently, the buffer was changed to PBS with Zeba Desalting Spin




13-23 pmol of the complex were incubated with increasing molar ratios of the respective
cross-linker to find an optimal cross-linker to protein complex ratio (figure 23). An optimal
ratio in this case is defined as the ratio that gives the most prominent and defined band on a
Coomassie-stained SDS-gel at the expected size of the complex. If the ratio is too low, the
band of the complex is not present or very faint and the bands of the individual proteins are still
prominent. Too high a ratio leads to a blurred band of the complex, which indicates unspecific
oligomerization.
Complexes with His-Nup214(1916-2033)-His (data not shown) and GST-Nup214(1968-2033)
could be successfully linked with BS3, BS2G and EGS, the optimal ratio being 50:1 for BS3 and













































































Figure 23: Titration of cross-linkers BS3 and EGS to GST-Nup214(1968-2033)-CRM1-RanGTP-
SPN1 complex. (A) BS3 and (B) EGS were titrated to 22.8 pmol pre-formed GST-Nup214(1968-2033)-
CRM1-RanGTP-SPN1 complex. The Coomassie-stained bands of the individual proteins as well as
the complex are indicated with an arrow. The optimal concentration chosen for further experiments are
marked by asterisks.
After the optimal ratio of cross-linker to protein complex had been determined, four samples
each with 22.8 pmol of the GST-Nup214(1968-2033)-CRM1-RanGTP-SPN1 complex were
linked with BS3 and EGS. For BS2G, 8 samples with 13 pmol complex per sample were
incubated, one half with a cross-linker:protein ration of 50:1, the other half with a ratio of 100:1.
The cross-linked samples were run on a SDS-gel, followed by Coomassie-staining. The gel
was then given to Romina Hofele (MPIbpc, Göttingen). The bands containing the complex
were cut out of the gel and subjected to in-gel trypsin digestion before analysis by MS/MS.
The experiment with EGS did not give any results. The samples with BS3 and BS2G both gave
a data set with a good sequence coverage of 73% for CRM1, 71% for SPN1 and 55% for Ran.
The sequence coverage of the GST-Nup214(1968-2033) was 60%, but only peptides of the
GST-tag were detected and no peptide for Nup214.
18 cross-links could be identified with BS3 and 13 with BS2G, thereof only five each were
intermolecular cross-links coupling two different proteins from the complex. The complete list
of identified cross-links can be found in the appendix (table S1).
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Even though there were no cross-links to Nup214 identified, the data sets were used as a
verification of the method itself. All obtained inter- and intra-molecular cross-links of CRM1,
SPN1 and Ran were mapped on the available crystal structure of the export complex (PDB ID:
3GJX, [127])(figure 24). The Cα-Cα distances of the identified linked residues was measured
in PyMOL. The maximum distance between two lysine side chains (8 Å each) and the 11.4 Å
spacer of BS3 or the 7.7 Å spacer of BS2G is 27.4 Å and 23.7 Å, respectively. All identified
distances cross-linked residues were within that range in the crystal structure, verifying the










Figure 24: Cross-links of the GST-Nup214(1968-2033)-CRM1-RanGTP-SPN1 complex mapped on
the crystal structure of the export complex. The structure shows CRM1 (gray), Ran (blue) and SPN1
(cyan) (PDB ID: 3GJX, [127]). Identified cross-linked residues are highlighted in purple. The cross-links
obtained by (A) BS3 and (B) BS2G were mapped on the structure and Cα-Cα distances were calculated
by PyMOL. (C)-(E) show selected regions of the structure in (A) and (F)-(H) show selected regions of
the structure in (B).
– 77 –
Results
Even though all four proteins of the complex were clearly cross-linked by BS3 and BS2G, no
cross-linked Nup214 peptides could be identified. The analyzed Nup214-fragment was very
hydrophobic due to its FG-repeat motives and in addition did not contain many sites for trypsin
digestion. Both properties combined rendered detection of that specific Nup214 fragment by
mass spectrometry highly unlikely.
Cross-linking of Nup214-CRM1-RanGTP-SPN1 complexes with BS3 and EDC indicates
interacting regions
As the previous cross-linking strategy had failed due to limitations of the MS/MS analysis,
the preparation of the MS sample after cross-linking was optimized by Romina Hofele
(MPIbpc, Göttingen). In addition, Nup214 mutants were generated that contained an additional
lysine and therefore an additional trypsin recognition site (Nup214-Lys mutants). This ad-
ditional lysine should yield smaller, and therefore better detectable peptides after trypsinization.
The Nup214-Lys mutants were prepared and Nup214-CRM1-RanGTP-SPN1 complexes were
assembled and purified by gel filtration at a preparative scale in PBS. The purified Nup214
complexes were then subjected to cross-linking with BS3. The optimal BS3:protein complex
ratio was determined by titration of the cross-linker (figure 25). A cross-linker:protein ratio of
200:1 proved best for all tested Nup214-Lys mutant complexes.
For MS analysis, 1300 pmol of the Nup214 complexes were cross-linked with BS3 in a total
volume of 1.5 ml in PBS. The cross-linked complex was directly subjected to in-solution trypsin
digestion and MS/MS analysis by Romina Hofele (MPIbpc, Göttingen). Only the samples of the








































































































































Figure 25: Cross-linking of His-Nup214(1916-2033)-His complexes by BS3. (A) The Nup214-CRM1-
RanGTP-SPN1 complexes were purified and subsequently the CRM1-RanGTP-SPN1 complexes
with (B) His-Nup214(1916-2033)-His, (C) His-Nup214(K1916-2033)-His and (D) His-Nup214(1916-
2033)A1999K-His were incubated with increasing amounts of BS3. The Coomassie-stained bands of
the individual proteins as well as of the complex are indicated with arrows. The optimal concentrations
chosen for further experiments are marked by asterisks.
2848 and 2660 spectra were obtained for two technical replicates of the complex with the
His-Nup214(1916-2033)-His and 2940 and 2882 for the complex with the His-Nup214(K1916-
2033)-His, around 45% corresponding to intermolecular cross-links in all four replicates. The
complete list of identified cross-links can be found in the appendix (tables S2, S3).
Many cross-links of the residues 1 and 2 of His-Nup214(1916-2033)-His and His-
Nup214(K1916-2033)-His were identified. In addition, also the artificially introduced K22
of His-Nup214(K1916-2033)-His formed various cross-links. Mapping of the detected cross-
links on the crystal structure of the export complex (PDB ID: 3GJX, [127]) revealed that these
three N-terminal lysines cross-link unspecifically to the whole surface of the export complex
(appendix, figures S2, S3). This suggests that the N-terminal region of the Nup214 fragments
is flexible and not stably bound to CRM1. Residues 1 and 2 as well as the artificially inserted
N-terminal lysine were therefore excluded from further analysis.
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Analysis focused on the cross-links by the Nup214 residues K1928, K1942, K1966 and K2010
of the His-Nup214(1916-2033)-His wildtype and mutant fragments. The identified cross-links
are summarized in table 23. The cross-links of the respective Nup214 residues to the export
complex proteins partially overlap, suggesting that, for example, K1928 as well as K1942 can
contact the CRM1 residue K680.
Table 23: Summary of the identified cross-links between His-
Nup214(1916-2033)-His fragments and the export complex.


















The asterisk indicates residues that are not present in the crystal
structure of the export complex (PDB ID: 3GJX, [127]).
Several cross-links of Nup214 to the export complex were identified with the previous ap-
proach. Therefore, the same strategy was used to cross-link the MBP-Nup214(1916-2033)-His
fragment, which had also been used for electron microscopy and crystallization approaches, to
the export complex CRM1-RanGTP-SPN1.
The optimal ratios of BS3 and EDC to the protein complex ratio were determined by titration
of the cross-linker (figure 26). A BS3:protein ratio of 200:1 and EDC:protein ratio of 10000:1























































































Figure 26: Cross-linking of the MBP-Nup214(1916-2033)-His complex by (A) BS3 and (B) EDC. The
Coomassie-stained bands of the individual proteins as well as the complex are indicated by an arrow.
The optimal concentration chosen for further experiments is marked with an asterisk.
For MS analysis, 1300 pmol of the MBP-Nup214(1916-2033) was cross-linked with BS3 or
EDC to pre-purified CRM1-RanGTP-SPN1 export complex in a total volume of 1.5 ml PBS.
The cross-linked complex was directly subjected to in-solution trypsin digestion and analyzed
by Romina Hofele (MPIbpc, Göttingen).
2384 spectra were obtained for the complex cross-linked with BS3 and 598 for EDC. The
reduced number of identified spectra for EDC can be explained by the fact that it is a zero-
length cross-linker and therefore has a smaller operation radius. The complete list of identified
cross-links can be found in the appendix (tables S4, S5).
The MBP-tag links indiscriminately to the complete surface of the export complex with BS3 as
well as EDC (appendix, figure S4) indicating that the N-terminal MBP-tag is flexible, which could
be expected from the previous results with the His-tagged Nup214 fragments. Cross-links of the
MBP-tag were therefore excluded from further analysis and only cross-links of actual Nup214
residues were analyzed. Only six cross-links of Nup214 to any of the export complex proteins
were identified in the two experiments, 4 cross-links with BS3 and 2 cross-links with EDC. The
identified cross-links are summarized in table 24.
Table 24: Summary of the identified cross-links between MBP-Nup214(1916-2033)-His
and the export complex.
Nup214 residue Linked protein Linked residue Cross-linker
K1928 SPN1 K167 BS3
K223 BS3
K1942 SPN1 K223 BS3
CRM1 D677 EDC
E1013 EDC
K2010 CRM1 K22 BS3
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For verification, the identified cross-links of the His- and MBP-tagged Nup214(1916-2033)
fragments to the export complex (tables 23, 24) were combined and mapped onto the crystal
structure of the export complex (PDB ID: 3GJX, [127]) (figure 27). Note that not all cross-linked
residues are actually present in the crystal structure. To assess the significance of the identified
cross-links, the distances of the cross-linked residues of the export complex were measured in
PyMOL.
The Nup214 residue K1928 links to CRM1 residue K680 as well as the SPN1 residues M1,
K167, K223 and K314 (figure 27A). The Cα-Cα distances of CRM1 K680 and SPN1 K167 to
SPN1 K223 in the export complex structure as measured by PyMOL are 12.6 Å and 14 Å,
respectively. Therefore, it is likely that the same Nup214 residue could cross-link either one of
them. On the other hand, the Cα-Cα distance of the SPN1 residues K223 and M1 is nearly 60
Å and they are located on completely opposite sides of the SPN1 protein. Therefore, these two
residues are too far apart to be cross-linked by the same Nup214 residue unless there were
significant structural changes in the Nup214 complex compared to the export complex.
Moreover, the Nup214 residue K1942 cross-links to SPN1 K223 as well as CRM1 residues
D677 and E1013 (figure 27B). The Cα-Cα distance of SPN1 K223 and CRM1 D677 is around
40 Å, the distances of CRM1 E1013 to CRM1 D677 and SPN1 K223 are around 70 Å and
80 Å, respectively. Linking of the same Nup214 residue to all three of the identified residues,
therefore is highly unlikely even if massive structural changes occur in the Nup214 complex
compared to the export complex.
The same is true for linking of the Nup214 residue K1966 to CRM1 residues K22 and K426,
which are nearly 65 Å apart in the export complex structure (figure 27C).
Interestingly, Nup214 K2010 cross-linked only to CRM1 K22 in all experiments with both the
His- and MBP-tagged Nup214(1916-2033) fragments (figure 27D). Therefore it seems likely
that Nup214 K2010 and CRM1 K22 are indeed in close proximity in the Nup214 complex.
Comparing the regions on the export complex to which the individual Nup214 proteins cross-
link suggests that the more N-terminal Nup214 residues K1928 and K1942 are located close to
the cargo-binding region on CRM1, whereas the more C-terminal residues K1966 and K2010
seem to be located in the region where the N- and C-termini of CRM1 come together. The
ambiguous cross-links as well as the small number of identified cross-links did not allow for a










































Figure 27: The identified cross-links of Nup214(1916-2033) were mapped on the crystal structure
of the export complex (PDB ID: 3GJX, [127]). The structure shows CRM1 (light gray), RanGTP
(medium gray) and SPN1 (dark gray). Cross-linked residues are highlighted in green. (A)-(D) show





Cross-linking mass spectrometry only gave a very speculative hint of the orientation of the
Nup214 fragment bound to CRM1 and electron microscopy did not identify the binding region
either. The CRM1-RanGTP-SPN1-Nup214 complex was therefore crystallized to identify the
interacting regions of Nup214 and CRM1.
Complex assembly and purification
As the CRM1-RanGTP-SPN1 export complex had been crystallized before (PDB ID: 3GJX,
[127]), a special focus was put on identifying a Nup214 fragment suitable for crystallization.
Nup214 fragments of various lengths and fused either to His-, GST- or MBP-tags were tested.
The only Nup214 fragment that could be crystallized bound to the CRM1-RanGTP-SPN1 ex-
port complex was MBP-Nup214(1916-2033)-His. This fragment was expressed from a newly
constructed vector, specifically designed for structural analysis as the original C-terminal end of
the MBP as well as the linker between MBP and the multiple cloning site including the protease
cleavage site had been removed and replaced by a short linker [212]. The short linker con-
sisted of three alanines as well as a glutamate and a phenylalanine residue which were derived
from the EcoRI restriction site used for cloning of the Nup214 fragment (compare figure 5). The
intention of the vector modification was to decrease the flexibility of the MBP-tag fused to the
Nup214 fragment. The more rigid linking should increase the chances of crystal formation. The
presence and position of the MBP-tag turned out to be crucial for crystallization of the Nup214
complex, as attempts to crystallize complexes with the same Nup214(1916-2033) fragment with
only a His-tag or with a C-terminally located MBP-tag did not produce any crystals. For com-
plex formation, full-length SPN1 and truncated SPN1(1-291) were tested, as the C-terminus of
SPN1 was prone to degradation not only as a single protein, but even in already formed com-
plexes and crystals. The CRM1-RanGTP-SPN1-Nup214 complex was assembled and purified
by gel filtration (figure 28). The gel filtration profiles of the complexes with full-length and trun-
cated SPN1 both showed a peak at around 165 ml, corresponding to the respective complexes.
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Figure 28: Purification of the CRM1-RanGTP-SPN1-Nup214 complex for crystallization. Com-
plexes of CRM1-His, Ran(1-180)Q69L-GTP and MBP-Nup214(1916-2033)-His were assembled
with full-length SPN1 and truncated SPN1(1-291). (A) Gel filtration profile of the CRM1-His/
Ran(1-180)Q69L-GTP/ MBP-Nup214(1916-2033)-His/ SPN1 complex. Peak 1 corresponds to the
formed complex, peak 2 to excess SPN1 and Nup214 and peak 3 to excess Ran. (B) The collected
fractions corresponding to gel filtration peak 1 from (A) were pooled and concentrated. (C) Gel filtration
profile of the CRM1-His/ Ran(1-180)Q69L-GTP/ MBP-Nup214(1916-2033)-His/ SPN1(1-291) complex.
Peak 1 corresponds to the formed complex, peak 2 to excess Nup214, peak 3 to excess SPN1(1-291)
and peak 4 to excess Ran. (D) The collected fractions corresponding to gel filtration peak 1 from (C)
were pooled and concentrated.
Crystallization screening and crystal optimizing
Initial crystallization screens were performed using the complex with full-length SPN1. Various
commercially available screens, e.g. from Hampton Research or Molecular Dimensions,
were tested either by manually setting up 24-well plates or with a crystallization robot. The
only crystals were observed in a condition containing 0.1 M HEPES pH 7.5, 10% PEG3350
and 0.2 M L-proline (condition #61, Index™ screen, Hampton Research). Crystals appeared
three days after setting up the plates. Crystals were small (figure 29A) and unstable as they
dissolved again when left in the condition for more than a week. The crystallization condition
was therefore optimized with respect to the proline concentration, PEG type and concentration,
pH and additives. A condition containing 5% (w/v) polyethylene glycol (PEG) 8000, 0.2 M
L-proline, 0.1 M Tris/HCl pH 7.5, 4 mM D-maltose and 180 mM LiCl proved most reliable in
crystal formation of the Nup214 complex. Cross-seeding with crystals of the same protein com-
plex was applied to reduce the number and increase the size of the formed crystals (figure 29B).
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Complexes containing full-length and truncated SPN1 were subjected to crystallization and
formed similar crystals under the same conditions. The complex with SPN1(1-291) diffracted
to a higher resolution and was therefore used for crystal optimization.
A B
Figure 29: Optimization of crystal formation. (A) Crystals from the initial crystallization conditions
were small and dissolved after a few days. (B) Crystals from the optimized condition grew to a size of
150 x 150 x 80 µm and diffracted to ∼3 Å after dehydration.
Crystals taken directly from the crystallization condition diffracted to a maximum resolution
of 7Å. A sophisticated dehydration strategy was therefore developed by Thomas Monecke
(Department of Molecular Structural Biology, Universität Göttingen) consisting of a stepwise
increase of the PEG concentration as well as complete removal of mother liquor with an
HC1c crystal humidifier (beamline 14.3, BESSY II, Berlin). Diffraction data was recorded and
processed and the model was built and refined by Thomas Monecke.
The Nup214 complex crystallized in the space group C2221. The model was built by molecular
replacement using the export complex (PDB ID: 3GJX) as a search model. The final model
had a resolution of 2.85 Å and contained the CRM1 residues 5-1048, SPN1 residues 1-287
and the RanGTP residues 7-179, along with the MBP-tag and the three fragments of Nup214
corresponding the the residues 1916-1951, 1980-1988 and 2009-2027 (figure 30).
Overall structure of the Nup214 complex
The overall architecture of CRM1, RanGTP and SPN1 is similar to the structure of the export
complex without Nup214 (PDB ID: 3GJX, [127]). Superposition of CRM1, RanGTP and SPN1
gave root mean square deviations (r.m.s.d.) of 0.68 Å for 975 common Cα atoms of CRM1,
0.33 Å for 171 common Cα atoms of RanGTP and 0.57 Å for 248 common Cα atoms of SPN1.
The HEAT repeats of CRM1 form the same closed toroid in the export complex and Nup214
complex structures (appendix, figure S8A). Also the conformations of the three most variable
features, the acidic loop, the NES binding cleft and the C-terminal helix is essentially unaltered
(appendix, figures S8B,C,D, respectively). Corresponding to the conformation of CRM1, also
the position and architecture of Ran(1-180)GTP and SPN(1-291) was similar in the Nup214
complex and the export complex. RanGTP interacts with CRM1 via the six N-terminal HEAT
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repeats, the acidic loop and HEAT repeats 17 and 19. Binding of SPN1 to CRM1 occurs via the
NES and the cap-binding domain to the outer surface of HEAT repeats 11-14. A third binding
interface containing the 12 C-terminal residues of SPN1, which is present in the structure of
the export complex is missing in the Nup214 complex as the truncated SPN1(1-291) instead of
the full-length SPN1 was used for crystallization.
The MBP-tag makes contacts to RanGTP and CRM1 HEAT repeat 15. In addition, MBP also
interacts with a symmetry-related Nup214 complex, thereby binding to CRM1 HEAT-repeats 12
and 13 as well the MBP-tag of the other molecule (data not shown).
Table 25: Crystal statistics.
Crystal 1 Crystal 2
Data collection
Space group C2221 C2221
Number of complexes in a. u. 1 1
Wavelength [Å] 0.9184 0.9184
Cell dimensions
a, b, c [Å] 111.57, 247.38, 209.98 112.33, 248.97, 210.57
α, β, γ [°] 90.0, 90.0, 90.0 90.0, 90.0, 90.0
Resolution [Å] 48.14-3.02 (3.12-3.02)* 48.49-2.85 (2.95-2.85)*
Rmerge 0.058 (0.793) 0.055 (0.571)
I / s(I) 15.34 (1.78) 15.52 (2.01)
Completeness [%] 98.4 (98.8) 98.2 (91.49)
Multiplicity 5.1 (5.2) 4.6 (4.1)
Refinement
Resolution [Å] 48.14-3.02 30.00-2.85






Bond lengths [Å] 0.017
Bond angles [°] 1.64
X-ray data collection, refinement and validation statistics for both crystals of the Nup214-CRM1-




Interactions of the Nup214 fragment with CRM1
The Nup214(1916-2033) fragment binds to CRM1 via several FG-repeats targeting hydropho-
bic pockets located along a large fraction of the outer perimeter of the CRM1 ring (figure
30). We identified three prominent FG-repeat regions of Nup214 (termed FG-sites 1-3) in
the structure. Each FG-site binds to CRM1 via at least two FG-repeats targeting a total of
seven hydrophobic pockets (termed FG-pockets I-VII) on CRM1. A summary of all interactions
between Nup214 and CRM1 can be found in the appendix (table S6).
The three FG-sites of Nup214 wind around the outer surface of CRM1, starting with N-terminus
of the Nup214 fragment located close to HEAT repeats 14A and 15A and the C-terminus of
the Nup214 fragment close to HEAT repeats 3A and 4A. The three Nup214 FG-sites bury a
surface of 1331 Å2, 408 Å2 and 664 Å2, respectively. Seven phenylalanines of Nup214 are
buried in hydrophobic pockets of the CRM1 molecule, whereas the connecting residues lie
loosely along the CRM1 surface. The linkers between the three identified Nup214 FG-sites are
not defined in the structure, but long enough to connect the respective regions. It is therefore
likely that all three Nup214 FG-sites derive from the same Nup214 fragment, although binding
of symmetry related Nup214 molecules cannot be excluded completely.
The 36 residues of FG-site 1, ranging from S1916 to G1951, bind to a region between HEAT
repeats 14-19. Three phenylalanines from FG-site 1 bind to hydrophobic pockets on CRM1.
F1922 is buried in FG-pocket I between 14A and 15A, F1938 and F1947 bind between HEAT
repeats 17A and 18A or 18A and 19A, respectively (figure 31B, E). F1992 is coordinated in
FG-pocket I by hydrophobic interactions with the CRM1 residues I669, of HEAT 14 as well
as Val720 and C723 of HEAT 15. Additionally, the main chain carbonyl of F1922 forms a
hydrogen bond to the side chain amide of N719 on CRM1. Residues 1924-1928 form a short
helical turn, and subsequently the Nup214 residues 1929-1936 wind along the surface of
HEAT repeats 15A-17A. A pitched β-turn described by Nup214 residues 1937-1940 allows the
phenyl side chain of F1938 to deeply insert into FG-pocket II between HEAT repeats 17A and
18A (figure 31B, E). F1938 forms hydrophobic interactions with F823 and F827, as well as
a polar interaction with E828 on CRM1. The chain proceeds closely wrapped around HEAT
repeat 18A and along the groove between HEAT repeats 18A and 19A where F1947 inserts
into FG-pocket III by interacting with P868 and F871 of HEAT repeat 18A as well as A910,
F914, S913 and Y918 of HEAT repeat 19A.
FG-site 2 encompasses nine Nup214 residues from 1980-1988 and lies across CRM1 HEAT
repeat 17-19 (figure 31C, F). F1982 and F1988 within that stretch bind to hydrophobic pockets
on CRM1. F1982 binds to FG-pocket IV, a shallow groove between HEAT repeats 17A and
18A, interacting with L831 on HEAT repeat 17A as well as S877, W880, D876 and L873 on
HEAT repeat 18A. A type II β-turn is described by F1982 and the adjacent G1983, leading to
another hydrophobic pocket which is occupied by F1988. Within this FG-pocket V, F1988 in-









Figure 30: Nup214 interactions on the CRM1-RanGTP-SPN1 export complex. CRM1 (light gray),
RanGTP (dark gray) and SPN1 (black) in surface representation. (A) Nup214 (in stick representation,
purple) interacts with CRM1 via several regions on the outer surface of the ring. Interacting phenylala-
nines of Nup214 are highlighted by transparent spheres. (B)-(C) MBP is located between two symmetry-
related Nup214 complexes.
The N-terminal CRM1 HEAT repeats 2-4 interact with FG-site 3 of Nup214 which is comprised
of residues 2009-2027 (figure 31D, G). F2012 is inserted into a deep hydrophobic pocket
(FG-pocket VI) between HEAT repeat 2-3 and forms interactions with V63 and D64 of HEAT
repeat 2A and Q98, G101 and I102 of HEAT repeat 3A. The depth of the pocket and the
insertion is reflected by an additional interaction of the F2012 phenyl group with L83 of HEAT
repeat 2B. The Nup214 chain proceeds with a kink and a short α-helical segment, which
crosses HEAT repeat 3 at a very close distance. F2024 is bound by I111 of HEAT repeat 3A
and D152, as well as I153 of HEAT repeat 4A within FG-pocket VII.
In summary, the obtained structure is the first crystal structure of CRM1 bound to a nucleo-
porin fragment. Three FG-binding sites of Nup214 were identified, each binding via several
phenylalanine residues to hydrophobic pockets along the CRM1 surface.
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Figure 31: Nup214-binding sites on CRM1. The MBP-tag of Nup214 was omitted for clarity reasons.
Nup214 (in stick representation, purple) interacts with CRM1 via three region on the outer surface of the
ring. Interacting phenylalanines of Nup214 are highlighted by transparent spheres. (A) The localization
of the three Nup214 FG-sites on the CRM1-RanGTP-SPN1 export complex. (B)-(D) Detailed view of
(B) FG-site 1 (Nup214 residues 1916-1951), FG-site 2 (Nup214 residues 1980-1988) and (D) FG-site 3
(Nup214 residues 2009-2027). (E)-(G) Schematic representation of the interactions of Nup214 pheny-
lalanines with hydrophobic pockets on CRM1 in FG-sites 1-3, respectively. FG-pockets I-VII on CRM1
are indicated in green.
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3.4 Functional characterization of CRM1-Nup214 interactions
3.4.1 Analysis of prominent features of Nup214 revealed several FG-repeats important
for CRM1-binding
It was previously shown that a conserved FG-repeat motif in Nup214 is important for its binding
to CRM1 [59]. The effect of this motif on CRM1-Nup214 interaction was further investigated
in this study by comparing the behavior of wildtype Nup214 to Nup214 mutants in which the
FG-residues of the motif were changed to SG. A mutant in which the five FG-repeats of the
motif, namely F1970, F1976, F1982, F1988 and F1994, were mutated to SG was termed "5SG"
mutant. Mutants that had only the first four of the FGs (F1970, F1976, F1982 and F1988)
mutated were called "4SG" mutants. Another feature frequently involved in protein-protein
interactions are charged amino acids. Hence, charged amino acids in Nup214 were analyzed
for their influence on binding to CRM1 in addition to FG-SG mutations. Single mutants were
designed, in which a charged amino acid was exchanged for an amino acid with an opposite
charge, e.g. Asp to Lys, or Lys to Glu. Furthermore, mutants in which all lysines were replaced
by alanines ("KA" mutant) or glutamic acids ("KE" mutant) were constructed. Likewise, a
mutant was constructed in which all acidic amino acids were mutated to lysine ("DE/K" mutant).
For analysis in biochemical assays, the mutations were introduced into a plasmid coding for
the recombinant fragment His-Nup214(1916-2033)-His.
All recombinant Nup214 mutants were expressed and purified with the standard Nup214
purification protocol. The purification yield of fragments in which phenylalanines were mutated
to serines was much higher compared to the wildtype. First, the His-Nup214(1916-2033)-
His fragments were tested for their ability to bind to the export complex. Five different
His-Nup214(1916-2033)-His fragments, namely 5SG, KA, KA 4SG, KE and a non-mutated
version (figure 32A), were incubated with pre-purified CRM1-RanGTP-SPN1 export complex.
Subsequently, complex formation was assessed by analytical gel filtration. Complexes of
all four Nup214 mutants eluted from the column at the same volume as the complex of
the non-mutated Nup214 fragment (figure 32B). Only the elution profile of the KE mutant
showed an asymmetric complex peak, indicating that the formed complex might not be as
stable as the other complexes. That the complex peak indeed contained all the four proteins
was confirmed by SDS-PAGE, followed by Coomassie-staining and Western blotting (data
not shown). Analysis of the same Nup214 mutants in pulldown assays with immobilized
GST-Rev showed more diverse binding of the different mutants. CRM1-binding to GST-Rev in
a pulldown assay could only be observed in presence of RanGTP and Nup214, a complex of
CRM1-RanGTP and Rev alone is not stable enough to be detected. Restricted binding of the
Nup214 mutants to CRM1 would therefore lead to reduced binding of CRM1 to the immobilized
GST-Rev. Indeed the sample with the Nup214 wildtype fragment and RanGTP showed the
strongest binding of CRM1 to the immobilized GST-Rev (figure 32C). Also the binding of the
Nup214 wildtype fragment was clearly detectable on the gel. By contrast, CRM1-binding in the
samples with the Nup214 mutants was clearly reduced. The Nup214 KA mutant showed the
strongest binding of the mutants indicated by a strong CRM1 band and clearly visible band for
Nup214 KA on the gel. Nup214 5SG, KA 4SG and KE mutations are apparently more drastic.
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CRM1-binding was even further reduced and the Nup214 fragments could hardly be detected
on the gel.
For more quantitative analysis, RanGAP assays were performed. Titration of the five Nup214
fragments to CRM1 and Ran loaded with 32P-γ-GTP in the absence of CRM1 cargo showed
strong reduction of GTP-hydrolysis upon RanGAP addition for the Nup214 wildtype fragment
(figure 32D). GTP-hydrolysis was reduced to ∼20% for 3 µM of the Nup214 wildtype fragment.
The Nup214 KA fragment which had previously exhibited the strongest binding of all tested
mutants in the pulldown assays (figure 32C), also resulted in the strongest reduction of
GTP-hydrolysis. The Nup214 KE mutant reduced GTP-hydrolysis to ∼60% for 3 µM of the
fragment. The two Nup214 mutants with mutated FG repeats, Nup214 5SG and Nup214 KA
4SG showed the weakest binding with more than 80% of the GTP hydrolyzed.
Next, the importance of the mutated residues in binding to CRM1 was assessed with an in
vitro export assay using stably transfected GFP-NFAT cells. The cells were permeabilized and
cytosol, ATP-regenerating system as well as increasing amounts of the Nup214 fragments
were added to the cells. Export of GFP-NFAT from the nucleus was quantified by flow
cytometry. Strong binding of the Nup214 fragment to CRM1 means that there is less CRM1
available for nuclear export, leading to reduced export of GFP-NFAT and a relative increase
in the residual nuclear fluorescence. Nup214 5SG, KA, KA 4SG and KE mutants as well as
the wildtype were titrated to the permeabilized cells. Flow cytometry analysis showed a clear
reduction in nuclear export of GFP-NFAT for the non-mutated Nup214 fragment, whereas the
export was hardly affected by all of the tested Nup214 mutants, indicating a reduced interaction
between the Nup214 mutants and CRM1 (figure 32E).
Analysis of the Nup214 5SG, KA, KA 4SG, KE mutants in a variety of cellular and biochemical












































































wt   1916 -                                                              - 2033
5SG   1916 -                                                              - 2033
KA/KE   1916 -                                                              - 2033
KA 4SG   1916 -                                                              - 2033
A
5SG            KA/KE
F1970         K1928
F1976         K1942
F1982 (*)    K1966








Figure 32: Analysis of Nup214 SG and charge exchange mutants in a variety of assays reveals
an importance for FG-repeats and lysines in CRM1-binding. (A) Schematic representation of the
recombinant Nup214 fragments used in the assays. Mutated FG-repeats are marked in gray, mutated
lysines are highlighted in blue. (*) indicates mutated residues referred to in figure 33. (B) 1 nmol
pre-purified export complex was mixed with the respective Nup214 fragment at a molar ratio of 1:3.
Complex formation was assessed by analytical gel filtration. 1 ml fractions were collected and ana-
lyzed by SDS-PAGE, followed by Coomassie-staining or Western blotting with an α-His antibody (data
not shown). (C) 50 pmol GST-Rev were immobilized on beads and incubated with CRM1 and the re-
spective His-Nup214(1916-2033)-His fragment in the absence or presence of RanGTP. Bound proteins
were analyzed by SDS-PAGE, followed by Coomassie-staining. (D) RanGAP assays: His-Nup214(1916-
2033)-His fragments (wildtype and mutants, as indicated) were titrated to CRM1 and Ran loaded with
32P-γ-GTP in the absence of CRM1 cargo. GTP-hydrolysis was initiated by the addition of RanGAP. The
mean and standard deviation of three independent experiments are shown. (E) The His-Nup214(1916-
2033)-His fragments were titrated to permeabilized GFP-NFAT cells. The residual nuclear fluorescence
was quantified by flow cytometry. The fluorescence intensity of a sample without Nup214 was set as




3.4.2 Analysis of the structure-derived Nup214 mutants confirms the importance of the
identified phenylalanines in CRM1-binding
Several interactions between CRM1 and Nup214 were identified by X-ray crystallography (see
section 3.3.3). Two of the phenylalanine residues of the previously investigated conserved
motif, F1982 and F1988, were visible in the crystal structure and were found to bind to
hydrophobic pockets on the CRM1 surface. In addition, several other phenylalanines were
identified that bound to different hydrophobic pockets on CRM1. To verify the molecular
interactions identified by the crystal structure, another set of Nup214 mutants were designed.
A Nup214 mutant in which all the phenylalanines that bound to the C-terminal arch of CRM1 in
the crystal structure (F1922, F1930, F1938, F1947, F1982 and F1988) were mutated to serine
was termed "X1". Accordingly, the phenylalanines that bound to the N-terminal arch of CRM1
in the crystal structure (F2012, F2024 and F2026) were mutated to serine in the Nup214 "X2"
mutant. The Nup214 "X3" mutant is a combination of X1 and X2. In accordance with the
previous set of Nup214 mutants, these structure-derived mutants were also introduced into the
plasmid coding for the recombinant fragment His-Nup214(1916-2033)-His. Additionally, the
mutations were also introduced into the plasmid coding for the Nup214 fragment that was used
in the crystallographic studies, MBP-Nup214(1916-2033)-His (figure 33A).
Pulldown assays showed reduced binding of CRM1 to GST-Rev in the presence of the the X1
and X2 mutant. In presence of the Nup214 X3 mutant, hardly any binding of CRM1 to GST-Rev
was detected (figure 33B).
For a more quantitative analysis, binding of the Nup214-X mutants to CRM1 was assessed
by RanGAP assays (figure 33C, D). The recombinant His-Nup214(1916-2033)-His and MBP-
Nup214(1916-2033)-His X-mutants were titrated to CRM1 and 32P-γ-GTP in the absence of
CRM1 cargo. The wildtype Nup214 fragments led to a strong resistance of the complex towards
RanGAP-induced GTP-hydrolysis. By contrast, more than 60% of the GTP was hydrolyzed
when titrating the His- or MBP-tagged Nup214 X1 or X2 mutants, implying a strongly reduced
binding of these Nup214 mutants to CRM1. Strikingly, the combinatorial Nup214 mutants in
which all of the phenylalanines that bound to CRM1 in the crystal structure were mutated did
not lead to any stabilization of the CRM1-RanGTP complex towards RanGAP, indicating that
this mutant is unable to bind CRM1.
Interestingly, results of the binding assays with the Nup214-X mutants resemble the results
of the binding assays of the truncated Nup214 fragments as described above (section 3.2.3).
Even though the truncated Nup214 fragments were able to bind the export complex, they did not
have a stabilizing effect on the complex (figure 18). In addition, the importance of the mutated
residues in binding to CRM1 was assessed with an in vitro export assay as described above.
Nup214 X1, X2 and X3 mutants as well as the wildtype were titrated to permeabilized GFP-
NFAT cells. Flow cytometry analysis showed a clear reduction in nuclear export of GFP-NFAT
for the non-mutated Nup214 fragment, whereas the export was hardly affected for the Nup214
X2 and X3 mutants, indicating a reduced interaction of the Nup214 mutants with CRM1 (figure
32E). Interestingly, the effect of Nup214 X1 on nuclear export was more prominent.
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These results indicate that the phenylalanines identified as CRM1-interacting residues in the
crystal structure indeed mediate binding of CRM1 and Nup214.
wt   1916 -                                                              - 2033
X1   1916 -                                                              - 2033
X2   1916 -                                                              - 2033



































































































Figure 33: Analysis of the structure-derived Nup214 mutants confirms the importance of the
identified phenylalanines in CRM1-binding. Schematic representation of the recombinant Nup214
fragments used in the following assays. Mutated FG-repeats are marked in gray. (B)-(C) RanGAP
assays: The respective (B) His-Nup214(1916-2033)-His or (C) MBP-Nup214(1916-2033)-His fragments
were titrated to CRM1 and Ran loaded with 32P-γ-GTP in the absence of CRM1 cargo. (D) 100 pmol
GST-Rev were immobilized in glutathione sepharose incubated with CRM1 and the respective His-
Nup214(1916-2033)-His fragment in the absence and presence of RanGTP. Bound proteins were
analyzed by SDS-PAGE, followed by Coomassie-staining. (E) Inhibition of nuclear export by His-
Nup214(1916-2033)-His fragments. The residual nuclear fluorescence was quantified by flow cytometry.
The fluorescence intensity of a sample without Nup214 was set as 100%. Normalized values and stan-
dard deviation of a minimum of two independent experiments were plotted.
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3.4.3 Importance of the identified binding residues in cellular context
For the above described biochemical analysis of Nup214 mutants, fragments containing the
residues 1916-2033 were used. To anticipate the relevance of the identified interacting residues
within the whole FG-repeat domain of Nup214, cellular binding assays were performed. The
mutations were introduced into a transfection plasmid coding for Nup214(1859-2090) fused to
RFP-cNLS for analysis in cellular assays. A scheme of all used RFP-Nup214-cNLS constructs
can be found in the appendix (figure S10).
The plasmids were co-transfected with GFP-SPN1 and the distribution of GFP-SPN1 localiza-
tion was counted in at least 100 cells (see figure 34). Exchange of the charged amino acids
alone did not have a strong effect on SPN1 localization, only the exchange of the lysines to
glutamic acid lead to a redistribution of GFP-SPN1 in ∼30% of the cells. Also the exchange
of a single phenylalanine (F1994S mutant) or conserved FG-repeat motif (4SG mutant) did
not affect GFP-SPN1 localization. Interestingly, the effect of combinatorial mutants was a lot
stronger than it could have been expected from the effect of the individual mutants. 5SG, the
combination of F1994S and 4SG, showed predominantly an equal distribution of GFP-SPN1
between the cytoplasm and the nucleus compared to a clear nuclear localization with both
individual mutants. Similar effects could be observed for mutants combining mutations of
hydrophobic as well as charged amino acids. The mutant showing the least binding to CRM1
was KE 5SG in which the lysines were mutated to glutamic acid and 5FGs were mutated to SG.
Localization of GFP-SPN1 was not affect at all when co-transfected with this mutant. This is
remarkable, as the Nup214(1859-2090) fragment contains 25 additional phenylalanines. The
crystal structure-derived Nup214-X mutants showed very diverse effects on CRM1-interaction.
Nup214 X2 did not alter GFP-SPN1 localization, Nup214 X1 led to some redistribution of
GFP-SPN1 in about 20% of the cells. The combination mutant Nup214 X3 led to cyto-
plasmic localization of GFP-SPN1 in about 50% of the cells and an equal distribution in the
remaining 50% of the cells, indicating the importance of the mutated residues in CRM1-binding.
From these results, it can be concluded that binding of CRM1 to Nup214 is indeed mediated by
phenylalanine residues, but is also affected by basic residues. Furthermore, the combination


















































Figure 34: Co-transfection of Nup214 mutants with GFP-SPN1. HeLa P4 cells were transfected
with plasmids coding for the Nup214(1859-2090) fragment fused to RFP-cNLS or the empty RFP-cNLS
vector were co-transfected with GFP-SPN1. Cells were analyzed by fluorescence microscopy after 24
hours. (A) shows a subset of the tested Nup214 mutants. All RFP-Nup214-cNLS constructs (red)
localized in the nucleus (blue). Localization of GFP-SPN1 is altered depending on the co-transfected
Nup214 construct (green). (B) The localization of GFP-SPN1 in 100 cells was quantified for predominant
cytoplasmic (C > N), equally distributed (C = N) and predominant nuclear (C < N) localization. The mean
and standard deviation of at least three independent experiments were plotted. Cells were transfected
and localization was determined by Christiane Spillner.
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3.4.4 Characterization of structure-derived CRM1 mutants
The crystal structure revealed multiple Nup214-binding pockets on CRM1 (figure 31, table
S6). CRM1 mutants were designed to obstruct that binding and therefore verify the identified
Nup214-binding sites. Seven binding pockets were identified that bound phenylalanines
of MBP-Nup214 in the crystal structure. Binding pockets were numbered from I to VII. An
additional pocket "L" binds a phenylalanine derived from the linker between the MBP and the
Nup214. It was nevertheless included in the analysis as there are various phenylalanines in
Nup214 upstream of the used aa1916-2033 fragment that could potentially interact with this
binding pocket. The binding pockets were predominantly hydrophobic, but for most of the
pockets no obvious interacting residue could be identified. The strategy for mutagenesis was
therefore to introduce larger residues into the binding pockets of CRM1 with the intention to
block access of the phenylalanine to the pocket (see figures 35 and 36). The complete list of
mutated CRM1 residues can be found in table 26.
Table 26: Mutated residues in CRM1.
FG-site # FG-Pocket # Residue # Original Residue Mutated Residue
1 L (linker) 680 K Q, R




I (F1922) 679 L R, W
723 C M
II (F1938) 823 F A
824 D K
III (F1947) 917 T E
918 Y W
2 IV (F1982) 880 W A
(aa1980-1988) V (F1988) 925 H W
928 S K
3 VI (F2012) 83 L F, R
(aa2009-2027) 102 I Q, W







































Figure 35: Phenylalanine-binding pockets on CRM1. Eight hydrophobic pockets on CRM1 were
identified from the crystal structure of the Nup214 complex. Selected residues were mutated to larger
amino acids to obstruct binding of Nup214 to the pockets. The CRM1 backbone is colored in gray, the
respective residues chosen for mutagenesis are highlighted in green. Nup214 is depicted in purple. (A)
Binding pocket L binds a phenylalanine from the linker between the MBP-tag and Nup214. (B)-(H) show
the binding pockets I-VII of F1922, F1938, F1947, F1982, F1988, F2012 and F2024, respectively.
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CRM1 single mutants were generated by site-directed mutagenesis on the pQE60-CRM1-His
plasmid. Double or multiple mutants were generated either by site-directed mutagenesis,
by cloning of synthesized gene fragments or by combining CRM1 fragments containing the
desired mutations. A selection of mutants were expressed. The purification was performed
with the same protocol as for the wildtype CRM1. All CRM1 mutants were readily expressed,
but only a subset were soluble and could be purified. Interestingly, especially mutation of
N-terminal residues led to insoluble protein. This includes mutations of the residues L83, I102
and L134, alone as well as in combination with any other mutations of the protein. The yield of
soluble protein was significantly lower in the mutants compared to the wildtype, yielding as little
as 15 µg from 12 liters of expression cultures in the case of the K680Q A731Q L679R D824K
mutant compared to several mg per liter expression culture for the wildtype. A complete list of
all generated CRM1 mutants and their expression and purification efficiency can be found in








Figure 36: Selected mutations of CRM1 were introduced into the structure in silico with PyMOL
to analyze their potential to block phenylalanine-binding to the respective hydrophobic pockets. The
mutations (A) K680Q A731Q, (B) L679R and (C) D824K are shown. The CRM1 backbone is colored in
gray, the respective mutated residues are highlighted in green. Nup214 is depicted in purple.
Based on the large number of binding pockets on CRM1 involved in the interaction with
Nup214, it was highly unlikely that a mutation of a single FG-pocket would have an drastic ef-
fect on Nup214-CRM1 binding. First, purified CRM1 mutants were tested for their ability to bind
phenylsepharose. Phenylsepharose is commonly used as a mimic of hydrophobic FG-repeats.
CRM1 mutants were incubated with phenylsepharose in the absence or presence of RanGTP
and NES peptide. In accord with the expectations, no significant difference in binding could
be observed between the different tested CRM1 mutants (figure 37). Furthermore, binding to















Figure 37: CRM1 mutants show no differences in binding to phenylsepharose. 25 pmol CRM1
mutants were incubated with 5 µl phenylsepharose in absence or presence of an excess of RanGTP
and NES peptide. Bound proteins were analyzed by SDS-PAGE, followed by Coomassie staining.
No difference in binding to phenylsepharose was observed for any of the CRM1 mutants.
Therefore, it was proceeded with a more sensitive analysis by RanGAP assays.
Available crystal structures of CRM1 show that conformational changes in the molecule are
mutually influenced by binding of RanGTP and cargo. To rule out that the mutations of CRM1
changed the affinity for RanGTP or cargo, an NES peptide was titrated to the respective CRM1
mutants and Ran loaded with 32P-γ-GTP. The stability of the complex was analyzed. Strikingly,
even though the CRM1 mutants were designed to inhibit Nup214-binding, most CRM1 mutants
also showed altered binding to NES peptide and/ or RanGTP (figure 38, left panel). Some
mutants like CRM1 S928K showed reduced NES-binding whereas CRM1 K680Q A731Q
showed an increase in NES-binding. The only mutants that exhibited unaltered NES complex
stability were CRM1 D824K, Y918W and W880A.
Titration of Nup214 to the respective CRM1 mutants and Ran loaded with 32P-γ-GTP revealed
that most of the tested CRM1 mutants were indeed impaired in their binding to Nup214 as as
levels of GTP-hydrolysis were increased upon addition of RanGAP compared to the wildtype
(figure 38, middle panel). Only CRM1 K680Q A731Q did not lead to increased GTP-hydrolysis.
Next, the CRM1 mutants were analyzed in a cellular context by in vitro export assays.
Cells stably transfected with GFP-NFAT were permeabilized and pre-incubated with an ATP-
regenerating system and LMB to remove or inactivate most of the endogenous CRM1. After
extensive washing, recombinant CRM1 mutants were added to a final concentration of 30 nM
and nuclear fluorescence at 0, 5, 10 and 25 minutes was analyzed by flow cytometry. Most
of the CRM1 mutants showed a somewhat slower nuclear export compared to the wildtype
(figure 38, right panel). The observed effects were small, but reproducible. Only CRM1 A156F
was able to export GFP-NFAT at the same rate of the non-mutated CRM1. In contrast, kinetics
with 100 nM of the CRM1 mutants did not show any variation (appendix, figure S13), indicating














































































































































































































































































































































































RanGAP assays nuclear export assay wt
mutant
Figure 38: CRM1 mutants showed diverse binding to NES/ RanGTP and Nup214. The CRM1
mutants were plotted (black square) individually in comparison to the wildtype CRM1 (white circle). The
average of the values is indicated by the black line for the CRM1 mutants and the dashed line for the
CRM1 wildtype. The individual values and averages of two independent experiments were plotted.
Square brackets indicate the altered FG-binding pocket of the CRM1 mutant. (left panel) NES peptide
or (middle panel) MBP-Nup214(1916-2033)-His was titrated to 100 nM of the CRM1 mutants and Ran
loaded with 32P-γ-GTP in RanGAP assays. (right panel) Permeabilized GFP-NFAT cells were incubated
with 30 nM of the respective CRM1 mutants. Residual nuclear fluorescence was analyzed by flow
cytometry. Values were normalized to fluorescence intensities at 0 minutes and plotted in relation to a
kinetic without added CRM1 (gray).
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As some single mutants showed an effect on Nup214 binding and nuclear export, it was tested
if these effects would be additive in CRM1 mutants with more than one mutated hydrophobic
pocket. A set of CRM1 mutants including D824K (FG binding pocket III) and K680Q A731Q
L679R (FG binding pockets L and I) as well as a combinatorial mutant of the two, namely K680Q
A731Q L679R D824K was analyzed for their binding of NES peptide and Nup214 in RanGAP
assays and furthermore for their effect on export of GFP-NFAT. Again, only D824K exhibited
nearly unaltered binding to an NES peptide and RanGTP. The K680Q A731Q L679R mutant as
well as the K680Q A731Q L679R D824K mutant, bound to the NES peptide stronger than the
wildtype (figure 39, left panel). K680Q A731Q L679R binding to Nup214 was comparable to
the wildtype, whereas CRM1 D824K showed decreased binding to Nup214. Surprisingly, the
effect on Nup214 binding was not additive for the K680Q A731Q L679R D824K mutant. On
the contrary, the decrease in Nup214 binding was slightly smaller as compared to the D824K
single mutant (figure 39, middle panel). Also the effect of the respective CRM1 mutants on
nuclear export of GFP-NFAT was not additive, although all three mutants showed reduced



































































































































































































RanGAP assays nuclear export assay wt
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Figure 39: Differences in NES and Nup214 are not additive for the tested CRM1 double and triple
mutants. The CRM1 mutants were plotted (black square) individually in comparison to the wildtype
CRM1 (white circle). The average of the values is indicated by the black line for the CRM1 mutants and
the dashed line for the CRM1 wildtype. The individual values and averages of three (RanGAP assays)
or two (export assay) independent experiments were plotted. Square brackets indicate the altered FG-
binding pocket of the CRM1 mutant. (left panel) NES peptide or (middle panel) MBP-Nup214(1916-
2033)-His was titrated to 30 nM of the CRM1 mutants and Ran loaded with 32P-γ-GTP in RanGAP
assays. (right panel) Permeabilized GFP-NFAT cells were incubated with 30 nM of the respective CRM1
mutants. Residual nuclear fluorescence was analyzed by flow cytometry. Values were normalized to
fluorescence intensities at 0 minutes and plotted in relation to a kinetic without added CRM1 (gray).
Note that the plotted export kinetic for CRM1 D824 is the same as in figure 38
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The description of additional mutants can be found in the appendix, figures S11 and S12.
The effects of the CRM1 mutants as observed in the described assays are summarized in table
27. For CRM1 mutants that showed altered NES/ RanGTP binding, no reliable conclusion about
Nup214 binding could be drawn as it would not be clear if reduced binding to Nup214 could
be attributed to actual impaired Nup214 binding or a general conformational change in CRM1.
Nevertheless, a role of the mutated binding pockets in Nup214 binding cannot be ruled out.
Five of the tested CRM1 mutants showed unaltered binding to an NES peptide and RanGTP. At
the same time, only two out of the five mutants showed reduced binding to Nup214 in RanGAP
assays. These mutations were D824K and W880K, corresponding to the binding pockets of
Nup214 F1938 and F1982, respectively. It can therefore be concluded that the binding pockets
II and IV on CRM1 indeed play an important role in CRM1-Nup214 interaction.








L744W L = = not tested
K680Q A731Q L > = <
F823A II < < not tested
D824K II = < <
T917E III = = not tested
Y918W III = = =
W880A IV = < not tested
S928K V < < <
F149W VII < < not tested
A156F VII < < =
L679W K680R L+I < < not tested
K680Q A731Q L679R L+I > < <
K680Q A731Q C723M L+I > = not tested
L679R L744W L+I = = not tested
C723M L744W L+I < < not tested
K680Q A731Q L679R D824K L+I+II > < <
Summary of the results from figures 38 and 39 as well as S11 and S12. "=" indicates comparable bind-
ing/ export by the CRM1 mutant compared to the wildtype. ">" indicates increased and "<" decreased
binding/ export by the CRM1 mutant.
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3.5 Analysis of RanBP3-CRM1 interactions
3.5.1 The stabilization of export complexes by RanBP3 is concentration-dependent
RanBP3 had previously been identified as a co-factor that stimulates CRM1-export complex
formation [240, 241]. The effect of RanBP3 on CRM1-export complex formation depended on
the kind of cargo as well as on the concentration of RanBP3. The effect of different RanBP3
concentrations on the stability of different export complex was therefore analyzed by RanGAP
assays, using either an NES peptide or SPN1 as cargo (figure 40). NES peptide or SPN1
were titrated to CRM1 and Ran loaded with 32P-γ-GTP in the presence of absence of ei-
ther a Nup214 fragment or different concentrations of RanBP3. Both tested concentrations
of RanBP3 showed an increased resistance of the NES peptide-CRM1-RanGTP complex as
well as of the SPN1-CRM1-RanGTP complex towards RanGAP-mediated GTP-hydrolysis. The
strongest stabilization was observed when Nup214 had been added. Interestingly, the lower
RanBP3 concentration led to an increased stabilization compared to the higher RanBP3 con-
centration for the NES peptide- as well as the SPN1-export complex. The observation that high
concentrations of RanBP3 might have a relatively destabilizing effect is in agreement with pub-
lished data [240]. It was recently suggested to arise from a weak interaction of the Ran binding
domain of RanBP3 with the acidic loop of CRM1 [176]. The published structure showed that the
NES binding cleft was closed when RanBP3 was bound to CRM1, but could be displaced by
binding of an NES. High concentrations of RanBP3 would therefore outcompete NES binding,
leading to a relative destabilization of the export complex [176].
Similar stabilization of the export complex by Nup214 and RanBP3 indicated that they might
have similar binding modes on CRM1.














































Figure 40: RanBP3 stabilizes export complexes. (A) SPN1 or (B) NES was titrated to CRM1 and
Ran loaded with 32P-γ-GTP in the presence of absence of either 3 µM MBP-Nup214(1930-2021)-His,
100 nM or 1000 nM RanBP3. 100 nM RanBP3 corresponded to a 1:5 molar ratio compared to CRM1
whereas 1000 nM RanBP3 was equivalent to a 2:1 molar ratio. The mean and standard deviation of two
independent experiments are shown. Some error bars are too small to be seen.
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3.5.2 RanBP3 and Nup214 compete for binding to CRM1 export complexes
Our crystal structures of the Nup214 complex as well as the recently published complex of the
yeast homologues of CRM1, RanGTP and RanBP3 ([176]) suggest overlapping binding sites
for Nup214 and RanBP3 on CRM1. It was therefore tested if Nup214 and RanBP3 competed
for CRM1-binding. GST-Nup214(1930-2021) was immobilized on beads and incubated with
pre-purified CRM1-RanGTP-SPN1 export complex and increasing amounts of RanBP3.
Addition of 20% molar amount of RanBP3 did not significantly affect binding of the export
complex to immobilized Nup214 fragment, whereas equimolar amounts of RanBP3 resulted in
considerably less binding of CRM1 and SPN1 (figure 41A).
For a more quantitative analysis, Halo assays were performed. The comparison of different
immobilized Nup214 fragments revealed that equimolar RanBP3 amounts nearly abolished
binding of CRM1 to shorter Nup214 fragments (residues 1930-2021 and 1968-2033) whereas












































Figure 41: RanBP3 and Nup214 compete for binding to CRM1 export complexes. (A) 250 pmol
GST or GST-Nup214(1930-2021) were immobilized on beads and incubated with pre-purified CRM1-
RanGTP-SPN1 export complex and increasing amounts of RanBP3 (50/250/500 pmol). Bound proteins
were analyzed by SDS-PAGE, followed by Coomassie-staining. (B) 50 pmol GST-Nup214(1930-2021),
GST-Nup214(1968-2033) or GST-Nup214(1859-2090) were immobilized on beads and incubated with
CRM1-Cy3, RanGTP or NES peptides in the absence or presence of 50 pmol RanBP3. Bound CRM1-
Cy3 was quantified by flow cytometry analysis. Absolute fluorescence intensities and standard devia-
tions of 3 independent experiments were plotted.
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3.5.3 RanBP3 and Nup214 can bind free CRM1 simultaneously, but not the CRM1 export
complex
Next, it was tested if binding of Nup214 and RanBP3 was mutually exclusive. GST-RanBP3
was immobilized and incubated either with pre-purified CRM1-RanGTP-SPN1 export complex
or CRM1 alone in the presence or absence of Nup214. Interestingly, binding of Nup214 to
immobilized RanBP3 could only be detected in the presence of free CRM1, but not in the pres-
ence of the export complex (figure 42). Furthermore, the tested Nup214(1916-2033) fragment
reduced binding of the export complex to immobilized RanBP3 in agreement with the results























































Figure 42: RanBP3 and Nup214 can bind free CRM1, but no CRM1 export complexes, simultane-
ously. 100 pmol GST-RanBP3 were immobilized and incubated with pre-purified CRM1-RanGTP-SPN1
export complex or CRM1 in absence or presence of His-Nup214(1916-2033)-His. Bound proteins were
analyzed by SDS-PAGE, followed by (A) Coomassie-staining and (B) Western blotting with an α-His
antibody to detect the His-tagged CRM1, SPN1 and Nup214.
It can therefore be concluded that Nup214 and RanBP3 compete for similar binding sites on





4.1 The Halo assay is a novel, semi-quantitative assay for the analysis of
protein-protein interactions
The Halo assay is a stable, semi-quantitative assay for the analysis of interactions between
CRM1 and a variety of cargoes and Nup214 fragments. The main advantages of the assay
compared to conventional gel-based pulldown assays are the easy quantification of the binding
by flow cytometry and the large detection range.
Binding of of Cy3-labeled CRM1 to various Nup214 fragments was probed. This included short
fragments with a very low affinity like the Nup214(1868-1990) fragment as well as very long,
high affinity fragments such as Nup214(1859-2090). Binding of CRM1 to Nup214(1968-1990)
could not be detected in previously described conventional pulldown assays [59] whereas with
the Halo assay a clear RanGTP-dependent binding was observed (figure 11). Compared to this
fragment, CRM1-binding of CRM1 to the Nup214(1859-2090) fragment was ∼1000x higher.
Conventional pulldown assays rely on the analysis of the interacting proteins by SDS-PAGE
followed by Coomassie- or silver staining or Western blotting. The detection limit of Coomassie
staining is generally set at 100 ng protein and 10 ng for colloidal Coomassie. Silver staining
allows for a detection of 1 ng [242]. Even though stains with a high sensitivity would allow the
detection of very low affinity binding, direct comparison with 1000x stronger binding fragment
would be difficult due to saturation of the staining.
The Halo assay therefore offers an advantage in comparison with conventional gel-based as-
says, as it has a detection range of at least 3 orders of magnitude.
The application range of the assay can easily be extended by fluorescence labeling of other
proteins of interest, for example import receptors or any other protein. Before using a new
protein in the assay, it should be ensured that the binding properties of the fluorescently la-
beled protein are the same as of the unlabeled protein. It is also possible to use two or more
differently labeled proteins in the same assay to allow for parallel quantification of the binding.
4.2 Structural analysis of a CRM1 export complex bound to long segments of
FG-repeats from Nup214
A complex containing CRM1-RanGTP-SPN1 and a Nup214(1916-2033) fragment was crystal-
lized in this work. The obtained crystal structure of the Nup214 complex is the first structure of
CRM1, or export receptors in general, with a nucleoporin-fragment. It also contains the longest
FG-repeat fragment observed in any available crystal structure. The crystallization of FG-
repeat-containing peptides is challenging as the fragments themselves are very hydrophobic
due to their sequence and also natively unfolded [34]. In addition, the interaction of transport
receptors with nucleoporins has to be transient in order for transport complexes to translocate
through the nuclear pore. Therefore, interactions of karyopherins with some fragments of
nucleoporins might not be stable enough to be captured in protein crystals.
Of all ten available crystal structures that contain FG-repeats, half were crystallized with short
FXFG- or GLFG-peptides that contained one or two phenylalanine residues. A crystal structure
of p15 and TAP bound to a 6-residue peptide derived from Nup214 (aa1810-1815) shows an
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interaction with one phenylalanine (PDB ID: 1JN5, [209]). Only four out of the ten structures
describe interactions between karyopherins and actual nucleoporin fragments. A structure of
truncated human importin β with a 7-residue fragment of S. cerevisiae Nsp1p (PDB ID: 1O6O,
[206]) identified one FG-binding pocket. Another crystal structure of S. cerevisiae importin β
bound to a 39-residues fragment of S. cerevisiae Nup1p (PDB ID: 2BPT, [207]) contained three
FG-binding pockets between the N-terminal HEAT repeats of importin β.
The only structure of CRM1 interacting with FG-repeats is the recently published structure
of the yeast Yrb2 complex (PDB ID: 3WYF, [176]) with two short FG-binding regions, each
binding three phenylalanine residues of Yrb2.
By contrast, our crystal structure of the Nup214 complex contains three FG-sites bound to
CRM1, each with several FG-motifs. FG-site 1 is the longest of the three sites, encompassing
34 residues including three phenylalanine residues bound to CRM1. Furthermore, this FG-site
is not observed in the structure of the Yrb2p complex and therefore might be exclusive for
Nup214-CRM1 interaction. FG-site 2 and 3 are 8 and 18 residues long, respectively, and each
bind to CRM1 with two FG-repeats. These two binding sites overlap with the binding sites of
Yrb2 on CRM1.
4.3 CRM1 conformation and function is highly sensitive towards manipulation
Crystal structures of CRM1 revealed that it is a highly flexible molecule that changes its con-
formation upon binding to other proteins like RanGTP, cargoes as well as assembly and dis-
sociation factors [127, 172, 177, 176]. Interaction with RanGTP and cargo leads CRM1 to
change from an open, S-shaped conformation [172], to a closed- ring-like structure [127]. This
massive structural change is accompanied by conformational changes within the most flexi-
ble structural features of the CRM1 molecule, the acidic loop, the NES binding cleft and the
C-terminal helix. It is not surprising that the conformational changes that occur are closely in-
terconnected. Folding-back of the acidic loop for example, triggers closing of the NES binding
cleft. In the same manner, manipulation of the CRM1 molecule by mutagenesis of individ-
ual residues might trigger changes within the molecule that exceed the intended function. 63
structure-derived CRM1 mutants were cloned in this work which were designed to interfere with
Nup214-binding (appendix, table S7). Of the 38 tested constructs, only 20 expressed a soluble
CRM1 mutant, but many of them with a very low yield compared to the wildtype. 18 mutants
were insoluble. Remarkably, solubility was not correlated with the number of mutated residues.
Several single mutants were insoluble whereas several double and triple mutants were soluble
and could be purified. Strikingly, mutations within the N-terminus, in particular residues L83,
I102 and L134, led to insoluble protein.
Aside from the expression and purification efficiency, also the properties of the soluble CRM1
mutants varied. The 20 purified CRM1 mutants exhibited very different tolerance towards freez-
ing and thawing as well as buffer exchanges. CRM1 H925W, for example, was completely pre-
cipitated after thawing, independent from the buffer it was frozen in.
16 purified CRM1 mutants could be tested in RanGAP assay for their binding to an NES peptide,
RanGTP and Nup214 (table 27). Only six of them (five single mutants and one double mutant)
exhibited an unaltered binding to RanGTP and an NES peptide. This is remarkable, as all the
– 109 –
Discussion
mutants were designed to only block access of the Nup214 phenylalanine side chains to the
hydrophobic pockets of CRM1. Even though some of the mutations chosen might appear quite
drastic, e.g. leucine to tryptophan or alanine to glutamine, those combinations were specifically
chosen, because according to the structure of the Nup214 complex, they seemed to be the
only amino acids large enough to inhibit phenylalanine-binding to the respective hydrophobic
pocket. Nevertheless, from the observed effects it is obvious that the introduced mutation led
to conformational changes within the CRM1 molecule, thereby altering its affinities to RanGTP
and/ or an NES peptide, even though the binding regions of RanGTP and cargoes are in dis-
tinctly different region on the CRM1 molecule compared to the mutated residues. Perhaps,
some introduced large amino acids act as a wedge between the two HEAT repeats forming
the respective hydrophobic pocket, thereby changing the plasticity of the whole molecule. This
could lead to decreased flexibility and sterical hinderance within the molecule when changing
from its open to its closed conformation. On the other hand, also the introduction of small
amino acids. e.g. F823A altered binding to NES/ RanGTP whereas the introduction of larger or
charged amino acids did not alter binding in case of the L679L L744W double mutant (table 27).
Regarding their intended effect, most CRM1 mutants were indeed decreased in their binding to
Nup214. For CRM1 mutants showing altered NES or RanGTP binding, it is difficult to interpret
their effect on interaction with Nup214 and overall nuclear export.
Overall, it can be concluded that the CRM1 structure is very sensitive towards manipulation due
to its sophisticated conformational changes and cooperative binding mechanisms. Mutants of
CRM1 and probably other karyopherins as well, should therefore be characterized carefully and
surveyed for unaltered binding to RanGTP and cargo before conclusions with respect to any
other interaction partner can be drawn.
4.4 Integrative structural and functional analysis reveals that Nup214 stabilizes
CRM1 export complexes by acting as a molecular clamp
4.4.1 Integration of electron microscopy, cross-linking mass spectrometry and crystal-
lography data suggests flexible regions of Nup214 between anchored phenylala-
nine residues in binding pockets of CRM1
The cross-linking mass spectrometry data suggested that the more N-terminally located
Nup214 residues are located closer to the cargo binding region on CRM1, whereas the more
C-terminal Nup214 residues are located in the region where the N- and C-termini of CRM1
come together. All identified cross-links from the above described datasets are summarized in
table 28. On the Nup214 fragments, only cross-links to the residues K1928, K1942, K1966 and
K2010 were identified. The obtained cross-links were mapped on the crystal structure of the




Table 28: Summary of the identified cross-links between Nup214 and the export complex.
Nup214 residue Linked protein Linked residue Cross-linker

















K1966 CRM1 K22 BS3
K426 BS3
K2010 CRM1 K22 BS3
Some of the cross-links confirmed the crystal structure of the Nup214 complex, others should
not have been linked judging from their position in the crystal structure. Even though false
positive cross-links can not be excluded completely, the good compliance of the obtained intra-
and intermolecular cross-links of CRM1, RanGTP and SPN1 with the crystal structure of the
export complex suggest that most of the identified cross-links are specific.
Nup214 residue K1928 and CRM1 residue K680 are 27.1 Å apart in the crystal structure of the
Nup214 complex and therefore within the range that can be covered by the cross-linker (figure
43A). On the other hand, SPN1 residue K167 is 57.0 Å apart from the Nup214 residue K1928
in the crystal structure and therefore the cross-linker should not be able to cover the distance
between them (figure 43B).
Nup214 K1942 targets six residues on two sides of the CRM1 molecule as well as five residues
on SPN1 and one on RanGTP (figure 43C). Most of these residues are too far away from K1942
in the crystal structure to be linked. K1942 lies within FG-site 1 on a loosely attached 8-residue
stretch between two hydrophobic pockets on CRM1 that anchor Nup214 residues F1938 and
F1947. From the cross-linking mass spectrometry data, one could speculate that this stretch
might be flexible when the complex is in solution, thereby allowing K1942 to cross-link to the
identified residues. Nevertheless, as long as Nup214 residues F1938 and F1947 are inserted




The same holds true for Nup214 residue K1966 (figure 43D). K1966 could not be identified
in the crystal structure of the Nup214 complex. It is located on a 29 residue-stretch between
FG-sites 1 and 2. That fact that no density could be observed for these residues in the X-
ray crystallography data already indicated a high flexibility of the region. This flexibility could









































Figure 43: The cross-linking results were mapped on the crystal structure of the Nup214 com-
plex. Nup214 (purple) in stick representation. Cross-linked residues of Nup214 are highlighted in blue.
(A)-(B) CRM1 is shown in gray as a cartoon representation. Cross-linked residues of CRM1 are high-
lighted in green and as stick representation. Cross-links of the Nup214 residue K1928 to (A) CRM1
K680 and SPN1 K223 and (B) SPN1 K167 are shown. Cross-links are shown with a dashed line, re-
spective Cα-Cα distances are indicated. (C)-(D) CRM1 is shown in gray as a cartoon representation.
Cross-linked residues of CRM1 are highlighted in green. (C) Nup214 K1942 cross-links to the indicated
residues of the export complex. (D) K1966 is not present in the crystal structure, but was shown to link
to CRM1 residues K22 and K426 on opposite sides of the CRM1 ring. (E) Nup214 K2010 links to CRM1
K22. The cross-link is indicated by a dashed line, the Cα-Cα distance between the two residues is 15.1
Å.
Nup214 residue K2010 links only to CRM1 residue K22 which is 15.1 Å away in the crystal
structure (figure 43E). As K2010 is very close to F2012, which is deeply inserted into a
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hydrophobic pocket on CRM1, it is not surprising that the position of K2010 seems fixed as
well, therefore allowing it only to cross-link to residues in close proximity.
The results of the cross-linking mass spectrometry and crystallization only partially match.
It is likely that the obtained crystal structure represents only one possible conformation of
the Nup214 complex. The Nup214 fragment contains many residues that are only loosely
attached to the CRM1 surface or cannot be observed by X-ray crystallography, because
they are too flexible. It is plausible that these flexible regions might behave differently when
the complex is in solution as in the cross-linking samples, compared to the crystal environment.
The flexibility of several region of CRM1 as suggested by missing densities in crystallography
data as well as cross-links all over the export complex by some Nup214 residues in the mass
spectrometry data, could also explain the challenge to obtain meaningful data with electron
microscopy. As single particle electron microscopy relies on averaging several thousands
of micrographs, flexible regions in a protein cannot be observed by electron microscopy.
The cross-linking data suggested high flexibility at the N-terminus of the Nup214 fragment
including its N-terminal tags, explaining why all tested tags could not be observed by electron
microscopy. Furthermore, the epitope of the Nup214 antibody used in electron microscopy
samples ranges from 1934-1946, a region including and adjoining the residues F1938 and
F1947 which are bound by hydrophobic pockets. The epitope might therefore not be accessible
to the antibody when Nup214 is bound to CRM1.
In summary, the structural data suggest that Nup214 binds to CRM1 mainly via the pheny-
lalanine side chain that insert into hydrophobic pockets on the CRM1 molecule. The residues
between these bound phenylalanines are either loosely attached to the outer surface of CRM1
or flexible in solution.
4.4.2 Nup214 couples the N- and C-terminal arch of CRM1
The crystal structure of the Nup214 complex revealed that Nup214 winds along the outer sur-
face of the CRM1 molecule from HEAT repeat 14 close to the cargo binding region on CRM1,
across the contact region of the CRM1 C- and N-termini up to HEAT repeat 4. Three binding
regions of Nup214 were identified on CRM1 and even though there was no density for Nup214
residues in the crystal structure that directly interact with the N- and C- terminal HEAT repeats
of CRM1, the structural data suggests that Nup214 stabilizes CRM1 export complexes by cou-
pling the N- and C-terminal arches of CRM1 through interactions of phenylalanine side chains







CRM1 stabilized by Nup214 in 
closed conformation
Figure 44: Nup214 stabilizes the closed conformation of CRM1 by acting as a molecular clamp.
Unbound CRM1 (gray) occurs mainly in the open conformation. CRM1 adapts a closed conformation
upon binding to RanGTP and/ or cargo which can be stabilized by Nup214 (purple).
This hypothesis could be reinforced by the binding assays with the structure-derived Nup214
mutants X1, X2 and X3. In the Nup214 X1 mutant all phenylalanine residues that bound to
CRM1 in the C-terminal half were mutated, whereas all phenylalanine residues that bound
to the N-terminal HEAT repeats of CRM1 were mutated in X2. While Nup214 X1 showed
reduced binding in pulldown assays, binding of Nup214 X2 was only slightly altered. Only the
combination of the mutations in the Nup214 X3 mutant abolished binding to CRM1 completely.
Also the effect of the Nup214 X1 and X2 mutations compared to the wildtype in cellular binding
assays was rather minimal. Nup214(1859-2090) X2 fused to RFP-cNLS did not have any effect
on the localization of the co-transfected GFP-SPN1 compared to the wildtype, the respective
X1 construct only led to re-localization of GFP-SPN1 in ∼30% of the cells. The binding assays
therefore indicate that binding of the Nup214 phenylalanines to either one of the CRM1 halves
is enough to mediate a stable binding. This is in strong contrast to the observed effects of the
X1 and X2 fragments in RanGAP assays. Even though both fragments clearly bind to CRM1
in the binding assays, they hardly stabilize the CRM1-RanGTP complex towards RanGAP-
mediated hydrolysis. This indicates that Nup214 can bind stably to CRM1 by interacting with
either one of the arches, but needs binding to both the C-terminal and the N-terminal halves of
CRM1 in order to stabilize the complex and protect it from RanGAP-induced GTP-hydrolysis.
This suggestion is in agreement with the observed binding behaviors and stabilization effect
of truncated Nup214 fragments. Nup214(1916-2033) and Nup214(1930-2021) fragments both
form stable export complexes with SPN1 (figure17). Truncation of residues 1916-1929 of the
N-terminus of the Nup214 standard fragment removes F1922, which is inserted in FG-pocket
I in the crystal structure of the Nup214 complex. On the other hand, truncation of residues
2022-2033 from the C-terminus of the standard fragment removes F2024, which was found
inserted into FG-pocket VII in the structure. The removal of either one of these interacting
phenylalanine residues led to a decrease in the stabilization against RanGAP-mediated
complex dissociation in RanGAP assays (figure 18A). Judging from the RanGAP assays, the
truncation of F1922 is less drastic than the truncation of F2024, which can be explained by the
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fact that the respective truncations contain four more phenylalanine residues binding to CRM1
in the C-terminal half of CRM1 and two more in the N-terminal half, respectively. Truncation of
the N- and the C-terminus as in the Nup214(1930-2021) fragment did not show any stabiliza-
tion of the CRM1-RanGTP complex in RanGAP assays, similar to the Nup214(1916-2033) X3
mutant, in which all binding phenylalanines were mutated to serine. In the absence of cargo,
as shown with the RanGAP assays, binding of the remaining phenylalanines is apparently not
strong enough to counteract the opening of the CRM1 molecule as initiated by interaction of
the Ran C-terminus with the acidic loop of CRM1. In the presence of a cargo, CRM1 is held
in the closed conformation by NES binding to the cleft. Nup214 does not have to counteract
conformational changes and therefore also the X1 and X2 mutant as well as the truncated
Nup214(1930-2021) can stably bind the export complex.
In summary, the crystal structure of the Nup214 complex combined with the Nup214 mutant
binding assay data suggest that Nup214 stabilizes the export complex by binding to hydropho-
bic pockets on the C- and N-terminal halves of CRM1, thereby acting as a molecular clamp.
The N- and C-terminus of CRM1 are held together by the clamp thereby defending the closed
conformation of the CRM1 molecule against intrinsic and extrinsic stimuli for complex dissocia-
tion. This would suggest that Nup214 has to detach from CRM1 before the dissociation of the
export complex can be induced by RanBP1 or Ran-binding domains of Nup358 [24].
4.5 Interaction of FG-nucleoporins and karyopherins might rely on overlapping
as well as specific binding sites
4.5.1 Comparison of binding sites from Nup214 and RanBP3 on CRM1
Crystal structures of FG-repeats bound to importin β revealed binding of GLFG and FXFG
repeats via phenylalanine side chains to overlapping hydrophobic pockets between HEAT
repeats 5/6, 6/7 and 7/8 indicating that these pockets bind phenylalanines most stably in
importin β [122, 206, 207].
A crystal structure of the RanBP3 yeast homologue Yrb2p in complex with the yeast ho-
mologues of CRM1 (Xpo1p) and Ran-GTP (Gsp1p-GTP) was published recently [176].
RanBP3 contains two FG-repeat motifs and a C-terminal Ran binding domain. Comparison
of the Nup214-CRM1-RanGTP-SPN1 crystal structure with the crystal structure of Xpo1p-
Gsp1pGTP-Yrb2p revealed partially overlapping binding sites for Nup214 and the RanBP3
homologue on CRM1 in a similar manner as shown for the GLFG and FXFG repeats in importin
β. Alignments for CRM1/Xpo1 and RanBP3/Yrb2 can be found in the appendix (figures S5, S7).
The overall crystal structure of human CRM1 as found by us and others is also similar to
the S. cerevisiae Xpo1p protein (appendix, figure S14A). The HEAT repeats of CRM1 within
the Nup214 complex structure and Xpo1p within the Yrb2 complex align very well and form
the characteristic ring-shaped structure. The major difference in CRM1 conformation of the
structures can be observed in two distinct regions, the acidic loop and the C-terminal helix
(appendix, figure S14B,C). In the structure of the Nup214 complex, the acidic loop of CRM1 is
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folded across its ring and interacts with residues on the inner surface of HEAT repeat 15. The
C-terminal helix (HEAT repeat 21B) is folded back onto the ring and located in a stack with
the other HEAT repeats. The position of the acidic loop as well as the C-terminal helix is in
accordance with other cargo-containing crystal structures of CRM1, e.g. in [127]. On the other
hand, the structure of Xpo1p in complex with Yrb2p shows distinctly different conformations
of these structural features. Here, the acidic loop of Xpo1p is folded back onto the inside of
the ring, its residues interacting with the inner surface of HEAT repeats 11 and 12. This is
similar to the position of the acidic loop in unligated CRM1 as well as CRM1 bound to RanBP1
[172, 177]. Strikingly different is the position of the C-terminal helix of Xpo1p. In all previously
available crystal structures in which the C-terminal helix had not been truncated, it was either
located in a stack with the other HEAT-repeats or spanning across the ring of the molecule
and interacting with the inner surface of HEAT repeats 10. The C-terminal helix of Xpo1p in
complex with Yrb2p is folded away from the ring, in exactly the opposite direction as found in
other structures (appendix, figure S14C) .
Comparison of the binding of Nup214 and Yrb2p to CRM1 or Xpo1p, respectively, reveals
similarities as well as differences in the interacting regions (figure 45). FG-repeats from
Nup214 and the RanBP3 homologue both bind to hydrophobic pockets on CRM1/ Xpo1p. The
Nup214 fragments wraps around the outer surface of the CRM1 toroid, starting at FG-site 1
between HEAT repeat 14 and 15 and continuing to FG-site 2 between HEAT repeat 19 and 20
and further more to FG-site 3 along HEAT repeats 2 to 4. Apart from the Ran binding domain,
only two short FG-repeat containing segments could be identified from Yrb2. The binding
regions of Yrb2 correspond to the Nup214 FG-site 2 and 3. The Yrb2 FG-fragments spanned
residues 97-110 and 141-155 and contained four and three phenylalanines, respectively.
Phenylalanines F98, F100 and F106 of the first segment and F142, F148 and F152 of the
second segment were shown to bind to hydrophobic pockets on Xpo1p. Yrb2p residue F100
binds to the same cavity as Nup214 residue F1982. The same is true for Yrb2p residues F106,
F142 and F152 binding to the same hydrophobic pockets as Nup214 residues F1988, F2012
and F2024, respectively. On the other hand, Yrb2p residues F98 and F148 do not have a
corresponding phenylalanine on Nup214. Furthermore the bound Nup214 residues F1922,
F1938 and F1947 do not have a corresponding phenylalanine on Yrb2p.
In agreement with these overlapping interaction sites of the RanBP3 homologue and Nup214
on CRM1 are the observations from the binding assays that suggested a mutually exclusive
binding for RanBP3 and Nup214 to the CRM1 export complex (figure 41). The comparison of
Nup214 and Yrb2 binding to CRM1 and Xpo1, respectively, suggests that the set of hydrophobic






















Figure 45: Comparison of the crystal structures of the Nup214-CRM1-RanGTP-SPN1 complex
and the Xpo1p-Gsp1pGTP-Yrb2p complex. Yrb2 is superimposed on the crystal structure of the
Nup214 complex. CRM1 (light gray, surface representation), RanGTP and SPN1 (dark gray, cartoon
representation) and Nup214 (purple, stick representation) from the Nup214 complex and Yrb2 (cyan,
stick representation) from the Yrb2 complex are shown. (A) The superposition of the two complexes
reveals that Yrb2 and Nup214 share FG-site 2 and 3 on CRM1, while FG-site 1, the longest Nup214
segment, is exclusive for Nup214. (B)-(C) Detail views of FG-site 2 and 3. Although the binding of
Nup214 and Yrb2 to hydrophobic pockets overlaps for some phenylalanine residues (e.g. Yrb2 F142




4.5.2 Implications for the interaction of CRM1 with other nucleoporins
It was shown that some binding sites for Nup214 and RanBP3 on CRM1 overlap, while others
are specific for the respective protein (figure 45). Therefore, it could be speculated that this is
true for the interaction of CRM1 with other FG-nucleoporins as well. CRM1 mutants impaired
for binding to Nup214 might therefore also be altered in their binding to other FG-Nups, e.g.
Nup62. This would have several implications on the interpretation of in vitro transport assays
with CRM1 mutants as described above (figures 38, 39). On one hand, the observed export
defect of some CRM1 mutants could not be attributed solely to a defect in Nup214-binding. It
could be an accumulation of binding defects to FG-nucleoporins in general that slows down
the export of the cargo. On the other hand, not only the export might be altered in CRM1
mutants with reduced binding affinities to FG-nucleoporins, also the re-import of CRM1 into
the nucleus relies on the interaction of CRM1 with FG-nucleoporins. Reduced export of NFAT
in the described transport assays can therefore not be equated with reduced binding of the
respective CRM1 mutants to Nup214. More likely, it can be ascribed to reduced binding to FG-
nucleoporins in general, leading to decreased export and re-import of the respective mutants.
The probability that a CRM1 mutant shows impaired binding to several FG-Nups increases with
every additional FG-pocket mutated. Nevertheless, keeping in mind that there might not only
be overlapping, but also exclusive FG-sites for binding of nucleoporins to CRM1, it cannot be




4.6 Regulation of nuclear transport by nucleoporin-karyopherin interactions
All current models of nucleocytoplasmic transport rely on the interaction of transport receptors
with FG-nucleoporins. Our crystal structure revealed seven FG-binding pockets on CRM1.
From the distribution of hydrophobicity on the structure it is likely that there are several more
pockets that did not bind the Nup214 fragment used in this study. It could be speculated
that the additional binding pockets interact with other FG-repeat regions in Nup214 that were
previously described [234].
The large number of FG-binding pockets on CRM1 is in accordance with previous molec-
ular dynamics studies, which suggested up to 14 binding sites for FG-repeats in the yeast
transport receptor Cse1p [243]. Therefore, the question arises why transport receptors have
so many different binding pockets. The results of this work indicate that the binding sites
of FG-nucleoporins to transport receptors overlap partially, but not completely. Therefore,
it could be speculated that transport receptors do not indiscriminately bind any nucleoporin
with any hydrophobic pocket on their surface. The pattern of phenylalanine residues within
the nucleoporins, as well as the residues that connect them might be an important factor
for the affinity of a transport receptor to a nucleoporin. Furthermore, also the pattern of
hydrophobic FG-binding pockets on a respective transport receptor could increase its affinity to
a nucleoporin with a corresponding pattern of phenylalanine residues. The need for a matching
pattern of phenylalanine residues in the FG-Nups and FG-binding pockets on the transport
receptor would explain why, for example, Nup214 interacts specifically with CRM1, but not
with other transport receptors (figure 13). In addition, the matching patterns of the FG-binding
pockets on CRM1 and the phenylalanines within Nup214 could explain why the tested Nup214
fragment an CRM1 interact with such high an avidity.
Furthermore, the patterns of FG-binding pockets on the surface of transport receptors are likely
to vary, depending on the conformation of the transport receptor. Extensive structural changes
between unbound receptors and RanGTP- or cargo-loaded transport receptors as observed
for CRM1 [127, 172], could induce different sets of hydrophobic pockets on their surface. This
could lead to a changed affinity of the receptors to specific nucleoporins in their unbound and
bound state. The interaction of transport receptors with different sets of nucleoporins in case
they are unbound, loaded with cargo or bound to any other transport factor, could have direct
consequences on the directionality of their translocation through the nuclear pore complex.
Therefore, it could be speculated that a changed affinity of transport receptors to nucleoporins
due to conformational changes upon binding to different proteins, could prime the receptors
for nuclear import or export, in which case models of nucleocytoplasmic transport should be





First, it should be tested if a combination of the two CRM1 mutations that exhibited unaltered
binding of CRM1 to NES and RanGTP, but reduced binding to a Nup214 fragment (CRM1
D824K and W800A mutants), would have an cumulative effect on Nup214-binding. Therefore,
the double mutant should be cloned and tested in RanGAP assays and an export assay as
described above for the other CRM1 mutants.
It was shown that the FG-binding sites for Nup214 and RanBP3 on CRM1 partially overlap. It
would therefore be interesting to test if this is also the case for other FG-nucleoporins. A first
step would be to check if different FG-nucleoporins compete for binding to CRM1. This could
be done by in vitro binding assays with different nucleoporins immobilized and titration of other
FG-nucleoporins, for example Nup62 or Nup98. Next, it could be tested if CRM1 mutants that
showed a defect in Nup214 binding, like CRM1 D824K, are also impaired in their binding to
other FG-nucleoporins. For this, RanGAP assays could be performed with CRM1 mutants and
titration of different FG-Nups in the same manner as described above for Nup214. Moreover,
possible CRM1-interacting FG-repeats in the other FG-nucleoporins could be identified by ana-
lyzing different Nup-mutants or truncations. It could also be attempted to get crystal structures
of the CRM1 export complex with other FG-nucleoporins to ultimately identify the respective
binding sites.
Once there is a first idea of where on CRM1 the other FG-nucleoporins bind to and which
residues on the nucleoporins mediate the binding, it would be interesting to see if other nucle-
oporins also stabilize the export complex by acting as a molecular clamp or if that is a specific
and novel mechanism of Nup214. With respect to the molecular clamp mechanism, analysis
should also focus on the Nup214(1859-2090) fragment, which corresponds to the major FG-
repeat region. The affinity of this Nup214 fragment to CRM1 is a lot higher compared to the
fragment used for the crystallization of the Nup214 complex. The Nup214(1859-2090) fragment
can form stable complexes with CRM1 and RanGTP even in the absence of cargo. Information
about which additional residues of this fragments are also involved in the binding to CRM1 and
moreover about the region on CRM1 that they interact with, could not only verify the molecular
clamp mechanism, but maybe also give an idea about how CRM1 export complexes bound to
Nup214 are actually able to dissociate.
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Figure S1: CRM1-Cy3 binding to a subset of Nup214 fragments can be compared by the inten-
sities of the fluorescent halos. 25 µg of GST or GST-Nup214 was immobilized on 2.5 µl glutathione
sepharose High Performance beads (GE Healthcare) equilibrated in transport buffer containing 10 mg/ml
BSA.The beads were washed twice with transport buffer containing 10 mg/ml BSA and incubated with
6.0 pmol CRM1-Cy3 and optionally 22.5 pmol RanGTP and 2.9 µl 4x assay buffer (500 mM NaCl,
40 mg/ml BSA, 1 mM DTT) in a total volume of 11.7 µl transport buffer + 10 mg/ml BSA at 4 °C for
55 minutes. The beads were washed once and subsequently mounted on a microscope slide. The sam-




C Cross-linking mass spectrometry data
C.1 Cross-linking of the GST-Nup214(1968-2033) complex with BS3 and BS2G
Table S1: Cross-linking of GST-Nup214 complex with BS3 and BS2G.
Linker XL Type Protein 1 Protein 2 Residue 1 Residue 2 Distance [Å] in 3GJX
BS3 intra CRM1 CRM1 190 195 8.3
BS3 intra CRM1 CRM1 455 594 20.2
BS3 intra CRM1 CRM1 446 594 19.5
BS3 intra CRM1 CRM1 446 700 18.5
BS3 intra CRM1 CRM1 594 700 15.4
BS3 intra CRM1 CRM1 686 693 10.9
BS3 intra CRM1 CRM1 693 700 10.7
BS3 intra SPN1 SPN1 75 77 not in structure
BS3 intra SPN1 SPN1 95 97 5.4
BS3 intra SPN1 SPN1 264 266 7.1
BS3 intra SPN1 SPN1 366 370 not in structure
BS3 intra Ran Ran 127 130 5.2
BS3 intra Ran Ran 132 134 9.4
BS3 inter CRM1 SPN1 563 75 not in structure
BS3 inter CRM1 SPN1 680 266 12.6
BS3 inter CRM1 SPN1 686 266 15.8
BS3 inter CRM1 SPN1 686 271 16.5
BS3 inter CRM1 Ran 700 127 17.8
BS2G intra CRM1 CRM1 190 192 5.5
BS2G intra CRM1 CRM1 700 757 10.0
BS2G intra CRM1 CRM1 446 594 19.5
BS2G intra CRM1 CRM1 560 563 5.3
BS2G intra CRM1 CRM1 693 700 10.7
BS2G intra SPN1 SPN1 75 77 not in structure
BS2G intra SPN1 SPN1 366 370 not in structure
BS2G intra Ran Ran 132 134 5.2
BS2G inter CRM1 SPN1 594 18 not in structure
BS2G inter CRM1 SPN1 594 24 not in structure
BS2G inter CRM1 SPN1 560 75 not in structure
BS2G inter CRM1 SPN1 680 266 12.6
BS2G inter CRM1 Ran 700 127 17.8
As the used His-SPN1 construct is elongated at the N-terminus due to the cloning strategy, the
Met3 from the SPN1 from 3GJX corresponds to Met44 in the cross-linking data.
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C.2 Cross-linking of His-Nup214(1916-2033)-His complexes with BS3
Table S2: Cross-linking of His-Nup214(1916-2033)-His complex with BS3.
Replicate
Type Protein 1 Protein 2 Residue 1 Residue 2 Spectrum Count
A inter Nup214 Ran 1 134 1
A inter Nup214 Ran 1 142 1
A inter Nup214 Ran 2 2 29
A inter Nup214 Ran 2 28 3
A inter Nup214 Ran 2 37 12
A inter Nup214 Ran 2 38 1
A inter Nup214 Ran 2 99 6
A inter Nup214 Ran 2 127 3
A inter Nup214 Ran 2 134 3
A inter Nup214 Ran 2 142 1
A inter Nup214 Ran 2 152 4
A inter Nup214 Ran 2 159 7
A inter Nup214 SPN1 1 80 1
A inter Nup214 SPN1 1 223 2
A inter Nup214 SPN1 1 313 1
A inter Nup214 SPN1 1 323 3
A inter Nup214 SPN1 2 32 3
A inter Nup214 SPN1 2 34 1
A inter Nup214 SPN1 2 52 4
A inter Nup214 SPN1 2 93 19
A inter Nup214 SPN1 2 144 1
A inter Nup214 SPN1 2 211 1
A inter Nup214 SPN1 2 223 32
A inter Nup214 SPN1 2 228 1
A inter Nup214 SPN1 2 314 9
A inter Nup214 SPN1 2 317 1
A inter Nup214 SPN1 2 321 1
A inter Nup214 SPN1 2 323 10
A inter Nup214 SPN1 2 327 8
A inter Nup214 SPN1 2 343 3
A inter Nup214 SPN1 34 223 2
A inter Nup214 SPN1 48 323 1
A inter Nup214 SPN1 48 343 1
A inter Nup214 CRM1 1 686 1
A inter Nup214 CRM1 2 122 1
A inter Nup214 CRM1 2 192 2
A inter Nup214 CRM1 2 426 5
A inter Nup214 CRM1 2 531 2
A inter Nup214 CRM1 2 534 8
A inter Nup214 CRM1 2 568 1
A inter Nup214 CRM1 2 594 3
A inter Nup214 CRM1 2 680 3
A inter Nup214 CRM1 2 686 2
A inter Nup214 CRM1 2 693 1
A inter Nup214 CRM1 2 700 7
A inter Nup214 CRM1 2 741 3
A inter Nup214 CRM1 2 757 1
A inter Nup214 CRM1 2 1049 3
A inter Nup214 CRM1 48 446 1
A inter Nup214 CRM1 116 22 2
A intra Nup214 Nup214 1 48 1
A intra Nup214 Nup214 2 2 2
A intra Nup214 Nup214 2 48 25
A intra Ran Ran 1 2 5
A intra Ran Ran 2 23 1
A intra Ran Ran 2 28 3
A intra Ran Ran 2 37 4
A intra Ran Ran 2 38 5
A intra Ran Ran 2 99 1
A intra Ran Ran 2 159 1
A intra Ran Ran 2 167 2
A intra Ran Ran 12 37 1
A intra Ran Ran 12 38 7
A intra Ran Ran 12 99 2
A intra Ran Ran 23 37 13
A intra Ran Ran 23 38 1
A intra Ran Ran 23 159 1
A intra Ran Ran 28 37 3
A intra Ran Ran 28 38 10
A intra Ran Ran 28 99 2
A intra Ran Ran 28 134 1
A intra Ran Ran 28 152 1
A intra Ran Ran 28 159 2
A intra Ran Ran 37 127 1
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Replicate Type Protein 1 Protein 2 Residue 1 Residue 2 Spectrum Count
A intra Ran Ran 37 152 14
A intra Ran Ran 38 99 3
A intra Ran Ran 99 123 5
A intra Ran Ran 99 130 2
A intra Ran Ran 99 132 19
A intra Ran Ran 99 134 30
A intra Ran Ran 99 141 5
A intra Ran Ran 99 142 11
A intra Ran Ran 99 159 1
A intra Ran Ran 123 130 4
A intra Ran Ran 123 134 5
A intra Ran Ran 123 141 1
A intra Ran Ran 123 142 2
A intra Ran Ran 123 152 2
A intra Ran Ran 123 159 2
A intra Ran Ran 127 130 9
A intra Ran Ran 127 132 25
A intra Ran Ran 127 134 2
A intra Ran Ran 127 152 20
A intra Ran Ran 127 159 1
A intra Ran Ran 134 141 2
A intra Ran Ran 134 142 3
A intra Ran Ran 134 152 1
A intra Ran Ran 134 159 3
A intra Ran Ran 142 159 6
A intra SPN1 SPN1 32 34 1
A intra SPN1 SPN1 32 93 3
A intra SPN1 SPN1 32 144 4
A intra SPN1 SPN1 32 223 1
A intra SPN1 SPN1 32 314 13
A intra SPN1 SPN1 32 317 6
A intra SPN1 SPN1 32 321 3
A intra SPN1 SPN1 32 323 10
A intra SPN1 SPN1 32 327 4
A intra SPN1 SPN1 32 343 5
A intra SPN1 SPN1 34 80 1
A intra SPN1 SPN1 34 93 2
A intra SPN1 SPN1 34 144 6
A intra SPN1 SPN1 34 314 4
A intra SPN1 SPN1 34 323 4
A intra SPN1 SPN1 34 327 1
A intra SPN1 SPN1 52 93 1
A intra SPN1 SPN1 52 314 4
A intra SPN1 SPN1 52 323 6
A intra SPN1 SPN1 52 327 1
A intra SPN1 SPN1 52 343 1
A intra SPN1 SPN1 80 80 8
A intra SPN1 SPN1 80 92 6
A intra SPN1 SPN1 80 93 6
A intra SPN1 SPN1 80 323 1
A intra SPN1 SPN1 81 93 2
A intra SPN1 SPN1 93 144 5
A intra SPN1 SPN1 128 144 3
A intra SPN1 SPN1 144 314 4
A intra SPN1 SPN1 144 317 1
A intra SPN1 SPN1 144 321 1
A intra SPN1 SPN1 144 323 6
A intra SPN1 SPN1 144 343 1
A intra SPN1 SPN1 167 211 2
A intra SPN1 SPN1 211 223 2
A intra SPN1 SPN1 211 314 2
A intra SPN1 SPN1 211 323 1
A intra SPN1 SPN1 211 327 1
A intra SPN1 SPN1 221 228 5
A intra SPN1 SPN1 223 223 4
A intra SPN1 SPN1 223 314 3
A intra SPN1 SPN1 223 323 4
A intra SPN1 SPN1 223 327 7
A intra SPN1 SPN1 223 343 6
A intra SPN1 SPN1 228 314 2
A intra SPN1 SPN1 298 314 5
A intra SPN1 SPN1 314 321 1
A intra SPN1 SPN1 314 327 20
A intra SPN1 SPN1 314 343 6
A intra SPN1 SPN1 314 345 3
A intra SPN1 SPN1 317 323 2
A intra SPN1 SPN1 317 327 2
A intra SPN1 SPN1 321 327 4
A intra SPN1 SPN1 314 323 8
A intra SPN1 SPN1 323 343 13
A intra SPN1 SPN1 327 345 1
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Replicate Type Protein 1 Protein 2 Residue 1 Residue 2 Spectrum Count
A intra CRM1 CRM1 1 1 2
A intra CRM1 CRM1 1 122 1
A intra CRM1 CRM1 1 144 1
A intra CRM1 CRM1 1 537 1
A intra CRM1 CRM1 2 122 2
A intra CRM1 CRM1 2 531 1
A intra CRM1 CRM1 54 88 16
A intra CRM1 CRM1 54 129 5
A intra CRM1 CRM1 54 522 1
A intra CRM1 CRM1 76 122 2
A intra CRM1 CRM1 88 92 13
A intra CRM1 CRM1 92 103 1
A intra CRM1 CRM1 92 144 26
A intra CRM1 CRM1 92 190 18
A intra CRM1 CRM1 92 192 7
A intra CRM1 CRM1 103 122 1
A intra CRM1 CRM1 103 144 6
A intra CRM1 CRM1 103 192 2
A intra CRM1 CRM1 103 1049 1
A intra CRM1 CRM1 104 144 1
A intra CRM1 CRM1 104 1049 3
A intra CRM1 CRM1 122 129 2
A intra CRM1 CRM1 144 190 6
A intra CRM1 CRM1 144 192 6
A intra CRM1 CRM1 144 312 1
A intra CRM1 CRM1 144 415 2
A intra CRM1 CRM1 144 492 3
A intra CRM1 CRM1 144 680 1
A intra CRM1 CRM1 172 192 1
A intra CRM1 CRM1 190 192 1
A intra CRM1 CRM1 190 522 1
A intra CRM1 CRM1 190 1049 4
A intra CRM1 CRM1 192 1049 7
A intra CRM1 CRM1 312 590 3
A intra CRM1 CRM1 331 534 1
A intra CRM1 CRM1 331 1049 1
A intra CRM1 CRM1 415 479 2
A intra CRM1 CRM1 415 674 3
A intra CRM1 CRM1 426 455 1
A intra CRM1 CRM1 426 492 2
A intra CRM1 CRM1 446 594 8
A intra CRM1 CRM1 446 700 11
A intra CRM1 CRM1 455 594 6
A intra CRM1 CRM1 455 1049 1
A intra CRM1 CRM1 492 522 5
A intra CRM1 CRM1 514 522 5
A intra CRM1 CRM1 514 560 11
A intra CRM1 CRM1 522 534 1
A intra CRM1 CRM1 522 560 43
A intra CRM1 CRM1 522 563 2
A intra CRM1 CRM1 531 534 14
A intra CRM1 CRM1 531 537 1
A intra CRM1 CRM1 531 680 2
A intra CRM1 CRM1 534 594 3
A intra CRM1 CRM1 537 563 1
A intra CRM1 CRM1 560 568 6
A intra CRM1 CRM1 560 594 1
A intra CRM1 CRM1 563 594 1
A intra CRM1 CRM1 594 700 18
A intra CRM1 CRM1 594 1049 8
A intra CRM1 CRM1 594 1051 1
A intra CRM1 CRM1 680 693 5
A intra CRM1 CRM1 680 741 2
A intra CRM1 CRM1 686 700 2
A intra CRM1 CRM1 693 700 11
A intra CRM1 CRM1 693 741 18
A intra CRM1 CRM1 693 757 19
A intra CRM1 CRM1 700 757 25
A intra CRM1 CRM1 752 757 2
A inter CRM1 SPN1 1 211 1
A inter CRM1 SPN1 1 223 1
A inter CRM1 SPN1 92 32 1
A inter CRM1 SPN1 92 323 1
A inter CRM1 SPN1 103 314 1
A inter CRM1 SPN1 339 93 1
A inter CRM1 SPN1 339 298 1
A inter CRM1 SPN1 367 223 1
A inter CRM1 SPN1 415 32 7
A inter CRM1 SPN1 426 93 2
A inter CRM1 SPN1 446 144 1
A inter CRM1 SPN1 446 223 1
– 145 –
Appendix
Replicate Type Protein 1 Protein 2 Residue 1 Residue 2 Spectrum Count
A inter CRM1 SPN1 492 93 1
A inter CRM1 SPN1 522 1 1
A inter CRM1 SPN1 522 32 9
A inter CRM1 SPN1 522 34 9
A inter CRM1 SPN1 531 81 1
A inter CRM1 SPN1 531 93 2
A inter CRM1 SPN1 534 34 1
A inter CRM1 SPN1 534 93 7
A inter CRM1 SPN1 534 144 2
A inter CRM1 SPN1 534 223 1
A inter CRM1 SPN1 534 323 1
A inter CRM1 SPN1 537 34 2
A inter CRM1 SPN1 537 54 1
A inter CRM1 SPN1 560 32 6
A inter CRM1 SPN1 560 34 1
A inter CRM1 SPN1 560 314 1
A inter CRM1 SPN1 563 32 5
A inter CRM1 SPN1 568 223 1
A inter CRM1 SPN1 594 314 2
A inter CRM1 SPN1 594 323 3
A inter CRM1 SPN1 594 327 1
A inter CRM1 SPN1 594 343 3
A inter CRM1 SPN1 674 223 6
A inter CRM1 SPN1 674 228 5
A inter CRM1 SPN1 680 223 24
A inter CRM1 SPN1 686 1 1
A inter CRM1 SPN1 686 128 1
A inter CRM1 SPN1 686 223 9
A inter CRM1 SPN1 700 223 1
A inter CRM1 SPN1 700 327 1
A inter CRM1 SPN1 741 223 10
A inter CRM1 SPN1 1049 32 1
A inter CRM1 SPN1 1049 34 1
A inter CRM1 SPN1 1051 32 1
A inter CRM1 Ran 1 1 2
A inter CRM1 Ran 1 123 1
A inter CRM1 Ran 2 2 7
A inter CRM1 Ran 2 60 8
A inter CRM1 Ran 122 2 4
A inter CRM1 Ran 122 99 1
A inter CRM1 Ran 144 142 1
A inter CRM1 Ran 144 152 1
A inter CRM1 Ran 331 134 8
A inter CRM1 Ran 339 132 1
A inter CRM1 Ran 426 159 6
A inter CRM1 Ran 446 127 2
A inter CRM1 Ran 446 132 1
A inter CRM1 Ran 446 134 1
A inter CRM1 Ran 455 123 2
A inter CRM1 Ran 455 132 2
A inter CRM1 Ran 455 134 2
A inter CRM1 Ran 492 159 4
A inter CRM1 Ran 563 159 1
A inter CRM1 Ran 674 167 2
A inter CRM1 Ran 700 127 30
A inter CRM1 Ran 700 159 1
A inter CRM1 Ran 741 28 1
A inter CRM1 Ran 741 37 3
A inter CRM1 Ran 757 37 13
A inter CRM1 Ran 757 60 1
A inter CRM1 Ran 757 127 19
A inter CRM1 Ran 757 152 14
A inter CRM1 Ran 1012 99 9
A inter CRM1 Ran 1049 99 3
A inter CRM1 Ran 1049 134 1
A inter SPN1 Ran 2 123 1
A inter SPN1 Ran 32 1 1
A inter SPN1 Ran 34 37 1
A inter SPN1 Ran 34 60 1
A inter SPN1 Ran 92 1 2
A inter SPN1 Ran 93 1 2
A inter SPN1 Ran 93 159 2
A inter SPN1 Ran 96 2 1
A inter SPN1 Ran 211 2 1
A inter SPN1 Ran 223 2 1
A inter SPN1 Ran 223 159 2
A inter SPN1 Ran 223 167 2
A inter SPN1 Ran 323 134 1
A inter SPN1 Ran 327 2 1
A inter SPN1 Ran 343 132 1
A inter SPN1 Ran 343 134 1
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Replicate Type Protein 1 Protein 2 Residue 1 Residue 2 Spectrum Count
A inter SPN1 Ran 343 152 1
A inter SPN1 Ran 345 1 1
B intra Nup214 Nup214 1 2 1
B intra Nup214 Nup214 2 2 6
B intra Nup214 Nup214 2 48 25
B intra Nup214 Nup214 48 116 1
B intra Ran Ran 1 2 6
B intra Ran Ran 2 28 3
B intra Ran Ran 2 37 3
B intra Ran Ran 2 38 5
B intra Ran Ran 2 99 1
B intra Ran Ran 2 134 1
B intra Ran Ran 2 159 2
B intra Ran Ran 2 167 1
B intra Ran Ran 12 38 6
B intra Ran Ran 23 37 13
B intra Ran Ran 23 38 5
B intra Ran Ran 28 37 2
B intra Ran Ran 28 38 7
B intra Ran Ran 28 99 1
B intra Ran Ran 28 159 2
B intra Ran Ran 37 127 1
B intra Ran Ran 37 134 2
B intra Ran Ran 37 152 14
B intra Ran Ran 38 99 4
B intra Ran Ran 38 159 1
B intra Ran Ran 99 123 2
B intra Ran Ran 99 130 3
B intra Ran Ran 99 132 15
B intra Ran Ran 99 134 26
B intra Ran Ran 99 141 4
B intra Ran Ran 99 142 11
B intra Ran Ran 99 159 1
B intra Ran Ran 123 130 5
B intra Ran Ran 123 134 3
B intra Ran Ran 123 152 1
B intra Ran Ran 123 159 2
B intra Ran Ran 127 130 10
B intra Ran Ran 127 132 23
B intra Ran Ran 127 134 2
B intra Ran Ran 127 152 21
B intra Ran Ran 127 159 2
B intra Ran Ran 134 141 2
B intra Ran Ran 134 142 2
B intra Ran Ran 134 159 3
B intra Ran Ran 142 142 2
B intra Ran Ran 142 159 7
B intra Ran Ran 159 159 2
B intra SPN1 SPN1 32 52 1
B intra SPN1 SPN1 32 93 3
B intra SPN1 SPN1 32 144 4
B intra SPN1 SPN1 32 314 12
B intra SPN1 SPN1 32 317 3
B intra SPN1 SPN1 32 321 1
B intra SPN1 SPN1 32 323 10
B intra SPN1 SPN1 32 327 4
B intra SPN1 SPN1 32 343 3
B intra SPN1 SPN1 34 52 1
B intra SPN1 SPN1 34 93 1
B intra SPN1 SPN1 34 144 5
B intra SPN1 SPN1 34 223 1
B intra SPN1 SPN1 34 314 3
B intra SPN1 SPN1 34 323 6
B intra SPN1 SPN1 34 327 3
B intra SPN1 SPN1 34 343 1
B intra SPN1 SPN1 52 93 1
B intra SPN1 SPN1 52 314 4
B intra SPN1 SPN1 52 323 5
B intra SPN1 SPN1 52 327 2
B intra SPN1 SPN1 52 343 2
B intra SPN1 SPN1 80 81 1
B intra SPN1 SPN1 80 92 6
B intra SPN1 SPN1 81 93 1
B intra SPN1 SPN1 81 96 1
B intra SPN1 SPN1 93 144 4
B intra SPN1 SPN1 93 314 1
B intra SPN1 SPN1 128 144 2
B intra SPN1 SPN1 144 314 4
B intra SPN1 SPN1 144 317 1
B intra SPN1 SPN1 144 323 5
B intra SPN1 SPN1 144 343 1
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Replicate Type Protein 1 Protein 2 Residue 1 Residue 2 Spectrum Count
B intra SPN1 SPN1 167 211 5
B intra SPN1 SPN1 211 223 1
B intra SPN1 SPN1 211 343 1
B intra SPN1 SPN1 221 228 6
B intra SPN1 SPN1 223 223 4
B intra SPN1 SPN1 223 314 3
B intra SPN1 SPN1 223 323 4
B intra SPN1 SPN1 223 327 7
B intra SPN1 SPN1 223 343 4
B intra SPN1 SPN1 223 345 1
B intra SPN1 SPN1 228 314 1
B intra SPN1 SPN1 298 314 4
B intra SPN1 SPN1 314 323 7
B intra SPN1 SPN1 314 327 14
B intra SPN1 SPN1 314 343 6
B intra SPN1 SPN1 314 345 1
B intra SPN1 SPN1 317 323 4
B intra SPN1 SPN1 321 323 1
B intra SPN1 SPN1 321 327 2
B intra SPN1 SPN1 323 343 14
B intra SPN1 SPN1 327 345 2
B intra CRM1 CRM1 1 22 1
B intra CRM1 CRM1 1 537 1
B intra CRM1 CRM1 2 122 2
B intra CRM1 CRM1 2 531 1
B intra CRM1 CRM1 54 88 17
B intra CRM1 CRM1 54 129 2
B intra CRM1 CRM1 76 122 1
B intra CRM1 CRM1 76 741 1
B intra CRM1 CRM1 88 92 13
B intra CRM1 CRM1 92 103 1
B intra CRM1 CRM1 92 144 23
B intra CRM1 CRM1 92 190 13
B intra CRM1 CRM1 92 192 7
B intra CRM1 CRM1 92 1049 1
B intra CRM1 CRM1 103 144 7
B intra CRM1 CRM1 103 192 2
B intra CRM1 CRM1 103 1049 1
B intra CRM1 CRM1 104 144 2
B intra CRM1 CRM1 104 560 1
B intra CRM1 CRM1 104 752 1
B intra CRM1 CRM1 104 1049 2
B intra CRM1 CRM1 122 129 2
B intra CRM1 CRM1 124 172 3
B intra CRM1 CRM1 144 190 6
B intra CRM1 CRM1 144 192 7
B intra CRM1 CRM1 144 492 1
B intra CRM1 CRM1 190 1049 3
B intra CRM1 CRM1 192 1049 8
B intra CRM1 CRM1 312 590 1
B intra CRM1 CRM1 312 594 1
B intra CRM1 CRM1 367 693 1
B intra CRM1 CRM1 415 479 4
B intra CRM1 CRM1 415 674 1
B intra CRM1 CRM1 426 492 1
B intra CRM1 CRM1 446 594 8
B intra CRM1 CRM1 446 700 10
B intra CRM1 CRM1 455 594 3
B intra CRM1 CRM1 479 492 1
B intra CRM1 CRM1 492 522 7
B intra CRM1 CRM1 514 522 4
B intra CRM1 CRM1 514 560 13
B intra CRM1 CRM1 522 534 3
B intra CRM1 CRM1 522 560 38
B intra CRM1 CRM1 522 563 2
B intra CRM1 CRM1 531 534 11
B intra CRM1 CRM1 531 537 1
B intra CRM1 CRM1 534 594 2
B intra CRM1 CRM1 560 568 4
B intra CRM1 CRM1 560 594 1
B intra CRM1 CRM1 563 594 2
B intra CRM1 CRM1 594 700 18
B intra CRM1 CRM1 594 1049 6
B intra CRM1 CRM1 680 693 3
B intra CRM1 CRM1 680 741 2
B intra CRM1 CRM1 686 700 1
B intra CRM1 CRM1 693 700 14
B intra CRM1 CRM1 693 741 12
B intra CRM1 CRM1 693 757 18
B intra CRM1 CRM1 700 757 20
B inter Nup214 Ran 1 1 1
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Replicate Type Protein 1 Protein 2 Residue 1 Residue 2 Spectrum Count
B inter Nup214 Ran 1 134 1
B inter Nup214 Ran 2 2 24
B inter Nup214 Ran 2 28 3
B inter Nup214 Ran 2 37 9
B inter Nup214 Ran 2 38 2
B inter Nup214 Ran 2 99 6
B inter Nup214 Ran 2 127 4
B inter Nup214 Ran 2 132 1
B inter Nup214 Ran 2 134 1
B inter Nup214 Ran 2 152 2
B inter Nup214 Ran 2 159 6
B inter Nup214 SPN1 1 223 1
B inter Nup214 SPN1 1 323 2
B inter Nup214 SPN1 2 32 4
B inter Nup214 SPN1 2 34 3
B inter Nup214 SPN1 2 52 6
B inter Nup214 SPN1 2 93 19
B inter Nup214 SPN1 2 96 1
B inter Nup214 SPN1 2 144 2
B inter Nup214 SPN1 2 221 1
B inter Nup214 SPN1 2 223 30
B inter Nup214 SPN1 2 228 3
B inter Nup214 SPN1 2 314 10
B inter Nup214 SPN1 2 317 1
B inter Nup214 SPN1 2 323 12
B inter Nup214 SPN1 2 327 7
B inter Nup214 SPN1 2 343 4
B inter Nup214 SPN1 48 223 1
B inter Nup214 SPN1 48 323 1
B inter Nup214 SPN1 48 327 1
B inter Nup214 CRM1 1 568 1
B inter Nup214 CRM1 1 594 1
B inter Nup214 CRM1 2 2 1
B inter Nup214 CRM1 2 192 2
B inter Nup214 CRM1 2 426 4
B inter Nup214 CRM1 2 531 1
B inter Nup214 CRM1 2 534 9
B inter Nup214 CRM1 2 568 2
B inter Nup214 CRM1 2 594 3
B inter Nup214 CRM1 2 680 2
B inter Nup214 CRM1 2 686 4
B inter Nup214 CRM1 2 693 1
B inter Nup214 CRM1 2 700 4
B inter Nup214 CRM1 2 741 2
B inter Nup214 CRM1 2 757 1
B inter Nup214 CRM1 2 1049 3
B inter Nup214 CRM1 48 426 1
B inter Nup214 CRM1 48 446 1
B inter Nup214 CRM1 48 514 1
B inter Nup214 CRM1 116 22 4
B inter CRM1 SPN1 1 96 1
B inter CRM1 SPN1 1 211 1
B inter CRM1 SPN1 1 221 1
B inter CRM1 SPN1 144 93 1
B inter CRM1 SPN1 331 52 1
B inter CRM1 SPN1 415 32 2
B inter CRM1 SPN1 426 93 2
B inter CRM1 SPN1 426 327 1
B inter CRM1 SPN1 446 144 1
B inter CRM1 SPN1 492 93 1
B inter CRM1 SPN1 514 1 1
B inter CRM1 SPN1 522 32 7
B inter CRM1 SPN1 522 34 11
B inter CRM1 SPN1 531 80 2
B inter CRM1 SPN1 531 81 2
B inter CRM1 SPN1 534 1 1
B inter CRM1 SPN1 534 32 1
B inter CRM1 SPN1 534 34 2
B inter CRM1 SPN1 534 93 9
B inter CRM1 SPN1 534 144 1
B inter CRM1 SPN1 534 223 1
B inter CRM1 SPN1 534 314 1
B inter CRM1 SPN1 534 323 1
B inter CRM1 SPN1 537 2 1
B inter CRM1 SPN1 537 34 3
B inter CRM1 SPN1 537 96 1
B inter CRM1 SPN1 560 32 11
B inter CRM1 SPN1 560 314 1
B inter CRM1 SPN1 563 32 2
B inter CRM1 SPN1 568 34 1
B inter CRM1 SPN1 594 314 3
– 149 –
Appendix
Replicate Type Protein 1 Protein 2 Residue 1 Residue 2 Spectrum Count
B inter CRM1 SPN1 594 323 4
B inter CRM1 SPN1 594 343 5
B inter CRM1 SPN1 674 223 6
B inter CRM1 SPN1 674 228 4
B inter CRM1 SPN1 680 223 28
B inter CRM1 SPN1 680 228 1
B inter CRM1 SPN1 686 223 12
B inter CRM1 SPN1 700 211 1
B inter CRM1 SPN1 700 223 1
B inter CRM1 SPN1 741 223 7
B inter CRM1 SPN1 1049 32 1
B inter CRM1 SPN1 1049 34 1
B inter CRM1 SPN1 1049 323 1
B inter CRM1 Ran 1 1 1
B inter CRM1 Ran 2 2 8
B inter CRM1 Ran 2 28 1
B inter CRM1 Ran 2 60 3
B inter CRM1 Ran 122 2 7
B inter CRM1 Ran 190 152 1
B inter CRM1 Ran 331 134 6
B inter CRM1 Ran 426 159 5
B inter CRM1 Ran 446 123 1
B inter CRM1 Ran 446 127 2
B inter CRM1 Ran 446 134 1
B inter CRM1 Ran 455 127 1
B inter CRM1 Ran 455 132 2
B inter CRM1 Ran 455 134 1
B inter CRM1 Ran 492 159 3
B inter CRM1 Ran 674 167 3
B inter CRM1 Ran 686 1 1
B inter CRM1 Ran 700 60 1
B inter CRM1 Ran 700 127 30
B inter CRM1 Ran 700 134 1
B inter CRM1 Ran 741 28 1
B inter CRM1 Ran 741 37 4
B inter CRM1 Ran 757 37 12
B inter CRM1 Ran 757 127 25
B inter CRM1 Ran 757 152 19
B inter CRM1 Ran 1012 99 11
B inter CRM1 Ran 1049 99 1
B inter CRM1 Ran 1049 134 1
B inter SPN1 Ran 92 1 1
B inter SPN1 Ran 93 159 2
B inter SPN1 Ran 96 12 1
B inter SPN1 Ran 167 152 1
B inter SPN1 Ran 211 2 1
B inter SPN1 Ran 223 2 2
B inter SPN1 Ran 223 142 1
B inter SPN1 Ran 223 159 3
B inter SPN1 Ran 223 167 6









Figure S2: The N-terminus of His-Nup214(1916-2033)-His unspecifically cross-links residues
across the surface of the export complex. The structure shows CRM1 (light gray), Ran (medium
gray) and SPN1 (dark gray) (PDB ID: 3GJX, [127]). The cross-links of the residues (A) 1 and (B) 2 of
His-Nup214(1916-2033)-His mapped onto the export complex are highlighted in green.
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Table S3: Cross-linking of His-Nup214(K1916-2033)-His complex with BS3.
Replicate
Type Protein 1 Protein 2 Residue 1 Residue 2 Spectrum Count
A intra Nup214mut Nup214mut 1 1 20
A intra Nup214mut Nup214mut 1 22 6
A intra Nup214mut Nup214mut 2 22 14
A intra Nup214mut Nup214mut 2 35 3
A intra Nup214mut Nup214mut 2 49 19
A intra Nup214mut Nup214mut 22 1 6
A intra Nup214mut Nup214mut 22 2 14
A intra Nup214mut Nup214mut 22 49 3
A intra Ran Ran 1 2 9
A intra Ran Ran 1 159 1
A intra Ran Ran 2 28 4
A intra Ran Ran 2 37 2
A intra Ran Ran 2 38 4
A intra Ran Ran 2 142 1
A intra Ran Ran 2 159 1
A intra Ran Ran 2 167 2
A intra Ran Ran 12 37 1
A intra Ran Ran 12 38 3
A intra Ran Ran 23 37 14
A intra Ran Ran 23 38 2
A intra Ran Ran 23 159 1
A intra Ran Ran 28 37 3
A intra Ran Ran 28 38 6
A intra Ran Ran 28 99 1
A intra Ran Ran 37 127 2
A intra Ran Ran 37 152 16
A intra Ran Ran 99 123 1
A intra Ran Ran 99 130 3
A intra Ran Ran 99 132 17
A intra Ran Ran 99 134 31
A intra Ran Ran 99 141 5
A intra Ran Ran 99 142 10
A intra Ran Ran 99 159 1
A intra Ran Ran 123 130 5
A intra Ran Ran 123 134 3
A intra Ran Ran 127 130 9
A intra Ran Ran 127 132 24
A intra Ran Ran 127 152 15
A intra Ran Ran 134 142 6
A intra Ran Ran 134 159 4
A intra Ran Ran 142 142 4
A intra Ran Ran 142 159 6
A intra SPN1 SPN1 2 2 4
A intra SPN1 SPN1 32 52 1
A intra SPN1 SPN1 32 93 3
A intra SPN1 SPN1 32 144 7
A intra SPN1 SPN1 32 223 1
A intra SPN1 SPN1 32 233 1
A intra SPN1 SPN1 32 314 10
A intra SPN1 SPN1 32 317 7
A intra SPN1 SPN1 32 321 5
A intra SPN1 SPN1 32 323 11
A intra SPN1 SPN1 32 327 6
A intra SPN1 SPN1 32 343 5
A intra SPN1 SPN1 34 52 3
A intra SPN1 SPN1 34 93 3
A intra SPN1 SPN1 34 144 6
A intra SPN1 SPN1 34 314 2
A intra SPN1 SPN1 34 317 1
A intra SPN1 SPN1 34 323 9
A intra SPN1 SPN1 34 327 1
A intra SPN1 SPN1 34 343 1
A intra SPN1 SPN1 52 93 3
A intra SPN1 SPN1 52 314 4
A intra SPN1 SPN1 52 323 5
A intra SPN1 SPN1 52 327 2
A intra SPN1 SPN1 52 345 1
A intra SPN1 SPN1 54 323 1
A intra SPN1 SPN1 80 80 4
A intra SPN1 SPN1 80 81 1
A intra SPN1 SPN1 80 92 10
A intra SPN1 SPN1 80 93 7
A intra SPN1 SPN1 81 93 2
A intra SPN1 SPN1 81 223 1
A intra SPN1 SPN1 93 144 6
A intra SPN1 SPN1 128 144 2
A intra SPN1 SPN1 144 314 5
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Replicate Type Protein 1 Protein 2 Residue 1 Residue 2 Spectrum Count
A intra SPN1 SPN1 144 317 2
A intra SPN1 SPN1 144 323 6
A intra SPN1 SPN1 167 211 5
A intra SPN1 SPN1 211 211 2
A intra SPN1 SPN1 211 223 2
A intra SPN1 SPN1 211 327 1
A intra SPN1 SPN1 211 343 1
A intra SPN1 SPN1 221 228 3
A intra SPN1 SPN1 223 223 4
A intra SPN1 SPN1 223 314 2
A intra SPN1 SPN1 223 317 2
A intra SPN1 SPN1 223 321 1
A intra SPN1 SPN1 223 323 3
A intra SPN1 SPN1 223 327 7
A intra SPN1 SPN1 223 343 10
A intra SPN1 SPN1 298 314 3
A intra SPN1 SPN1 298 317 3
A intra SPN1 SPN1 314 323 10
A intra SPN1 SPN1 314 327 20
A intra SPN1 SPN1 314 343 7
A intra SPN1 SPN1 314 345 5
A intra SPN1 SPN1 317 323 3
A intra SPN1 SPN1 317 327 5
A intra SPN1 SPN1 317 343 1
A intra SPN1 SPN1 321 323 2
A intra SPN1 SPN1 321 327 6
A intra SPN1 SPN1 323 343 14
A intra SPN1 SPN1 323 345 5
A intra SPN1 SPN1 327 345 1
A intra CRM1 CRM1 1 1 2
A intra CRM1 CRM1 1 2 1
A intra CRM1 CRM1 1 144 1
A intra CRM1 CRM1 1 537 1
A intra CRM1 CRM1 2 103 1
A intra CRM1 CRM1 2 122 3
A intra CRM1 CRM1 2 686 2
A intra CRM1 CRM1 2 700 1
A intra CRM1 CRM1 54 88 16
A intra CRM1 CRM1 54 129 6
A intra CRM1 CRM1 76 122 3
A intra CRM1 CRM1 88 92 7
A intra CRM1 CRM1 92 144 24
A intra CRM1 CRM1 92 190 9
A intra CRM1 CRM1 92 192 7
A intra CRM1 CRM1 92 1049 1
A intra CRM1 CRM1 103 112 2
A intra CRM1 CRM1 103 144 5
A intra CRM1 CRM1 103 192 1
A intra CRM1 CRM1 103 1049 1
A intra CRM1 CRM1 104 144 1
A intra CRM1 CRM1 104 1049 1
A intra CRM1 CRM1 124 172 1
A intra CRM1 CRM1 144 190 7
A intra CRM1 CRM1 144 192 5
A intra CRM1 CRM1 144 312 2
A intra CRM1 CRM1 144 492 2
A intra CRM1 CRM1 144 693 1
A intra CRM1 CRM1 190 1049 3
A intra CRM1 CRM1 192 1049 10
A intra CRM1 CRM1 312 590 1
A intra CRM1 CRM1 415 426 2
A intra CRM1 CRM1 415 479 6
A intra CRM1 CRM1 415 537 1
A intra CRM1 CRM1 426 492 2
A intra CRM1 CRM1 426 700 1
A intra CRM1 CRM1 446 568 1
A intra CRM1 CRM1 446 594 8
A intra CRM1 CRM1 446 700 9
A intra CRM1 CRM1 446 757 2
A intra CRM1 CRM1 455 594 5
A intra CRM1 CRM1 455 1049 5
A intra CRM1 CRM1 492 522 7
A intra CRM1 CRM1 514 522 5
A intra CRM1 CRM1 514 560 10
A intra CRM1 CRM1 522 534 3
A intra CRM1 CRM1 522 560 44
A intra CRM1 CRM1 522 563 3
A intra CRM1 CRM1 531 534 13
A intra CRM1 CRM1 531 537 1
A intra CRM1 CRM1 531 680 1
A intra CRM1 CRM1 537 568 2
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Replicate Type Protein 1 Protein 2 Residue 1 Residue 2 Spectrum Count
A intra CRM1 CRM1 560 568 5
A intra CRM1 CRM1 560 594 1
A intra CRM1 CRM1 594 700 20
A intra CRM1 CRM1 594 1049 9
A intra CRM1 CRM1 680 693 3
A intra CRM1 CRM1 680 741 6
A intra CRM1 CRM1 686 700 2
A intra CRM1 CRM1 686 983 1
A intra CRM1 CRM1 693 700 12
A intra CRM1 CRM1 693 741 16
A intra CRM1 CRM1 693 757 15
A intra CRM1 CRM1 700 757 25
A inter Nup214mut Ran 1 142 3
A inter Nup214mut Ran 2 1 1
A inter Nup214mut Ran 2 2 18
A inter Nup214mut Ran 2 28 3
A inter Nup214mut Ran 2 37 11
A inter Nup214mut Ran 2 38 1
A inter Nup214mut Ran 2 99 5
A inter Nup214mut Ran 2 127 2
A inter Nup214mut Ran 2 134 3
A inter Nup214mut Ran 2 152 2
A inter Nup214mut Ran 2 159 1
A inter Nup214mut Ran 22 1 1
A inter Nup214mut Ran 22 134 1
A inter Nup214mut Ran 49 2 1
A inter Nup214mut SPN1 1 32 1
A inter Nup214mut SPN1 1 93 1
A inter Nup214mut SPN1 1 223 4
A inter Nup214mut SPN1 1 314 2
A inter Nup214mut SPN1 1 323 1
A inter Nup214mut SPN1 2 32 2
A inter Nup214mut SPN1 2 34 2
A inter Nup214mut SPN1 2 52 4
A inter Nup214mut SPN1 2 80 2
A inter Nup214mut SPN1 2 93 12
A inter Nup214mut SPN1 2 144 2
A inter Nup214mut SPN1 2 211 3
A inter Nup214mut SPN1 2 223 22
A inter Nup214mut SPN1 2 228 2
A inter Nup214mut SPN1 2 314 6
A inter Nup214mut SPN1 2 317 1
A inter Nup214mut SPN1 2 323 8
A inter Nup214mut SPN1 2 327 5
A inter Nup214mut SPN1 2 343 2
A inter Nup214mut SPN1 22 34 2
A inter Nup214mut SPN1 22 80 3
A inter Nup214mut SPN1 22 211 2
A inter Nup214mut SPN1 22 223 14
A inter Nup214mut SPN1 22 317 1
A inter Nup214mut SPN1 22 327 1
A inter Nup214mut SPN1 35 1 1
A inter Nup214mut SPN1 35 223 7
A inter Nup214mut SPN1 35 314 1
A inter Nup214mut SPN1 49 1 1
A inter Nup214mut SPN1 49 2 1
A inter Nup214mut SPN1 49 223 2
A inter Nup214mut CRM1 1 560 1
A inter Nup214mut CRM1 1 686 1
A inter Nup214mut CRM1 2 192 2
A inter Nup214mut CRM1 2 426 1
A inter Nup214mut CRM1 2 534 5
A inter Nup214mut CRM1 2 594 2
A inter Nup214mut CRM1 2 680 3
A inter Nup214mut CRM1 2 686 4
A inter Nup214mut CRM1 2 700 1
A inter Nup214mut CRM1 2 741 1
A inter Nup214mut CRM1 2 757 1
A inter Nup214mut CRM1 2 1049 2
A inter Nup214mut CRM1 22 104 1
A inter Nup214mut CRM1 22 415 2
A inter Nup214mut CRM1 22 531 1
A inter Nup214mut CRM1 22 686 1
A inter Nup214mut CRM1 22 700 2
A inter Nup214mut CRM1 35 680 2
A inter Nup214mut CRM1 49 446 1
A inter Nup214mut CRM1 73 426 2
A inter Nup214mut CRM1 117 22 3
A inter CRM1 SPN1 1 313 1
A inter CRM1 SPN1 1 314 1
A inter CRM1 SPN1 104 1 2
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Replicate Type Protein 1 Protein 2 Residue 1 Residue 2 Spectrum Count
A inter CRM1 SPN1 144 211 1
A inter CRM1 SPN1 331 228 1
A inter CRM1 SPN1 415 32 3
A inter CRM1 SPN1 426 93 2
A inter CRM1 SPN1 446 144 1
A inter CRM1 SPN1 446 314 1
A inter CRM1 SPN1 492 93 1
A inter CRM1 SPN1 522 32 7
A inter CRM1 SPN1 522 34 9
A inter CRM1 SPN1 522 80 1
A inter CRM1 SPN1 531 80 1
A inter CRM1 SPN1 531 93 1
A inter CRM1 SPN1 534 32 1
A inter CRM1 SPN1 534 34 1
A inter CRM1 SPN1 534 93 6
A inter CRM1 SPN1 534 144 1
A inter CRM1 SPN1 534 323 1
A inter CRM1 SPN1 537 34 6
A inter CRM1 SPN1 560 32 11
A inter CRM1 SPN1 560 314 1
A inter CRM1 SPN1 560 317 1
A inter CRM1 SPN1 563 32 4
A inter CRM1 SPN1 568 34 1
A inter CRM1 SPN1 594 314 1
A inter CRM1 SPN1 594 323 4
A inter CRM1 SPN1 594 343 1
A inter CRM1 SPN1 674 221 1
A inter CRM1 SPN1 674 223 8
A inter CRM1 SPN1 674 228 6
A inter CRM1 SPN1 674 314 1
A inter CRM1 SPN1 680 223 25
A inter CRM1 SPN1 680 345 1
A inter CRM1 SPN1 686 1 1
A inter CRM1 SPN1 686 223 9
A inter CRM1 SPN1 700 223 2
A inter CRM1 SPN1 741 223 9
A inter CRM1 SPN1 757 323 1
A inter CRM1 SPN1 1049 34 1
A inter CRM1 Ran 1 1 2
A inter CRM1 Ran 1 123 1
A inter CRM1 Ran 2 2 10
A inter CRM1 Ran 2 28 1
A inter CRM1 Ran 2 60 6
A inter CRM1 Ran 92 123 2
A inter CRM1 Ran 92 141 1
A inter CRM1 Ran 122 2 5
A inter CRM1 Ran 124 2 1
A inter CRM1 Ran 312 2 1
A inter CRM1 Ran 331 134 6
A inter CRM1 Ran 426 159 5
A inter CRM1 Ran 446 127 4
A inter CRM1 Ran 446 132 1
A inter CRM1 Ran 446 134 1
A inter CRM1 Ran 446 152 1
A inter CRM1 Ran 455 123 1
A inter CRM1 Ran 455 127 1
A inter CRM1 Ran 455 132 7
A inter CRM1 Ran 455 134 7
A inter CRM1 Ran 492 159 6
A inter CRM1 Ran 560 37 1
A inter CRM1 Ran 568 159 1
A inter CRM1 Ran 674 167 2
A inter CRM1 Ran 680 2 1
A inter CRM1 Ran 700 123 1
A inter CRM1 Ran 700 127 29
A inter CRM1 Ran 741 28 2
A inter CRM1 Ran 741 37 4
A inter CRM1 Ran 757 37 13
A inter CRM1 Ran 757 60 1
A inter CRM1 Ran 757 127 20
A inter CRM1 Ran 757 152 20
A inter CRM1 Ran 1012 99 13
A inter CRM1 Ran 1049 99 2
A inter CRM1 Ran 1049 134 1
A inter SPN1 Ran 34 1 1
A inter SPN1 Ran 34 159 1
A inter SPN1 Ran 80 2 1
A inter SPN1 Ran 93 1 2
A inter SPN1 Ran 93 2 2
A inter SPN1 Ran 93 159 2
A inter SPN1 Ran 167 152 1
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Replicate Type Protein 1 Protein 2 Residue 1 Residue 2 Spectrum Count
A inter SPN1 Ran 211 2 1
A inter SPN1 Ran 223 2 2
A inter SPN1 Ran 223 134 1
A inter SPN1 Ran 223 159 4
A inter SPN1 Ran 223 167 3
A inter SPN1 Ran 314 123 1
A inter SPN1 Ran 343 134 2
A inter SPN1 Ran 345 134 1
B intra Nup214mut Nup214mut 1 1 4
B intra Nup214mut Nup214mut 1 2 1
B intra Nup214mut Nup214mut 1 22 2
B intra Nup214mut Nup214mut 2 2 2
B intra Nup214mut Nup214mut 2 22 18
B intra Nup214mut Nup214mut 2 35 5
B intra Nup214mut Nup214mut 2 49 16
B intra Nup214mut Nup214mut 22 49 3
B intra Nup214mut Nup214mut 49 117 1
B intra Ran Ran 1 2 5
B intra Ran Ran 1 28 1
B intra Ran Ran 2 23 1
B intra Ran Ran 2 28 4
B intra Ran Ran 2 37 1
B intra Ran Ran 2 38 6
B intra Ran Ran 2 99 1
B intra Ran Ran 2 142 1
B intra Ran Ran 2 159 1
B intra Ran Ran 2 167 2
B intra Ran Ran 12 37 1
B intra Ran Ran 12 38 1
B intra Ran Ran 12 99 1
B intra Ran Ran 23 37 12
B intra Ran Ran 23 38 1
B intra Ran Ran 23 159 1
B intra Ran Ran 28 37 2
B intra Ran Ran 28 38 6
B intra Ran Ran 28 99 2
B intra Ran Ran 28 159 1
B intra Ran Ran 37 127 3
B intra Ran Ran 37 132 1
B intra Ran Ran 37 152 12
B intra Ran Ran 38 99 1
B intra Ran Ran 99 123 2
B intra Ran Ran 99 130 2
B intra Ran Ran 99 132 17
B intra Ran Ran 99 134 28
B intra Ran Ran 99 141 3
B intra Ran Ran 99 142 10
B intra Ran Ran 99 159 1
B intra Ran Ran 123 130 6
B intra Ran Ran 123 134 1
B intra Ran Ran 123 159 1
B intra Ran Ran 127 130 7
B intra Ran Ran 127 132 29
B intra Ran Ran 127 152 20
B intra Ran Ran 134 141 3
B intra Ran Ran 134 142 2
B intra Ran Ran 134 152 1
B intra Ran Ran 134 159 3
B intra Ran Ran 142 142 4
B intra Ran Ran 142 159 3
B intra SPN1 SPN1 32 52 1
B intra SPN1 SPN1 32 93 3
B intra SPN1 SPN1 32 144 5
B intra SPN1 SPN1 32 223 1
B intra SPN1 SPN1 32 314 9
B intra SPN1 SPN1 32 317 10
B intra SPN1 SPN1 32 321 5
B intra SPN1 SPN1 32 323 14
B intra SPN1 SPN1 32 327 2
B intra SPN1 SPN1 32 343 3
B intra SPN1 SPN1 34 52 2
B intra SPN1 SPN1 34 93 3
B intra SPN1 SPN1 34 144 8
B intra SPN1 SPN1 34 314 4
B intra SPN1 SPN1 34 317 1
B intra SPN1 SPN1 34 323 8
B intra SPN1 SPN1 34 327 2
B intra SPN1 SPN1 52 93 1
B intra SPN1 SPN1 52 314 3
B intra SPN1 SPN1 52 323 3
B intra SPN1 SPN1 52 327 1
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Replicate Type Protein 1 Protein 2 Residue 1 Residue 2 Spectrum Count
B intra SPN1 SPN1 52 343 1
B intra SPN1 SPN1 80 81 2
B intra SPN1 SPN1 80 92 9
B intra SPN1 SPN1 80 93 6
B intra SPN1 SPN1 80 144 2
B intra SPN1 SPN1 81 93 5
B intra SPN1 SPN1 93 144 5
B intra SPN1 SPN1 128 144 4
B intra SPN1 SPN1 144 314 4
B intra SPN1 SPN1 144 317 2
B intra SPN1 SPN1 144 321 1
B intra SPN1 SPN1 144 323 4
B intra SPN1 SPN1 167 211 7
B intra SPN1 SPN1 211 211 2
B intra SPN1 SPN1 211 223 2
B intra SPN1 SPN1 211 314 2
B intra SPN1 SPN1 211 323 1
B intra SPN1 SPN1 211 343 2
B intra SPN1 SPN1 221 228 5
B intra SPN1 SPN1 223 223 4
B intra SPN1 SPN1 223 314 2
B intra SPN1 SPN1 223 317 1
B intra SPN1 SPN1 223 321 2
B intra SPN1 SPN1 223 323 5
B intra SPN1 SPN1 223 327 7
B intra SPN1 SPN1 223 343 6
B intra SPN1 SPN1 223 345 1
B intra SPN1 SPN1 298 314 4
B intra SPN1 SPN1 298 317 2
B intra SPN1 SPN1 314 321 1
B intra SPN1 SPN1 314 323 10
B intra SPN1 SPN1 314 327 12
B intra SPN1 SPN1 314 343 9
B intra SPN1 SPN1 314 345 5
B intra SPN1 SPN1 317 323 3
B intra SPN1 SPN1 317 327 7
B intra SPN1 SPN1 317 343 1
B intra SPN1 SPN1 321 323 1
B intra SPN1 SPN1 321 327 3
B intra SPN1 SPN1 323 343 12
B intra SPN1 SPN1 323 345 6
B intra SPN1 SPN1 327 345 3
B intra CRM1 CRM1 1 2 1
B intra CRM1 CRM1 1 537 1
B intra CRM1 CRM1 2 112 1
B intra CRM1 CRM1 2 122 9
B intra CRM1 CRM1 2 312 1
B intra CRM1 CRM1 54 88 23
B intra CRM1 CRM1 54 129 7
B intra CRM1 CRM1 76 122 2
B intra CRM1 CRM1 88 92 9
B intra CRM1 CRM1 92 144 25
B intra CRM1 CRM1 92 190 11
B intra CRM1 CRM1 92 192 6
B intra CRM1 CRM1 92 700 1
B intra CRM1 CRM1 92 1049 1
B intra CRM1 CRM1 103 112 2
B intra CRM1 CRM1 103 144 7
B intra CRM1 CRM1 103 192 1
B intra CRM1 CRM1 103 1049 1
B intra CRM1 CRM1 104 1049 2
B intra CRM1 CRM1 122 129 2
B intra CRM1 CRM1 124 172 1
B intra CRM1 CRM1 144 190 4
B intra CRM1 CRM1 144 192 6
B intra CRM1 CRM1 144 492 1
B intra CRM1 CRM1 190 1049 2
B intra CRM1 CRM1 192 1049 9
B intra CRM1 CRM1 312 594 1
B intra CRM1 CRM1 339 1049 1
B intra CRM1 CRM1 415 479 4
B intra CRM1 CRM1 426 492 1
B intra CRM1 CRM1 446 568 1
B intra CRM1 CRM1 446 594 9
B intra CRM1 CRM1 446 700 9
B intra CRM1 CRM1 446 757 2
B intra CRM1 CRM1 455 594 7
B intra CRM1 CRM1 455 1049 3
B intra CRM1 CRM1 492 522 9
B intra CRM1 CRM1 514 522 5
B intra CRM1 CRM1 514 560 15
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Replicate Type Protein 1 Protein 2 Residue 1 Residue 2 Spectrum Count
B intra CRM1 CRM1 522 534 1
B intra CRM1 CRM1 522 560 38
B intra CRM1 CRM1 522 563 3
B intra CRM1 CRM1 522 741 1
B intra CRM1 CRM1 531 534 13
B intra CRM1 CRM1 531 537 1
B intra CRM1 CRM1 531 680 2
B intra CRM1 CRM1 534 594 2
B intra CRM1 CRM1 537 568 1
B intra CRM1 CRM1 560 568 9
B intra CRM1 CRM1 560 594 2
B intra CRM1 CRM1 560 700 1
B intra CRM1 CRM1 563 522 3
B intra CRM1 CRM1 563 594 2
B intra CRM1 CRM1 594 700 19
B intra CRM1 CRM1 594 1049 5
B intra CRM1 CRM1 680 693 6
B intra CRM1 CRM1 680 741 4
B intra CRM1 CRM1 686 700 2
B intra CRM1 CRM1 686 741 2
B intra CRM1 CRM1 686 983 1
B intra CRM1 CRM1 693 700 11
B intra CRM1 CRM1 693 741 18
B intra CRM1 CRM1 693 757 13
B intra CRM1 CRM1 700 741 1
B intra CRM1 CRM1 700 757 22
B intra CRM1 CRM1 752 757 1
B inter Nup214mut Ran 2 2 22
B inter Nup214mut Ran 2 28 2
B inter Nup214mut Ran 2 37 10
B inter Nup214mut Ran 2 99 7
B inter Nup214mut Ran 2 127 2
B inter Nup214mut Ran 2 134 2
B inter Nup214mut Ran 2 142 1
B inter Nup214mut Ran 2 152 1
B inter Nup214mut Ran 2 159 4
B inter Nup214mut Ran 22 132 1
B inter Nup214mut Ran 22 134 1
B inter Nup214mut Ran 22 159 1
B inter Nup214mut SPN1 1 34 1
B inter Nup214mut SPN1 1 223 1
B inter Nup214mut SPN1 1 321 1
B inter Nup214mut SPN1 2 32 4
B inter Nup214mut SPN1 2 34 1
B inter Nup214mut SPN1 2 52 2
B inter Nup214mut SPN1 2 80 1
B inter Nup214mut SPN1 2 93 11
B inter Nup214mut SPN1 2 144 2
B inter Nup214mut SPN1 2 211 1
B inter Nup214mut SPN1 2 223 22
B inter Nup214mut SPN1 2 228 1
B inter Nup214mut SPN1 2 314 4
B inter Nup214mut SPN1 2 317 1
B inter Nup214mut SPN1 2 323 8
B inter Nup214mut SPN1 2 327 5
B inter Nup214mut SPN1 2 343 1
B inter Nup214mut SPN1 22 34 1
B inter Nup214mut SPN1 22 223 17
B inter Nup214mut SPN1 22 314 1
B inter Nup214mut SPN1 22 321 1
B inter Nup214mut SPN1 35 223 8
B inter Nup214mut SPN1 35 314 1
B inter Nup214mut SPN1 49 1 1
B inter Nup214mut SPN1 49 223 2
B inter Nup214mut SPN1 49 327 1
B inter Nup214mut CRM1 2 426 1
B inter Nup214mut CRM1 2 534 9
B inter Nup214mut CRM1 2 594 1
B inter Nup214mut CRM1 2 680 3
B inter Nup214mut CRM1 2 686 5
B inter Nup214mut CRM1 2 693 1
B inter Nup214mut CRM1 2 741 1
B inter Nup214mut CRM1 2 1049 2
B inter Nup214mut CRM1 22 415 1
B inter Nup214mut CRM1 22 686 1
B inter Nup214mut CRM1 22 693 1
B inter Nup214mut CRM1 22 700 1
B inter Nup214mut CRM1 22 741 2
B inter Nup214mut CRM1 35 680 1
B inter Nup214mut CRM1 49 426 1
B inter Nup214mut CRM1 49 446 1
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Replicate Type Protein 1 Protein 2 Residue 1 Residue 2 Spectrum Count
B inter Nup214mut CRM1 49 680 2
B inter Nup214mut CRM1 117 22 2
B inter CRM1 SPN1 1 223 1
B inter CRM1 SPN1 2 211 1
B inter CRM1 SPN1 92 228 1
B inter CRM1 SPN1 104 1 1
B inter CRM1 SPN1 122 81 1
B inter CRM1 SPN1 144 314 1
B inter CRM1 SPN1 331 228 1
B inter CRM1 SPN1 415 32 4
B inter CRM1 SPN1 426 93 3
B inter CRM1 SPN1 446 221 1
B inter CRM1 SPN1 446 321 1
B inter CRM1 SPN1 492 93 1
B inter CRM1 SPN1 522 32 6
B inter CRM1 SPN1 522 34 13
B inter CRM1 SPN1 531 80 1
B inter CRM1 SPN1 531 93 2
B inter CRM1 SPN1 534 93 7
B inter CRM1 SPN1 534 96 1
B inter CRM1 SPN1 534 144 2
B inter CRM1 SPN1 534 223 1
B inter CRM1 SPN1 537 2 2
B inter CRM1 SPN1 537 34 4
B inter CRM1 SPN1 560 32 8
B inter CRM1 SPN1 560 323 1
B inter CRM1 SPN1 563 32 3
B inter CRM1 SPN1 563 314 1
B inter CRM1 SPN1 594 314 3
B inter CRM1 SPN1 594 323 4
B inter CRM1 SPN1 594 343 4
B inter CRM1 SPN1 674 223 9
B inter CRM1 SPN1 674 228 5
B inter CRM1 SPN1 674 314 1
B inter CRM1 SPN1 674 323 1
B inter CRM1 SPN1 680 223 29
B inter CRM1 SPN1 680 345 2
B inter CRM1 SPN1 686 93 1
B inter CRM1 SPN1 686 223 12
B inter CRM1 SPN1 700 2 1
B inter CRM1 SPN1 700 223 1
B inter CRM1 SPN1 700 317 1
B inter CRM1 SPN1 741 223 11
B inter CRM1 SPN1 1049 32 1
B inter CRM1 SPN1 1049 34 1
B inter CRM1 SPN1 1049 323 2
B inter CRM1 Ran 1 1 3
B inter CRM1 Ran 2 2 11
B inter CRM1 Ran 2 28 1
B inter CRM1 Ran 2 60 5
B inter CRM1 Ran 92 123 2
B inter CRM1 Ran 92 142 1
B inter CRM1 Ran 122 2 4
B inter CRM1 Ran 124 134 1
B inter CRM1 Ran 331 123 1
B inter CRM1 Ran 331 134 7
B inter CRM1 Ran 426 159 5
B inter CRM1 Ran 446 127 4
B inter CRM1 Ran 446 132 1
B inter CRM1 Ran 446 152 1
B inter CRM1 Ran 455 123 1
B inter CRM1 Ran 455 127 2
B inter CRM1 Ran 455 132 7
B inter CRM1 Ran 455 134 5
B inter CRM1 Ran 492 159 6
B inter CRM1 Ran 560 152 1
B inter CRM1 Ran 674 167 2
B inter CRM1 Ran 700 127 27
B inter CRM1 Ran 700 159 1
B inter CRM1 Ran 741 28 4
B inter CRM1 Ran 741 37 6
B inter CRM1 Ran 757 37 11
B inter CRM1 Ran 757 127 19
B inter CRM1 Ran 757 152 16
B inter CRM1 Ran 1012 99 11
B inter CRM1 Ran 1049 99 2
B inter CRM1 Ran 1049 134 2
B inter SPN1 Ran 92 1 2
B inter SPN1 Ran 93 159 2
B inter SPN1 Ran 128 2 1
B inter SPN1 Ran 167 152 1
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Replicate Type Protein 1 Protein 2 Residue 1 Residue 2 Spectrum Count
B inter SPN1 Ran 223 2 3
B inter SPN1 Ran 223 159 2
B inter SPN1 Ran 223 167 3
B inter SPN1 Ran 314 123 1
B inter SPN1 Ran 323 99 1
B inter SPN1 Ran 323 132 1
B inter SPN1 Ran 323 152 1
B inter SPN1 Ran 343 134 2
B inter SPN1 Ran 343 152 1










Figure S3: The N-terminus of His-Nup214(K1916-2033)-His unspecifically cross-links residues
across the surface of the export complex. The structure shows CRM1 (light gray), Ran (medium
gray) and SPN1 (dark gray) (PDB ID: 3GJX, [127]). The cross-links of the residues (A) 1, (B) 2 and (C)
22 of His-Nup214(K1916-2033)-His mapped onto the export complex are highlighted in green.
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C.3 Cross-linking of the MBP-Nup214(1916-2033)-His complex with BS3 and EDC
Table S4: Cross-linking of the MBP-Nup214(1916-2033)-His complex with BS3.
Linker Type Protein 1 Protein 2 Residue 1 Residue 2 Spectrum Count
BS3 intra MBP-Nup214 MBP-Nup214 1 296 1
BS3 intra MBP-Nup214 MBP-Nup214 16 27 1
BS3 intra MBP-Nup214 MBP-Nup214 16 43 3
BS3 intra MBP-Nup214 MBP-Nup214 16 298 23
BS3 intra MBP-Nup214 MBP-Nup214 16 306 1
BS3 intra MBP-Nup214 MBP-Nup214 26 30 26
BS3 intra MBP-Nup214 MBP-Nup214 26 35 19
BS3 intra MBP-Nup214 MBP-Nup214 26 43 5
BS3 intra MBP-Nup214 MBP-Nup214 27 35 1
BS3 intra MBP-Nup214 MBP-Nup214 27 43 2
BS3 intra MBP-Nup214 MBP-Nup214 30 43 1
BS3 intra MBP-Nup214 MBP-Nup214 30 120 2
BS3 intra MBP-Nup214 MBP-Nup214 35 47 11
BS3 intra MBP-Nup214 MBP-Nup214 47 400 2
BS3 intra MBP-Nup214 MBP-Nup214 84 103 13
BS3 intra MBP-Nup214 MBP-Nup214 84 120 1
BS3 intra MBP-Nup214 MBP-Nup214 84 176 2
BS3 intra MBP-Nup214 MBP-Nup214 84 306 10
BS3 intra MBP-Nup214 MBP-Nup214 84 314 3
BS3 intra MBP-Nup214 MBP-Nup214 89 103 1
BS3 intra MBP-Nup214 MBP-Nup214 89 306 5
BS3 intra MBP-Nup214 MBP-Nup214 89 314 3
BS3 intra MBP-Nup214 MBP-Nup214 103 128 1
BS3 intra MBP-Nup214 MBP-Nup214 103 176 34
BS3 intra MBP-Nup214 MBP-Nup214 103 274 20
BS3 intra MBP-Nup214 MBP-Nup214 103 400 1
BS3 intra MBP-Nup214 MBP-Nup214 120 138 23
BS3 intra MBP-Nup214 MBP-Nup214 120 314 22
BS3 intra MBP-Nup214 MBP-Nup214 128 143 2
BS3 intra MBP-Nup214 MBP-Nup214 138 180 1
BS3 intra MBP-Nup214 MBP-Nup214 138 201 9
BS3 intra MBP-Nup214 MBP-Nup214 138 203 1
BS3 intra MBP-Nup214 MBP-Nup214 141 201 3
BS3 intra MBP-Nup214 MBP-Nup214 143 128 2
BS3 intra MBP-Nup214 MBP-Nup214 143 176 1
BS3 intra MBP-Nup214 MBP-Nup214 145 180 2
BS3 intra MBP-Nup214 MBP-Nup214 171 180 12
BS3 intra MBP-Nup214 MBP-Nup214 171 468 1
BS3 intra MBP-Nup214 MBP-Nup214 176 176 4
BS3 intra MBP-Nup214 MBP-Nup214 176 190 5
BS3 intra MBP-Nup214 MBP-Nup214 176 201 1
BS3 intra MBP-Nup214 MBP-Nup214 176 257 4
BS3 intra MBP-Nup214 MBP-Nup214 180 201 3
BS3 intra MBP-Nup214 MBP-Nup214 180 400 1
BS3 intra MBP-Nup214 MBP-Nup214 190 190 2
BS3 intra MBP-Nup214 MBP-Nup214 190 252 7
BS3 intra MBP-Nup214 MBP-Nup214 201 220 19
BS3 intra MBP-Nup214 MBP-Nup214 201 298 1
BS3 intra MBP-Nup214 MBP-Nup214 252 274 4
BS3 intra MBP-Nup214 MBP-Nup214 257 298 1
BS3 intra MBP-Nup214 MBP-Nup214 274 278 5
BS3 intra MBP-Nup214 MBP-Nup214 278 306 1
BS3 intra MBP-Nup214 MBP-Nup214 296 306 1
BS3 intra MBP-Nup214 MBP-Nup214 298 314 5
BS3 intra MBP-Nup214 MBP-Nup214 314 314 6
BS3 intra Ran Ran 1 38 1
BS3 intra Ran Ran 23 37 1
BS3 intra Ran Ran 28 37 4
BS3 intra Ran Ran 28 38 10
BS3 intra Ran Ran 37 123 1
BS3 intra Ran Ran 37 127 3
BS3 intra Ran Ran 37 152 16
BS3 intra Ran Ran 99 127 1
BS3 intra Ran Ran 99 130 1
BS3 intra Ran Ran 99 132 8
BS3 intra Ran Ran 99 134 22
BS3 intra Ran Ran 99 141 1
BS3 intra Ran Ran 99 142 9
BS3 intra Ran Ran 123 130 7
BS3 intra Ran Ran 127 130 3
BS3 intra Ran Ran 127 132 27
BS3 intra Ran Ran 127 152 26
BS3 intra Ran Ran 127 159 1
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Linker Type Protein 1 Protein 2 Residue 1 Residue 2 Spectrum Count
BS3 intra Ran Ran 134 141 1
BS3 intra Ran Ran 134 159 2
BS3 intra Ran Ran 142 159 1
BS3 intra SPN1 SPN1 2 2 2
BS3 intra SPN1 SPN1 2 262 1
BS3 intra SPN1 SPN1 32 32 2
BS3 intra SPN1 SPN1 32 52 1
BS3 intra SPN1 SPN1 32 93 2
BS3 intra SPN1 SPN1 32 144 4
BS3 intra SPN1 SPN1 32 314 6
BS3 intra SPN1 SPN1 32 323 6
BS3 intra SPN1 SPN1 32 327 2
BS3 intra SPN1 SPN1 32 343 2
BS3 intra SPN1 SPN1 34 52 3
BS3 intra SPN1 SPN1 34 93 1
BS3 intra SPN1 SPN1 34 144 3
BS3 intra SPN1 SPN1 34 314 1
BS3 intra SPN1 SPN1 34 323 1
BS3 intra SPN1 SPN1 52 81 1
BS3 intra SPN1 SPN1 52 93 4
BS3 intra SPN1 SPN1 52 314 4
BS3 intra SPN1 SPN1 52 323 6
BS3 intra SPN1 SPN1 52 327 2
BS3 intra SPN1 SPN1 52 343 3
BS3 intra SPN1 SPN1 80 80 2
BS3 intra SPN1 SPN1 80 81 1
BS3 intra SPN1 SPN1 80 92 1
BS3 intra SPN1 SPN1 80 93 2
BS3 intra SPN1 SPN1 93 144 2
BS3 intra SPN1 SPN1 128 233 1
BS3 intra SPN1 SPN1 144 314 2
BS3 intra SPN1 SPN1 144 323 1
BS3 intra SPN1 SPN1 167 211 6
BS3 intra SPN1 SPN1 211 223 2
BS3 intra SPN1 SPN1 221 228 1
BS3 intra SPN1 SPN1 223 314 4
BS3 intra SPN1 SPN1 223 323 3
BS3 intra SPN1 SPN1 223 327 3
BS3 intra SPN1 SPN1 223 343 4
BS3 intra SPN1 SPN1 298 314 2
BS3 intra SPN1 SPN1 314 327 1
BS3 intra SPN1 SPN1 317 323 1
BS3 intra SPN1 SPN1 321 323 2
BS3 intra SPN1 SPN1 323 343 2
BS3 intra CRM1 CRM1 1 22 3
BS3 intra CRM1 CRM1 1 537 1
BS3 intra CRM1 CRM1 2 22 2
BS3 intra CRM1 CRM1 54 88 5
BS3 intra CRM1 CRM1 76 122 2
BS3 intra CRM1 CRM1 76 560 1
BS3 intra CRM1 CRM1 88 54 5
BS3 intra CRM1 CRM1 88 92 5
BS3 intra CRM1 CRM1 92 103 1
BS3 intra CRM1 CRM1 92 124 1
BS3 intra CRM1 CRM1 92 144 6
BS3 intra CRM1 CRM1 92 190 3
BS3 intra CRM1 CRM1 92 192 2
BS3 intra CRM1 CRM1 92 1012 1
BS3 intra CRM1 CRM1 144 172 1
BS3 intra CRM1 CRM1 144 190 4
BS3 intra CRM1 CRM1 192 1049 3
BS3 intra CRM1 CRM1 415 479 1
BS3 intra CRM1 CRM1 415 674 2
BS3 intra CRM1 CRM1 426 492 1
BS3 intra CRM1 CRM1 446 594 5
BS3 intra CRM1 CRM1 446 700 5
BS3 intra CRM1 CRM1 455 594 3
BS3 intra CRM1 CRM1 492 522 4
BS3 intra CRM1 CRM1 514 522 1
BS3 intra CRM1 CRM1 514 560 5
BS3 intra CRM1 CRM1 522 514 1
BS3 intra CRM1 CRM1 522 534 4
BS3 intra CRM1 CRM1 522 560 6
BS3 intra CRM1 CRM1 531 534 2
BS3 intra CRM1 CRM1 560 594 1
BS3 intra CRM1 CRM1 594 700 19
BS3 intra CRM1 CRM1 594 1049 2
BS3 intra CRM1 CRM1 680 693 2
BS3 intra CRM1 CRM1 693 700 7
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Linker Type Protein 1 Protein 2 Residue 1 Residue 2 Spectrum Count
BS3 intra CRM1 CRM1 693 757 4
BS3 intra CRM1 CRM1 700 757 24
BS3 intra CRM1 CRM1 752 757 4
BS3 intra CRM1 CRM1 1049 1049 2
BS3 inter MBP-Nup214 Ran 143 134 1
BS3 inter MBP-Nup214 Ran 176 37 1
BS3 inter MBP-Nup214 Ran 176 123 1
BS3 inter MBP-Nup214 Ran 180 123 1
BS3 inter MBP-Nup214 Ran 201 28 2
BS3 inter MBP-Nup214 Ran 298 37 1
BS3 inter MBP-Nup214 SPN1 26 223 2
BS3 inter MBP-Nup214 SPN1 27 223 1
BS3 inter MBP-Nup214 SPN1 30 223 3
BS3 inter MBP-Nup214 SPN1 30 228 1
BS3 inter MBP-Nup214 SPN1 35 223 1
BS3 inter MBP-Nup214 SPN1 43 223 19
BS3 inter MBP-Nup214 SPN1 47 223 27
BS3 inter MBP-Nup214 SPN1 84 223 3
BS3 inter MBP-Nup214 SPN1 89 223 2
BS3 inter MBP-Nup214 SPN1 103 223 30
BS3 inter MBP-Nup214 SPN1 120 223 3
BS3 inter MBP-Nup214 SPN1 138 223 4
BS3 inter MBP-Nup214 SPN1 141 54 2
BS3 inter MBP-Nup214 SPN1 145 262 1
BS3 inter MBP-Nup214 SPN1 176 223 18
BS3 inter MBP-Nup214 SPN1 180 223 38
BS3 inter MBP-Nup214 SPN1 190 223 7
BS3 inter MBP-Nup214 SPN1 201 223 5
BS3 inter MBP-Nup214 SPN1 274 223 8
BS3 inter MBP-Nup214 SPN1 298 223 1
BS3 inter MBP-Nup214 SPN1 314 223 2
BS3 inter MBP-Nup214 SPN1 386 167 1
BS3 inter MBP-Nup214 SPN1 386 223 11
BS3 inter MBP-Nup214 SPN1 400 223 1
BS3 inter MBP-Nup214 CRM1 16 144 3
BS3 inter MBP-Nup214 CRM1 30 339 1
BS3 inter MBP-Nup214 CRM1 43 22 1
BS3 inter MBP-Nup214 CRM1 84 312 1
BS3 inter MBP-Nup214 CRM1 120 531 10
BS3 inter MBP-Nup214 CRM1 176 531 1
BS3 inter MBP-Nup214 CRM1 203 92 2
BS3 inter MBP-Nup214 CRM1 203 693 1
BS3 inter MBP-Nup214 CRM1 220 560 1
BS3 inter MBP-Nup214 CRM1 257 92 1
BS3 inter MBP-Nup214 CRM1 278 534 3
BS3 inter MBP-Nup214 CRM1 314 144 1
BS3 inter MBP-Nup214 CRM1 468 22 2
BS3 inter CRM1 SPN1 2 128 1
BS3 inter CRM1 SPN1 331 52 1
BS3 inter CRM1 SPN1 415 32 2
BS3 inter CRM1 SPN1 415 54 1
BS3 inter CRM1 SPN1 492 93 3
BS3 inter CRM1 SPN1 522 32 12
BS3 inter CRM1 SPN1 522 34 13
BS3 inter CRM1 SPN1 531 80 1
BS3 inter CRM1 SPN1 531 81 2
BS3 inter CRM1 SPN1 531 93 2
BS3 inter CRM1 SPN1 534 34 1
BS3 inter CRM1 SPN1 534 93 6
BS3 inter CRM1 SPN1 560 32 8
BS3 inter CRM1 SPN1 560 34 1
BS3 inter CRM1 SPN1 560 314 1
BS3 inter CRM1 SPN1 563 32 4
BS3 inter CRM1 SPN1 674 223 6
BS3 inter CRM1 SPN1 680 223 27
BS3 inter CRM1 SPN1 686 223 10
BS3 inter CRM1 SPN1 741 223 7
BS3 inter CRM1 SPN1 1049 323 1
BS3 inter CRM1 Ran 2 60 1
BS3 inter CRM1 Ran 331 134 15
BS3 inter CRM1 Ran 426 159 3
BS3 inter CRM1 Ran 446 127 1
BS3 inter CRM1 Ran 446 132 1
BS3 inter CRM1 Ran 492 159 6
BS3 inter CRM1 Ran 700 123 1
BS3 inter CRM1 Ran 700 127 35
BS3 inter CRM1 Ran 741 37 2
BS3 inter CRM1 Ran 757 37 12
BS3 inter CRM1 Ran 757 127 16
– 163 –
Appendix
Linker Type Protein 1 Protein 2 Residue 1 Residue 2 Spectrum Count
BS3 inter CRM1 Ran 757 152 20
BS3 inter CRM1 Ran 1012 99 11
BS3 inter CRM1 Ran 1049 99 3
BS3 inter CRM1 Ran 1049 134 1
BS3 inter SPN1 Ran 80 71 1
BS3 inter SPN1 Ran 93 159 1
BS3 inter SPN1 Ran 167 152 1
BS3 inter SPN1 Ran 221 159 2
Table S5: Cross-linking of the MBP-Nup214(1916-2033)-His complex with EDC.
Linker Type Protein 1 Protein 2 Residue 1 Residue 2 Spectrum Count
EDC intra MBP-Nup214 MBP-Nup214 23 27 6
EDC intra MBP-Nup214 MBP-Nup214 26 29 2
EDC intra MBP-Nup214 MBP-Nup214 27 31 1
EDC intra MBP-Nup214 MBP-Nup214 30 39 3
EDC intra MBP-Nup214 MBP-Nup214 31 43 4
EDC intra MBP-Nup214 MBP-Nup214 31 47 2
EDC intra MBP-Nup214 MBP-Nup214 35 45 3
EDC intra MBP-Nup214 MBP-Nup214 35 46 3
EDC intra MBP-Nup214 MBP-Nup214 39 47 4
EDC intra MBP-Nup214 MBP-Nup214 42 47 30
EDC intra MBP-Nup214 MBP-Nup214 47 79 2
EDC intra MBP-Nup214 MBP-Nup214 56 84 1
EDC intra MBP-Nup214 MBP-Nup214 56 400 1
EDC intra MBP-Nup214 MBP-Nup214 79 103 10
EDC intra MBP-Nup214 MBP-Nup214 83 89 6
EDC intra MBP-Nup214 MBP-Nup214 84 288 2
EDC intra MBP-Nup214 MBP-Nup214 84 372 1
EDC intra MBP-Nup214 MBP-Nup214 88 103 1
EDC intra MBP-Nup214 MBP-Nup214 96 103 4
EDC intra MBP-Nup214 MBP-Nup214 112 128 12
EDC intra MBP-Nup214 MBP-Nup214 120 131 34
EDC intra MBP-Nup214 MBP-Nup214 120 132 7
EDC intra MBP-Nup214 MBP-Nup214 180 372 9
EDC intra MBP-Nup214 MBP-Nup214 190 359 7
EDC intra MBP-Nup214 MBP-Nup214 190 372 1
EDC intra MBP-Nup214 MBP-Nup214 278 372 2
EDC intra MBP-Nup214 MBP-Nup214 288 306 1
EDC intra MBP-Nup214 MBP-Nup214 398 400 1
EDC intra Ran Ran 28 34 1
EDC intra Ran Ran 28 36 7
EDC intra Ran Ran 36 38 6
EDC intra Ran Ran 91 99 1
EDC intra Ran Ran 99 107 1
EDC intra Ran Ran 148 159 1
EDC intra SPN1 SPN1 1 110 1
EDC intra SPN1 SPN1 2 110 1
EDC intra SPN1 SPN1 32 39 12
EDC intra SPN1 SPN1 32 42 2
EDC intra SPN1 SPN1 34 202 1
EDC intra SPN1 SPN1 39 314 2
EDC intra SPN1 SPN1 42 52 1
EDC intra SPN1 SPN1 52 42 1
EDC intra SPN1 SPN1 52 57 14
EDC intra SPN1 SPN1 54 57 14
EDC intra SPN1 SPN1 77 81 1
EDC intra SPN1 SPN1 78 81 3
EDC intra SPN1 SPN1 80 82 1
EDC intra SPN1 SPN1 144 202 1
EDC intra SPN1 SPN1 215 228 1
EDC intra SPN1 SPN1 220 223 3
EDC intra SPN1 SPN1 220 314 1
EDC intra CRM1 CRM1 22 24 2
EDC intra CRM1 CRM1 84 92 1
EDC intra CRM1 CRM1 88 1039 2
EDC intra CRM1 CRM1 92 468 1
EDC intra CRM1 CRM1 190 1039 1
EDC intra CRM1 CRM1 312 332 2
EDC intra CRM1 CRM1 434 693 1
EDC intra CRM1 CRM1 439 700 1
EDC intra CRM1 CRM1 443 446 2
EDC intra CRM1 CRM1 529 534 1
EDC intra CRM1 CRM1 683 693 5
EDC intra CRM1 CRM1 693 683 5
EDC intra CRM1 CRM1 693 754 1
EDC intra CRM1 CRM1 700 754 2
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Linker Type Protein 1 Protein 2 Residue 1 Residue 2 Spectrum Count
EDC intra CRM1 CRM1 752 754 2
EDC intra CRM1 CRM1 1012 1017 1
EDC intra CRM1 CRM1 1039 1049 2
EDC inter MBP-Nup214 Ran 15 2 2
EDC inter MBP-Nup214 Ran 15 28 1
EDC inter MBP-Nup214 Ran 29 38 1
EDC inter MBP-Nup214 Ran 30 107 1
EDC inter MBP-Nup214 Ran 372 159 4
EDC inter MBP-Nup214 SPN1 29 2 1
EDC inter MBP-Nup214 SPN1 35 3 1
EDC inter MBP-Nup214 SPN1 35 74 1
EDC inter MBP-Nup214 SPN1 39 2 1
EDC inter MBP-Nup214 SPN1 315 228 1
EDC inter MBP-Nup214 CRM1 56 446 1
EDC inter MBP-Nup214 CRM1 59 446 1
EDC inter MBP-Nup214 CRM1 103 575 1
EDC inter MBP-Nup214 CRM1 176 443 1
EDC inter MBP-Nup214 CRM1 289 22 1
EDC inter MBP-Nup214 CRM1 359 522 1
EDC inter MBP-Nup214 CRM1 400 677 1
EDC inter MBP-Nup214 CRM1 400 1013 2
EDC inter CRM1 SPN1 334 54 1
EDC inter CRM1 SPN1 436 313 1
EDC inter CRM1 SPN1 529 34 4
EDC inter CRM1 SPN1 757 318 1
EDC inter CRM1 SPN1 1032 93 1
EDC inter CRM1 Ran 426 2 1
EDC inter CRM1 Ran 459 123 1
EDC inter CRM1 Ran 797 99 1
EDC inter CRM1 Ran 840 134 1







Figure S4: The MBP-tag of Nup214(1916-2033) cross-links indiscriminately to the surface of the
export complex and was therefore excluded from further analysis. The structure shows CRM1 (light
gray), Ran (medium gray) and SPN1 (dark gray) (PDB ID: 3GJX, [127]). The cross-links by (A) BS3 and
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Figure S5: Alignment of H. sapiens CRM1 (gi 68052989/ sp O14980.1) and S. cerevisiae Xpo1p
(gi 399300/ sp P30822.1)
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Figure S6: Alignment of H. sapiens Nup214 (gi 205831380/ sp P35658.2) and S. cerevisiae Nup159
(gi 731862/ sp P40477.1).
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Figure S7: Alignment of H. sapiens RanBP3 (gi 51316528/ sp Q9H6Z4.1) and S. cerevisiae Yrb2p
(gi 731821/ sp P40517.1)
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E Interactions of Nup214 to CRM1 in the crystal structure of the Nup214 com-
plex
Table S6: Interactions of Nup214 to CRM1 in the crystal structure.
FG-site Nup214 residues CRM1 residue HEAT repeat interaction type
1 Thr1918 Asn727 15A polar
Ala730 15A hydrophobic/ vdW
Ser1919 Glu726 15A hydrophobic/ vdW
Asn727 15A polar
Leu1921 Val676 14A hydrophobic/ vdW
Phe1922 [I] Ile669 14A hydrophobic/ vdW
Asn719 15A polar
Val720 15A hydrophobic/ vdW
Cys723 15A hydrophobic/ vdW
Ser1925 His11 (*) N-term (*) hydrophobic/ vdW
Lys1928 Asp782 16A polar
Phe1930 Val31 (*) 1A (*) hydrophobic/ vdW
Cys34 (*) 1A (*) hydrophobic/ vdW
Ala46 (*) 1B (*) hydrophobic/ vdW
Val49 (*) 1B (*) hydrophobic/ vdW
Gly1931 Gln42 (*) 1B (*) polar
Ser1936 Asp824 17A polar
Ser1937 Asp824 17A polar
Phe1938 [II] Phe823 17A hydrophobic/ vdW
Phe827 17A hydrophobic/ vdW
Glu828 17A hydrophobic/ vdW
Gln1941 Pro867 18A hydrophobic/ vdW
Pro1943 Leu864 18A hydrophobic/ vdW
Ala865 18A hydrophobic/ vdW
Ile866 18A hydrophobic/ vdW
Thr1944 Pro868 18A hydrophobic/ vdW
Phe1947 [III] Pro868 18A hydrophobic/ vdW
Phe871 18A hydrophobic/ vdW
Ala910 19A hydrophobic/ vdW
Ser913 19A hydrophobic/ vdW
Phe914 19A hydrophobic/ vdW
Tyr918 19A hydrophobic/ vdW
Ser1948 Thr917 19A hydrophobic/ vdW
2 Phe1982 [IV] Leu831 17A hydrophobic/ vdW
Leu873 18A hydrophobic/ vdW
Asp876 18A hydrophobic/ vdW
Ser877 18A hydrophobic/ vdW
Trp880 18A hydrophobic/ vdW
Gly1983 Asp876 18A polar
Gly1984 His925 19A polar
Ser1985 His925 19A hydrophobic/ vdW
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FG-site Nup214 residues CRM1 residue HEAT repeat interaction type
Pro1986 Gln924 19A hydrophobic/ vdW
His925 19A hydrophobic/ vdW
Ser928 19A hydrophobic/ vdW
Phe1988 [V] Leu873 18A hydrophobic/ vdW
Asp876 18A hydrophobic/ vdW
Phe927 19A hydrophobic/ vdW
Ser928 19A hydrophobic/ vdW
Thr931 19A hydrophobic/ vdW
3 Lys2010 Gln98 3A polar
Val2011 Gly101 3A hydrophobic/ vdW
Phe2012 [VI] Val63 2A hydrophobic/ vdW
Asp64 2A polar
Gln98 3A polar
Gly101 3A hydrophobic/ vdW
Ile102 3A hydrophobic/ vdW
Leu83 3B hydrophobic/ vdW
Glu2014 Glu68 2A polar
Ala2017 Tyr105 3A hydrophobic/ vdW
Ser2020 Gly108 3A hydrophobic/ vdW
Ala2021 Gly108 3A hydrophobic/ vdW
Lys104 3A hydrophobic/ vdW
Val107 3A hydrophobic/ vdW
Phe2024 [VII] Ile111 3A hydrophobic/ vdW
Asp152 4A hydrophobic/ vdW
Ile153 4A hydrophobic/ vdW
Gly2025 4A polar
Polar interactions (e.g. hydrogen bonds) are ≤ 3.5 Å while hydrophobic and van-der-Waals
(vdW) interactions are ≤ 4 Å. The asterisk indicates interactions to the symmetry-related CRM1
molecule. Numbers in square brackets indicate the respective binding pockets on CRM1 that the
phenylalanine residues bind to.
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F Comparison of the CRM1-RanGTP-SPN1 architecture in the crystal structure





Figure S8: Comparison of the CRM1-RanGTP-SPN1 architecture in the crystal structure of the
Nup214 complex and the export complex. (A) The export complex (PDB ID: 3GJX, blue) was aligned
with CRM1 (light gray), RanGTP (medium gray) and SPN1 (dark gray) from the Nup214 complex. (B)
The Acidic loop is in a closed conformation in both structures. (C) The NES binding cleft is in an open
conformation in both structures. Binding of the NES in the binding cleft is unaltered. (D) The C-terminal
helix is located in a stack with the other HEAT repeats in both structures.
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G Nup214 fragments and mutants
1916 -         -1929
1930 -                                                                  - 2033
1859 -                                                                                                                                          - 2090
1916 -                                                                         - 2033
1916 -                                                                 - 2021
1930 -                                                         - 2021
1968 -                                               - 2033
1991 -                                 - 2033
1968 -                - 1990
2022 -           - 2033
Figure S9: Nup214 fragments of different lengths used in this study.
wt   1859 -                                                                                                                                          - 2090
KA/ KE F1994   1859 -                                                                                                                                          - 2090
X3   1859 -                                                                                                                                          - 2090
X2   1859 -                                                                                                                                          - 2090
X1   1859 -                                                                                                                                          - 2090
DE/ K   1859 -                                                                                                                                          - 2090
KA/ KE 5SG   1859 -                                                                                                                                          - 2090
KA/ KE 4SG   1859 -                                                                                                                                          - 2090
KA/ KE   1859 -                                                                                                                                          - 2090
5SG   1859 -                                                                                                                                          - 2090
4SG   1859 -                                                                                                                                          - 2090
F1994S   1859 -                                                                                                                                          - 2090
wt   1916 -                                                                       - 2033
X3   1916 -                                                                       - 2033
X2   1916 -                                                                       - 2033
X1   1916 -                                                                       - 2033
KA 4SG   1916 -                                                                       - 2033
KA/ KE   1916 -                                                                       - 2033
5SG   1916 -                                                                       - 2033
Figure S10: Nup214 mutants used in this study. Mutated phenylalanines are colored in gray, mutated




Table S7: CRM1 mutants designed to impair binding to Nup214.




L744W L yes soluble
M748R L no




F823A II yes soluble
D824K II yes soluble
T917E III yes soluble
Y918W III yes soluble
W880A IV yes soluble
H925W V yes soluble
S928K V yes soluble
L83F VI yes insoluble
L83R VI no
I102Q VI yes insoluble
I102W VI yes insoluble
L134F VII yes insoluble
F149W VII yes soluble
D152W VII no
A156F VII yes soluble
N167R VII no
L679W K680R L+I yes soluble
K680Q A731Q L679R L+I yes soluble
K680Q A731Q C723M L+I yes soluble
L679R L744W L+I yes soluble
L679W L744W L+I no
C723M L744W L+I yes soluble
L83F L744W L+VI yes insoluble
L83F C723M i+VI yes insoluble
D824K S928K III+V yes soluble
I102W F149W VI+VII no
I102W N167R VI+VII no
I102W D152F VI+VII no
L83F F149W VI+VII yes insoluble
L83R F149W VI+VII no
I102Q F149W VI+VII no
L83F D152W VI+VII yes insoluble
L83R D152W VI+VII no
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Mutated residues Pockets Expression tested Protein
I102Q D152W VI+VII no
L83F A156F VI+VII yes soluble
L83R A156F VI+VII no
I102Q A156F VI+VII no
K680Q A731Q L679R D824K L+I+II yes soluble
K680Q A731Q L679R S928K L+I+V yes soluble
L83F K680Q A731Q L679R L+I+VI yes insoluble
K680Q A731Q L679R F149W L+I+VII yes insoluble
I102Q F149W L744W L+VI+VII no
I102Q F149W C723M L+VI+VII yes insoluble
L83F D152W K680Q A731Q C723M L+I+VI+VII yes insoluble
L83F D152W L679W L744W L+I+VI+VII yes insoluble
L83F D152W C723M L744W L+I+VI+VII yes insoluble
L83F A156F K680Q A731Q C723M L+I+VI+VII yes insoluble
L83F A156F L679W L744W L+I+VI+VII yes insoluble
L83F A156F C723M L744W L+I+VI+VII yes insoluble
I102Q F149W K680Q A731Q C723M L+I+VI+VII yes insoluble
I102Q F149W L679W L744W L+I+VI+VII no










































































































































































Figure S11: CRM1 single mutants showed diverse binding to NES and Nup214. CRM1 mutants
showed diverse binding to NES/ RanGTP and Nup214. The CRM1 mutants were plotted (black square)
individually in comparison to the wildtype CRM1 (white circle). The average of the values is indicated
by the black line for the CRM1 mutants and the dashed line for the CRM1 wildtype. The individual
values and averages of two independent experiments were plotted. Square brackets indicate the altered
FG-binding pocket of the CRM1 mutant. (left panel) NES peptide or (middle panel) MBP-Nup214(1916-
2033)-His was titrated to 100 nM of the CRM1 mutants and Ran loaded with 32P-γ-GTP in RanGAP
assays. (right panel) Permeabilized GFP-NFAT cells were incubated with 30 nM of the respective CRM1
mutants. Residual nuclear fluorescence was analyzed by flow cytometry. Values were normalized to















































































































































































Figure S12: CRM1 double and triple mutants showed diverse binding to NES and Nup214. CRM1
mutants showed diverse binding to NES/ RanGTP and Nup214. The CRM1 mutants were plotted (black
square) individually in comparison to the wildtype CRM1 (white circle). The average of the values is
indicated by the black line for the CRM1 mutants and the dashed line for the CRM1 wildtype. The
individual values and averages of two independent experiments were plotted. Square brackets indicate
the altered FG-binding pocket of the CRM1 mutant. (left panel) NES peptide or (middle panel) MBP-
Nup214(1916-2033)-His was titrated to 100 nM of the CRM1 mutants and Ran loaded with 32P-γ-GTP
in RanGAP assays. (right panel) Permeabilized GFP-NFAT cells were incubated with 30 nM of the
respective CRM1 mutants. Residual nuclear fluorescence was analyzed by flow cytometry. Values were
































K680Q A731Q L679R [L+I]
A156F [VII]
K680Q A731Q [L]
Figure S13: Export kinetics. 100 nM CRM1 mutants were titrated to permeabilized GFP-NFAT cells
together with Ran and an ATP-regenerating system. Residual nuclear fluorescence was analyzed by
flow cytometry. The average and standard deviation of two independent experiments were plotted.
Some of the error bars are too small to be seen.
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I Comparison of CRM1 from the Nup214 complex crystal structure to Xpo1p







Figure S14: Comparison of CRM1 from the Nup214 complex crystal structure to Xpo1p from the
Yrb2 complex (PDB ID: 3WYF). (A) The overall structure of CRM1 (gray) and Xpo1 (green) is similar,









BSA bovine serum albumin
CRM1 chromosome region maintenance 1




E. coli Escherichia coli
EDTA ethylenediaminetetraacetic acid
EtOH ethanol





H. sapiens/ Hs Homo sapiens
HCl hydrochloric acid
HEAT Huntingtin Elongation Factor A Subunit Tor
HEPES 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid





MBP Maltose binding protein
MCS multiple cloning site
MPIbpc Max Planck Institute for Biophysical Chemistry
M. musculus/ Mm Mus musculus
NES nuclear export signal
NFAT nuclear factor of activated T-cells
NLS nuclear localization signal
NPC nuclear pore complex
Nup nucleoporin
PAGE polyacrylamide gel electrophoresis
PCR polymerase chain reaction
PDB Protein Data Base
PMSF phenylmethylsulphonyl fluoride
Ran Ras-related nuclear protein
RCC1 Regulator of chromatin condensation 1
RFP red fluorescent protein
rpm rotations per minute
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S. cerevisiae/ Sc Saccharomyces cerevisiae
SDS sodium dodecyl sulphate
siRNA small interfering RNA
SPN1 snurportin 1
SV40 Simian virus 40
TAE Tris/ Acetate/ EDTA
Triton X-100 4-octylphenol polyethoxylate
Tween 20 polyoxyethylene (20) sorbitan monolaurate
UV ultraviolet
v/v volume per volume
w/o without
w/v weight per volume
WGA wheat germ agglutinin
wt wildtype
K Amino acid codes
Table S9: Amino acid codes.




Aspartic Acid Asp D
Cystein Cys C
Glutamine Gln Q
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